

# CITATION REPORT

List of articles citing

Phases of A beta-deposition in the human brain and its relevance for the development of AD

DOI: 10.1212/wnl.58.12.1791  
Neurology, 2002, 58, 1791-800.

**Source:** <https://exaly.com/paper-pdf/33608682/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2281	Immunotherapy for Alzheimer's disease. <b>2003</b> , 2, 215-20		89
2280	Toward a molecular neuropsychiatry of neurodegenerative diseases. <b>2003</b> , 54, 147-54		80
2279	Genetic association of acyl-coenzyme A: cholesterol acyltransferase with cerebrospinal fluid cholesterol levels, brain amyloid load, and risk for Alzheimer's disease. <b>2003</b> , 8, 635-8		55
2278	Neuronal expression of GFAP in patients with Alzheimer pathology and identification of novel GFAP splice forms. <b>2003</b> , 8, 786-96		114
2277	Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography. <b>2003</b> , 13, 781-9, ix		60
2276	Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. <b>2003</b> , 100, 9572-7		322
2275	Focal right inferotemporal atrophy in AD with disproportionate visual constructive impairment. <i>Neurology</i> , <b>2003</b> , 61, 1485-91	6.5	38
2274	Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline. <b>2003</b> , 62, 1287-301		247
2273	Current World Literature. <b>2003</b> , 16, 731-748		
2272	References. <b>2003</b> , 79, 297-476		
2271	Induction of brain-derived neurotrophic factor in plaque-associated glial cells of aged APP23 transgenic mice. <b>2004</b> , 24, 2421-30		105
2270	Argyrophilic grain disease: a late-onset dementia with distinctive features among tauopathies. <b>2004</b> , 24, 269-83		106
2269	Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. <b>2004</b> , 9, 664-83		228
2268	PET imaging of amyloid in Alzheimer's disease. <b>2004</b> , 3, 519-27		358
2267	Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer's disease in vivo?. <b>2004</b> , 31, 1540-3		4
2266	Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. <b>2004</b> , 55, 306-19		3088
2265	Dynamic Mapping of Alzheimer's Disease. <b>2004</b> , 87-112		

2264	Towards defining the neuropathological substrates of vascular dementia. <b>2004</b> , 226, 75-80	215
2263	Looking for the link between plaques and tangles. <b>2004</b> , 25, 735-9; discussion 743-6	44
2262	Reduced levels of Abeta 40 and Abeta 42 in brains of smoking controls and Alzheimer's patients. <b>2004</b> , 15, 351-60	61
2261	Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. <b>2004</b> , 25, 5-18; author reply 49-62	681
2260	The possible role of myelin destruction as a precipitating event in Alzheimer's disease. <b>2004</b> , 25, 25-31	27
2259	Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models. <b>2004</b> , 22, 453-65	109
2258	In vivo study of acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer disease. <b>2004</b> , 21, 136-43	109
2257	References. <b>2004</b> , 399-578	
2256	Amyloid beta-peptide(1-42) and hydrogen peroxide-induced toxicity are mediated by TRPM2 in rat primary striatal cultures. <b>2005</b> , 95, 715-23	157
2255	The impact of argyrophilic grain disease on the development of dementia and its relationship to concurrent Alzheimer's disease-related pathology. <b>2005</b> , 31, 270-9	53
2254	Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. <b>2005</b> , 25, 1528-47	566
2253	No association of a non-synonymous PLA2 polymorphism with Alzheimer's disease and disease-related traits. <b>2005</b> , 132B, 21-3	12
2252	Model-guided microarray implicates the retromer complex in Alzheimer's disease. <b>2005</b> , 58, 909-19	294
2251	[Post-mortem diagnosis of Alzheimer's disease]. <b>2005</b> , 26, 201-13	23
2250	Apolipoprotein E co-localizes with newly formed amyloid beta-protein (Abeta) deposits lacking immunoreactivity against N-terminal epitopes of Abeta in a genotype-dependent manner. <b>2005</b> , 110, 459-71	42
2249	Alzheimer's disease pathology influences severity and topographical distribution of cerebral amyloid angiopathy. <b>2005</b> , 110, 222-31	122
2248	Technology Insight: imaging amyloid plaques in the living brain with positron emission tomography and MRI. <b>2005</b> , 1, 96-105	17
2247	Cholesterol 25-hydroxylase on chromosome 10q is a susceptibility gene for sporadic Alzheimer's disease. <b>2005</b> , 2, 233-41	46

2246	Effects of chronic glucocorticoid administration on insulin-degrading enzyme and amyloid-beta peptide in the aged macaque. <b>2005</b> , 64, 139-46	73
2245	Can a herpes simplex virus type 1 neuroinvasive score be correlated to other risk factors in Alzheimer's disease?. <b>2005</b> , 64, 320-7	13
2244	Axonal transport and Alzheimer's disease. <b>2006</b> , 75, 607-27	229
2243	Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. <b>2006</b> , 33, 94-102	105
2242	Nutritional factors, cognitive decline, and dementia. <b>2006</b> , 69, 1-19	68
2241	Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. <b>2006</b> , 27, 394-401	197
2240	La lunga attesa: towards a molecular approach to neuroimaging and therapeutics in Alzheimer's disease. <b>2006</b> , 19, 453-74	11
2239	Visual association pathology in preclinical Alzheimer disease. <b>2006</b> , 65, 621-30	116
2238	Selective vulnerability of different types of commissural neurons for amyloid beta-protein-induced neurodegeneration in APP23 mice correlates with dendritic tree morphology. <b>2006</b> , 129, 2992-3005	40
2237	Targeting cell death in dementia. <b>2006</b> , 20, S3-7	13
2236	Quantitative analysis of neurofibrillary pathology in a general population to reappraise neuropathological criteria for senile dementia of the neurofibrillary tangle type (tangle-only dementia): the Hisayama Study. <b>2006</b> , 26, 508-18	33
2235	Excitatory amino acid transporter EAAT-2 in tangle-bearing neurons in Alzheimer's disease. <b>2002</b> , 12, 405-11	36
2234	Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid-beta(42) peptide in vascular dementia. <b>2006</b> , 32, 103-18	110
2233	Linking molecular motors to Alzheimer's disease. <b>2006</b> , 99, 193-200	25
2232	fMRI of working memory in patients with mild cognitive impairment and probable Alzheimer's disease. <b>2006</b> , 16, 193-206	144
2231	Alzheimer 100--highlights in the history of Alzheimer research. <b>2006</b> , 113, 1603-23	91
2230	Assessments of the accumulation severities of amyloid beta-protein and hyperphosphorylated tau in the medial temporal cortex of control and Alzheimer's brains. <b>2006</b> , 22, 657-68	45
2229	Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. <i>Neurology</i> , <b>2006</b> , 67, 1575-80	6.5 185

2228	Challenges in neuronal apoptosis. <b>2006</b> , 3, 377-91		66
2227	The role of MRI and PET/SPECT in Alzheimer's disease. <b>2006</b> , 6, 629-47		30
2226	The frontal assessment battery does not differentiate frontotemporal dementia from Alzheimer's disease. <b>2006</b> , 22, 125-31		60
2225	GGA1 is expressed in the human brain and affects the generation of amyloid beta-peptide. <b>2006</b> , 26, 12838-46		68
2224	Phosphorylation of actin-depolymerizing factor/cofilin by LIM-kinase mediates amyloid beta-induced degeneration: a potential mechanism of neuronal dystrophy in Alzheimer's disease. <b>2006</b> , 26, 6533-42		140
2223	Radioligand development for PET imaging of beta-amyloid (Abeta)--current status. <b>2007</b> , 14, 19-52		114
2222	Recent advances in the development of amyloid imaging agents. <b>2007</b> , 7, 1773-89		67
2221	Alzheimer's Disease. <b>2007</b> , 69-82		5
2220	Structural magnetic resonance imaging-derived biomarkers for Alzheimer's disease. <b>2007</b> , 1, 79-92		4
2219	Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. <i>Neurology</i> , <b>2007</b> , 68, 501-8	6.5	406
2218	Imaging beta-amyloid burden in aging and dementia. <i>Neurology</i> , <b>2007</b> , 68, 1718-25	6.5	883
2217	PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. <i>Neurology</i> , <b>2007</b> , 68, 1603-6		266
2216	Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. <b>2007</b> , 27, 6174-84		313
2215	Chapter 2 Alzheimer's Disease. <b>2007</b> , 33-58		1
2214	Visuospatial planning and problem solving in Alzheimer's disease patients: a study with the Tower of London Test. <b>2007</b> , 24, 424-8		24
2213	Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. <b>2007</b> , 48, 547-52		172
2212	PET and SPECT imaging in psychiatric disorders. <b>2007</b> , 52, 146-57		62
2211	Amyloid imaging in Alzheimer's disease. <b>2007</b> , 20, 398-402		69

2210	Beta-amyloid pathology in the entorhinal cortex of rats induces memory deficits: implications for Alzheimer's disease. <b>2007</b> , 147, 28-36	67
2209	Impact of amyloid imaging on drug development in Alzheimer's disease. <b>2007</b> , 34, 809-22	105
2208	Abeta Peptide and Alzheimer's Disease. <b>2007</b> ,	1
2207	The dentate gyrus in Alzheimer's disease. <b>2007</b> , 163, 723-40	42
2206	Autopsy-confirmed Alzheimer's disease versus clinically diagnosed Alzheimer's disease in the Cache County Study on Memory and Aging: a comparison of quantitative MRI and neuropsychological findings. <b>2007</b> , 29, 553-60	9
2205	Amyloid imaging in vivo: implications for Alzheimer's disease management. <b>2007</b> , 1, 337-49	3
2204	Topographical distribution of cerebral amyloid angiopathy and its effect on cognitive decline are influenced by Alzheimer disease pathology. <b>2007</b> , 257, 49-55	82
2203	Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. <b>2007</b> , 62, 229-34	420
2202	Seeing what Alzheimer saw. <b>2007</b> , 13, 129-31	8
2201	A prize catch for diabetic retinopathy. <b>2007</b> , 13, 131-2	20
2200	Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. <b>2007</b> , 1097, 114-45	151
2199	MRI of Vascular Dementia and Differential Diagnoses. <b>2007</b> , 17, 88-97	6
2198	How a neuropsychiatric brain bank should be run: a consensus paper of Brainnet Europe II. <b>2007</b> , 114, 527-37	41
2197	Non-invasive measurement of vagus activity in the brainstem - a methodological progress towards earlier diagnosis of dementias?. <b>2007</b> , 114, 613-9	36
2196	The enigma of vascular cognitive disorder and vascular dementia. <b>2007</b> , 113, 349-88	175
2195	Mutant ubiquitin and p62 immunoreactivity in cases of combined multiple system atrophy and Alzheimer's disease. <b>2007</b> , 113, 403-16	32
2194	Alzheimer disease models and human neuropathology: similarities and differences. <b>2008</b> , 115, 5-38	299
2193	Metabolic correlates of executive dysfunction. Different patterns in mild and very mild Alzheimer's disease. <b>2007</b> , 254, 1052-65	27

2192	Amyloid plaque imaging in vivo: current achievement and future prospects. <b>2008</b> , 35 Suppl 1, S46-50	60
2191	Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. <b>2008</b> , 35, 2169-81	217
2190	Oligomeric and fibrillar species of beta-amyloid (A beta 42) both impair mitochondrial function in P301L tau transgenic mice. <b>2008</b> , 86, 1255-67	98
2189	The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias. <b>2008</b> , 38, 1-15	81
2188	Tracing of temporo-entorhinal connections in the human brain: cognitively impaired argyrophilic grain disease cases show dendritic alterations but no axonal disconnection of temporo-entorhinal association neurons. <b>2008</b> , 115, 175-83	11
2187	Cerebral amyloid angiopathy and its relationship to Alzheimer's disease. <b>2008</b> , 115, 599-609	240
2186	Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium. <b>2008</b> , 18, 484-96	270
2185	Medullary autonomic pathology in carotid sinus hypersensitivity. <b>2008</b> , 34, 403-11	34
2184	Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. <b>2008</b> , 7, 129-35	551
2183	Biomarkers for early diagnosis of Alzheimer disease: 'ALzheimer ASSociated gene'--a new blood biomarker?. <b>2008</b> , 12, 1094-117	37
2182	Parenchymal and vascular Abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease. <b>2008</b> , 12, 1848-62	90
2181	Amyloid imaging in Alzheimer's disease. <b>2008</b> , 46, 1636-41	58
2180	Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: inverse correlation with A beta levels. <b>2008</b> , 29, 210-21	126
2179	[11C]PIB binding in Parkinson's disease dementia. <b>2008</b> , 39, 1027-33	120
2178	Appearance modeling of 11C PiB PET images: characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging. <b>2008</b> , 43, 430-9	70
2177	The amyloid cascade hypothesis. <b>2008</b> , 4, 176-8	74
2176	Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. <b>2008</b> , 65, 1304-9	179
2175	Voxel-based analysis of 11C-PIB scans for diagnosing Alzheimer's disease. <b>2008</b> , 49, 1262-9	37

2174	Systematic appraisal using immunohistochemistry of brain pathology in aged and demented subjects. <b>2008</b> , 25, 423-32	21
2173	Biopsy support for the validity of Pittsburgh compound B positron emission tomography with a twist. <b>2008</b> , 65, 1281-3	10
2172	Cerebral small vessel disease-induced apolipoprotein E leakage is associated with Alzheimer disease and the accumulation of amyloid beta-protein in perivascular astrocytes. <b>2008</b> , 67, 842-56	60
2171	Morphometric changes in the episodic memory network and tau pathologic features correlate with memory performance in patients with mild cognitive impairment. <b>2008</b> , 29, 1183-9	44
2170	Argyrophilic grain disease. <b>2008</b> , 89, 553-63	22
2169	Inflammatory mediators in the frontal lobe of patients with mixed and vascular dementia. <b>2008</b> , 25, 278-86	26
2168	<sup>11</sup> C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnesic mild cognitive impairment. <b>2008</b> , 131, 665-80	716
2167	Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. <b>2008</b> , 33, 240-56	211
2166	The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches. <b>2008</b> , 15, 685-707	136
2165	Striatal beta-amyloid deposition in Parkinson disease with dementia. <b>2008</b> , 67, 155-61	106
2164	Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B. <b>2008</b> , 22, 261-8	103
2163	Is brain banking of psychiatric cases valuable for neurobiological research?. <b>2008</b> , 63, 255-66	18
2162	Taking the next steps in the diagnosis of Alzheimer's disease: the use of biomarkers. <b>2008</b> , 13, 7-10	23
2161	Oxidative stress in neurodegeneration and available means of protection. <b>2008</b> , 13, 3288-311	84
2160	Diminished perisomatic GABAergic terminals on cortical neurons adjacent to amyloid plaques. <b>2009</b> , 3, 28	72
2159	Education attenuates the effect of medial temporal lobe atrophy on cognitive function in Alzheimer's disease: the MIRAGE study. <b>2009</b> , 17, 855-62	35
2158	Brain metabolic correlates of cerebrospinal fluid beta-amyloid 42 and tau in Alzheimer's disease. <b>2009</b> , 27, 474-80	11
2157	Isolation and characterization of patient-derived, toxic, high mass amyloid beta-protein (A $\beta$ ) assembly from Alzheimer disease brains. <b>2009</b> , 284, 32895-905	136



2156	Animal models for Alzheimer's disease and frontotemporal dementia: a perspective. <b>2009</b> , 1,	27
2155	Creutzfeldt-jakob, Parkinson, lewy body dementia and Alzheimer diseases: from diagnosis to therapy. <b>2009</b> , 9, 2-11	6
2154	Hippocampal tau pathology is related to neuroanatomical connections: an ageing population-based study. <b>2009</b> , 132, 1324-34	129
2153	Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. <b>2009</b> , 66, 60-7	130
2152	In vivo mapping of amyloid toxicity in Alzheimer disease. <i>Neurology</i> , <b>2009</b> , 72, 1504-11	6.5 72
2151	Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. <b>2009</b> , 50, 1251-9	231
2150	Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. <b>2009</b> , 34, 107-12	158
2149	Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. <b>2009</b> , 35, 352-8	265
2148	Brainstem Alzheimer's-like pathology in the triple transgenic mouse model of Alzheimer's disease. <b>2009</b> , 35, 415-25	34
2147	Region-specific susceptibilities to cuprizone-induced lesions in the mouse forebrain: Implications for the pathophysiology of schizophrenia. <b>2009</b> , 1270, 121-30	54
2146	Amyloid imaging in mild cognitive impairment subtypes. <b>2009</b> , 65, 557-68	276
2145	Die Alzheimer-Demenz: von der Pathologie zu therapeutischen Ansätzen. <b>2009</b> , 121, 3074-3105	37
2144	In vitro and in vivo staining characteristics of small, fluorescent, Abeta42-binding D-enantiomeric peptides in transgenic AD mouse models. <b>2009</b> , 4, 276-82	50
2143	Alzheimer's disease: from pathology to therapeutic approaches. <b>2009</b> , 48, 3030-59	467
2142	Auricular vagus somatosensory evoked potentials in vascular dementia. <b>2009</b> , 116, 473-7	12
2141	Far field potentials from brain stem after transcutaneous vagus nerve stimulation: optimization of stimulation and recording parameters. <b>2009</b> , 116, 1237-42	64
2140	Criteria for the neuropathological diagnosis of dementing disorders: routes out of the swamp?. <b>2009</b> , 117, 101-10	41
2139	Assessment of beta-amyloid deposits in human brain: a study of the BrainNet Europe Consortium. <b>2009</b> , 117, 309-20	119

2138	Classification and basic pathology of Alzheimer disease. <b>2009</b> , 118, 5-36	632
2137	The morbid anatomy of dementia in Parkinson's disease. <b>2009</b> , 118, 587-98	72
2136	Altered mitochondria, energy metabolism, voltage-dependent anion channel, and lipid rafts converge to exhaust neurons in Alzheimer's disease. <b>2009</b> , 41, 425-31	141
2135	Update on amyloid imaging: from healthy aging to Alzheimer's disease. <b>2009</b> , 9, 345-52	51
2134	Amyloid imaging in Alzheimer's disease and other dementias. <b>2009</b> , 3, 246-61	23
2133	An unusual cause of dysphagia and dysarthria. <b>2009</b> , 35, 218-21	1
2132	The dorsal raphe nucleus shows phospho-tau neurofibrillary changes before the transentorhinal region in Alzheimer's disease. A precocious onset?. <b>2009</b> , 35, 406-416	137
2131	Spinocerebellar ataxia type 6 (SCA6): neurodegeneration goes beyond the known brain predilection sites. <b>2009</b> , 35, 515-27	39
2130	Brain banking: opportunities, challenges and meaning for the future. <b>2009</b> , 10, 70-8	90
2129	Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels. <b>2009</b> , 1180, 56-67	84
2128	Computational selection of inhibitors of Abeta aggregation and neuronal toxicity. <b>2009</b> , 17, 5189-97	35
2127	Widespread thalamic and cerebellar degeneration in a patient with a complicated hereditary spastic paraplegia (HSP). <b>2009</b> , 191, 203-11	8
2126	Characterization of cognition alteration across the course of the disease in APP751SL mice with parallel estimation of cerebral Abeta deposition. <b>2009</b> , 201, 147-57	12
2125	Clinical severity of Alzheimer's disease is associated with PIB uptake in PET. <b>2009</b> , 30, 1902-9	74
2124	[(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients. <b>2009</b> , 54, 347-57	72
2123	Comparison of Abeta levels in the brain of familial and sporadic Alzheimer's disease. <b>2009</b> , 55, 243-52	54
2122	Amyloid-beta(25-35) impairs memory and increases NO in the temporal cortex of rats. <b>2009</b> , 63, 129-37	53
2121	Capillary cerebral amyloid angiopathy is associated with vessel occlusion and cerebral blood flow disturbances. <b>2009</b> , 30, 1936-48	102

2120	Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. <b>2009</b> , 65, 927-34	216
2119	[Morphologic and molecular neuropathology of Alzheimer's disease]. <b>2009</b> , 67, 127-35	3
2118	PET in the Evaluation of Alzheimer's Disease and Related Disorders. <b>2009</b> ,	6
2117	Seeded growth of beta-amyloid fibrils from Alzheimer's brain-derived fibrils produces a distinct fibril structure. <b>2009</b> , 106, 7443-8	256
2116	Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease. <b>2009</b> , 1, 6	97
2115	Mapping the effect of APOE epsilon4 on gray matter loss in Alzheimer's disease in vivo. <b>2009</b> , 45, 1090-8	61
2114	Resting-state BOLD networks versus task-associated functional MRI for distinguishing Alzheimer's disease risk groups. <b>2009</b> , 47, 1678-90	176
2113	Signal regulatory protein-beta1: a microglial modulator of phagocytosis in Alzheimer's disease. <b>2009</b> , 175, 2528-39	52
2112	Extracellular amyloid-beta and cytotoxic glial activation induce significant entorhinal neuron loss in young PS1(M146L)/APP(751SL) mice. <b>2009</b> , 18, 755-76	32
2111	Alzheimer's disease selective vulnerability and modeling in transgenic mice. <b>2009</b> , 18, 243-51	28
2110	Hyperphosphorylated tau in the occipital cortex in aged nondemented subjects. <b>2009</b> , 68, 653-60	14
2109	Immunotherapy in a natural model of Abeta pathogenesis: the aging beagle. <b>2009</b> , 8, 98-113	10
2108	The role of positron emission tomography imaging of beta-amyloid in patients with Alzheimer's disease. <b>2010</b> , 31, 4-11	15
2107	Genetic ablation of luteinizing hormone receptor improves the amyloid pathology in a mouse model of Alzheimer disease. <b>2010</b> , 69, 253-61	32
2106	The isolated and combined effects of folic acid and synthetic bioactive compounds against Abeta(25-35)-induced toxicity in human microglial cells. <b>2010</b> , 15, 1632-44	7
2105	Biomarkers of Alzheimer's and Parkinson's Disease. <b>2010</b> , 89-117	
2104	Modulation of tau pathology in tau transgenic models. <b>2010</b> , 38, 996-1000	9
2103	Pittsburgh compound B as a marker of cognitive decline. <b>2010</b> , 5, 519-526	

2102	Neuropathologic alterations in mild cognitive impairment: a review. <b>2010</b> , 19, 221-8	159
2101	Microstructural diffusion changes are independent of macrostructural volume loss in moderate to severe Alzheimer's disease. <b>2010</b> , 19, 963-76	71
2100	Quantitative analysis of [18F]FDDNP PET using subcortical white matter as reference region. <b>2010</b> , 37, 575-88	27
2099	[Visualization of amyloid with positron emission tomography. Useful improvement in the diagnosis of dementia?]. <b>2010</b> , 81, 602-6	4
2098	Quantification of myelin loss in frontal lobe white matter in vascular dementia, Alzheimer's disease, and dementia with Lewy bodies. <b>2010</b> , 119, 579-89	162
2097	Vascular pathology in the aged human brain. <b>2010</b> , 119, 277-90	225
2096	Protein coding of neurodegenerative dementias: the neuropathological basis of biomarker diagnostics. <b>2010</b> , 119, 389-408	79
2095	Analysis of microdissected human neurons by a sensitive ELISA reveals a correlation between elevated intracellular concentrations of Abeta42 and Alzheimer's disease neuropathology. <b>2010</b> , 119, 543-54	55
2094	Amyotrophic lateral sclerosis: dash-like accumulation of phosphorylated TDP-43 in somatodendritic and axonal compartments of somatomotor neurons of the lower brainstem and spinal cord. <b>2010</b> , 120, 67-74	47
2093	Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. <b>2010</b> , 120, 185-93	226
2092	Capillary cerebral amyloid angiopathy identifies a distinct APOE epsilon4-associated subtype of sporadic Alzheimer's disease. <b>2010</b> , 120, 169-83	68
2091	Neuropathology of the recessive A673V APP mutation: Alzheimer disease with distinctive features. <b>2010</b> , 120, 803-12	53
2090	Diagnosis and biomarkers of predementia in Alzheimer's disease. <b>2010</b> , 8, 89	76
2089	Analysis of Alzheimer's disease severity across brain regions by topological analysis of gene co-expression networks. <b>2010</b> , 4, 136	66
2088	Sex effects of interleukin-6 deficiency on neuroinflammation in aged C57Bl/6 mice. <b>2010</b> , 1318, 11-22	9
2087	First appraisal of brain pathology owing to A30P mutant alpha-synuclein. <b>2010</b> , 67, 684-9	75
2086	Endogenous neurosteroid synthesis modulates seizure frequency. <b>2010</b> , 67, 689-93	42
2085	Amyloid and tau proteins in cortical brain biopsy and Alzheimer's disease. <b>2010</b> , 68, 446-53	98

2084	Secreted amyloid precursor protein and holo-APP bind amyloid beta through distinct domains eliciting different toxic responses on hippocampal neurons. <b>2010</b> , 88, 1795-803	10
2083	Synthesis and evaluation of 18F-fluoroethylated benzothiazole derivatives for in vivo imaging of amyloid plaques in Alzheimer's disease. <b>2010</b> , 68, 1066-72	14
2082	Amyloid in skin and brain: what's the link?. <b>2010</b> , 19, 953-7	8
2081	. <b>2010</b> ,	15
2080	. <b>2010</b> ,	4
2079	Neocortical variation of Abeta load in fully expressed, pure Alzheimer's disease. <b>2010</b> , 19, 57-68	15
2078	Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse Model. <b>2010</b> , 2010,	16
2077	Target-specific PET probes for neurodegenerative disorders related to dementia. <b>2010</b> , 51, 1418-30	47
2076	CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease. <b>2010</b> , 30, 2088-101	164
2075	What are the causes of pre-existing dementia in patients with intracerebral haemorrhages?. <b>2010</b> , 133, 3281-9	64
2074	Alzheimer's disease: spect and pet tracers for beta-amyloid imaging. <b>2010</b> , 7, 477-86	10
2073	Frontal lobe white matter hyperintensities and neurofibrillary pathology in the oldest old. <i>Neurology</i> , <b>2010</b> , 75, 2071-8	6.5 68
2072	From alpha to omega with Abeta: targeting the multiple molecular appearances of the pathogenic peptide in Alzheimer's disease. <b>2010</b> , 17, 198-212	22
2071	Amyloid PET Ligands for Dementia. <b>2010</b> , 5, 33-53	20
2070	Pharmacological Models for Preclinical Testing: From Mouse to Dog to Nonhuman Primates. 159-175	1
2069	Progression of cerebral amyloid load is associated with the apolipoprotein E $\epsilon$ genotype in Alzheimer's disease. <b>2010</b> , 68, 879-84	83
2068	Capillary CAA and perivascular A $\beta$ deposition: two distinct features of Alzheimer's disease pathology. <b>2010</b> , 299, 155-62	41
2067	The APOE-491 A/T promoter polymorphism effect on cognitive profile of Alzheimer's patients. <b>2010</b> , 472, 199-203	2

2066	Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia. <b>2010</b> , 486, 19-23	51
2065	Neurogenesis in mouse models of Alzheimer's disease. <b>2010</b> , 1802, 872-80	67
2064	Neuronal gene expression in non-demented individuals with intermediate Alzheimer's Disease neuropathology. <b>2010</b> , 31, 549-66	58
2063	Plaque and tangle imaging and cognition in normal aging and Alzheimer's disease. <b>2010</b> , 31, 1669-78	83
2062	Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. <b>2010</b> , 223, 334-46	120
2061	The Alzheimer's disease neuroimaging initiative: progress report and future plans. <b>2010</b> , 6, 202-11.e7	332
2060	Callosal atrophy in mild cognitive impairment and Alzheimer's disease: different effects in different stages. <b>2010</b> , 49, 141-9	81
2059	CSF biomarker pathology correlates with a medial temporo-parietal network affected by very mild to moderate Alzheimer's disease but not a fronto-striatal network affected by healthy aging. <b>2010</b> , 49, 1820-30	23
2058	The use of PET in Alzheimer disease. <b>2010</b> , 6, 78-87	274
2057	Neuropathological alterations in Alzheimer disease. <b>2011</b> , 1, a006189	1682
2056	A pathophysiological framework of hippocampal dysfunction in ageing and disease. <b>2011</b> , 12, 585-601	594
2055	Peripheral Lewy body pathology in Parkinson's disease and incidental Lewy body disease: four cases. <b>2011</b> , 310, 100-6	18
2054	Time-course and regional analyses of the physiopathological changes induced after cerebral injection of an amyloid I $\beta$ fragment in rats. <b>2011</b> , 179, 315-34	101
2053	Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease. <b>2011</b> , 179, 1373-84	249
2052	Roles of $\beta$ adrenergic receptors in Alzheimer's disease: implications for novel therapeutics. <b>2011</b> , 84, 111-7	37
2051	Detection of age-dependent working memory deterioration in APP751SL mice. <b>2011</b> , 218, 129-37	6
2050	Region-specific distribution of $\beta$ amyloid peptide and cytokine expression in TgCRND8 mice. <b>2011</b> , 492, 5-10	15
2049	Lifespan brain activity, $\beta$ amyloid, and Alzheimer's disease. <b>2011</b> , 15, 520-6	151

2048	Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. <b>2011</b> , 34, 430-42	235
2047	On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia. <b>2011</b> , 95, 649-62	43
2046	Alzheimer's disease as homeostatic responses to age-related myelin breakdown. <b>2011</b> , 32, 1341-71	351
2045	Early-onset dysfunction of retrosplenial cortex precedes overt amyloid plaque formation in Tg2576 mice. <b>2011</b> , 174, 71-83	13
2044	Tower of London Test: A Comparison between Conventional Statistic Approach and Modelling Based on Artificial Neural Network in Differentiating Fronto-Temporal Dementia from Alzheimer's Disease. <b>2011</b> , 24, 149-158	10
2043	Mapping the structural brain changes in Alzheimer's disease: the independent contribution of two imaging modalities. <b>2011</b> , 26 Suppl 3, 263-74	35
2042	Epidemiological neuropathology: the MRC Cognitive Function and Aging Study experience. <b>2011</b> , 25, 359-72	83
2041	Sodium/myo-Inositol transporters: substrate transport requirements and regional brain expression in the TgCRND8 mouse model of amyloid pathology. <b>2011</b> , 6, e24032	26
2040	Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. <b>2011</b> , 70, 960-9	1068
2039	Attentional control in normal aging and Alzheimer's disease. <b>2011</b> , 25, 353-67	28
2038	Deposition of hyperphosphorylated tau in cerebellum of PS1 E280A Alzheimer's disease. <b>2011</b> , 21, 452-63	46
2037	The role of NOS in the impairment of spatial memory and damaged neurons in rats injected with amyloid beta 25-35 into the temporal cortex. <b>2011</b> , 98, 67-75	41
2036	Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease. <b>2011</b> , 10, 187-98	348
2035	Functional network disruption in the degenerative dementias. <b>2011</b> , 10, 829-43	333
2034	Staging of the cognitive decline in Alzheimer's disease: insights from a detailed neuropsychological investigation of mild cognitive impairment and mild Alzheimer's disease. <b>2012</b> , 27, 423-32	25
2033	De rol van de pariëtaalkwab in de vroege fase van de ziekte van Alzheimer. <b>2011</b> , 15, 113-120	
2032	The pathological process underlying Alzheimer's disease in individuals under thirty. <b>2011</b> , 121, 171-81	520
2031	Glutamyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-A $\beta$ deposits in hippocampus via distinct cellular mechanisms. <b>2011</b> , 121, 705-19	41

2030	Alzheimer's pathogenesis: is there neuron-to-neuron propagation?. <b>2011</b> , 121, 589-95	238
2029	Volume reduction in subcortical regions according to severity of Alzheimer's disease. <b>2011</b> , 258, 1013-20	51
2028	Alzheimer's disease: ageing-related or age-related? New hypotheses from an old debate. <b>2011</b> , 32, 1241-7	5
2027	Nerve cells immunoreactive for p62 in select hypothalamic and brainstem nuclei of controls and Parkinson's disease cases. <b>2011</b> , 118, 809-19	23
2026	Alzheimer's disease: effects of $\beta$ amyloid on mitochondria. <b>2011</b> , 11, 13-21	98
2025	Neurobiology of the aging dog. <b>2011</b> , 33, 485-96	35
2024	Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. <b>2011</b> , 70, 532-40	452
2023	PET imaging of brain amyloid in dementia: a review. <b>2011</b> , 26, 991-9	105
2022	Similar amyloid-burden in posterior cortical atrophy and Alzheimer's disease. <b>2011</b> , 134, 2036-43	96
2021	Using positron emission tomography and Carbon 11-labeled Pittsburgh Compound B to image Brain Fibrillar $\beta$ amyloid in adults with down syndrome: safety, acceptability, and feasibility. <b>2011</b> , 68, 890-6	57
2020	Intrahippocampal amyloid- $\beta$ (1-40) injections injure medial septal neurons in rats. <b>2011</b> , 8, 832-40	18
2019	Therapeutic interventions targeting Beta amyloid pathogenesis in an aging dog model. <b>2011</b> , 9, 651-61	14
2018	$\beta$ Amyloid (1-42) Levels in Cerebrospinal Fluid and Cerebral Atrophy in Mild Cognitive Impairment and Alzheimer's Disease. <b>2011</b> , 1, 393-401	
2017	Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. <b>2011</b> , 134, 293-300	75
2016	Telomere shortening reduces Alzheimer's disease amyloid pathology in mice. <b>2011</b> , 134, 2044-56	60
2015	Precuneus amyloid burden is associated with reduced cholinergic activity in Alzheimer disease. <i>Neurology</i> , <b>2011</b> , 77, 39-47	6.5 59
2014	Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease. <b>2011</b> , 134, 301-17	109
2013	Changes in dietary folate intake differentially affect oxidised lipid and mitochondrial DNA damage in various brain regions of rats in the absence/presence of intracerebroventricularly injected amyloid $\beta$ peptide challenge. <b>2011</b> , 105, 1294-302	12



2012	Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. <b>2012</b> , 64, 27-81	66
2011	Reduced tissue levels of noradrenaline are associated with behavioral phenotypes of the TgCRND8 mouse model of Alzheimer's disease. <b>2012</b> , 37, 1934-44	48
2010	Demenz: Was kann der Radiologe sagen?. <b>2012</b> , 02, 131-148	0
2009	Breakpoint sequence analysis of an APP locus duplication associated with autosomal dominant Alzheimer's disease and severe cerebral amyloid angiopathy. <b>2012</b> , 28, 303-8	8
2008	Clinical and anatomical correlates of gait dysfunction in Alzheimer's disease. <b>2013</b> , 33, 495-505	26
2007	APOE4 predicts amyloid- $\beta$ in cortical brain biopsy but not idiopathic normal pressure hydrocephalus. <b>2012</b> , 83, 1119-24	20
2006	Effect of a CNS-Sensitive Anticholinesterase Methane Sulfonyl Fluoride on Hippocampal Acetylcholine Release in Freely Moving Rats. <b>2012</b> , 2012, 708178	2
2005	Different clinical phenotypes in siblings with a presenilin-1 P264L mutation. <b>2012</b> , 33, 132-40	5
2004	A $\beta$ Deposition in aging is associated with increases in brain activation during successful memory encoding. <b>2012</b> , 22, 1813-23	105
2003	Alzheimer's disease, cerebrovascular disease, and the $\beta$ amyloid cascade. <b>2012</b> , 39, 712-28	128
2002	Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. <b>2012</b> , 71, 266-73	563
2001	Stable size distribution of amyloid plaques over the course of Alzheimer disease. <b>2012</b> , 71, 694-701	32
2000	Cortical brain biopsy in long-term prognostication of 468 patients with possible normal pressure hydrocephalus. <b>2012</b> , 10, 166-9	40
1999	Peptides for therapy and diagnosis of Alzheimer's disease. <b>2012</b> , 18, 755-67	88
1998	Cerebellar amyloid- $\beta$ plaques: disturbed cortical circuitry in APP/PS1 transgenic mice as a model of familial Alzheimer's disease. <b>2012</b> , 31, 285-300	18
1997	The Alzheimer myth and biomarker research in dementia. <b>2012</b> , 31 Suppl 3, S203-9	30
1996	Context-dependent toxicity of amyloid- $\beta$ peptides on mouse cerebellar cells. <b>2012</b> , 30, 41-51	2
1995	.	2

1994	Antibody 9D5 recognizes oligomeric pyroglutamate amyloid- $\beta$ in a fraction of amyloid- $\beta$ deposits in Alzheimer's disease without cross-reactivity with other protein aggregates. <b>2012</b> , 29, 361-71	15
1993	Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. <b>2012</b> , 71, 362-81	1145
1992	Cerebral $\beta$ amyloid deposition predicts HIV-associated neurocognitive disorders in APOE $\epsilon$ carriers. <b>2012</b> , 26, 2327-35	82
1991	Cerebrospinal fluid and PET biomarkers for in vivo diagnosis of posterior cortical atrophy as the early onset and focal variant of Alzheimer's disease. <b>2012</b> , 7, 403-407	
1990	Presence of Striatal Amyloid Plaques in Parkinson's Disease Dementia Predicts Concomitant Alzheimer's Disease: Usefulness for Amyloid Imaging. <b>2012</b> , 2, 57-65	31
1989	Discovering Aberrant Patterns of Human Connectome in Alzheimer's Disease via Subgraph Mining. <b>2012</b> ,	4
1988	Alzheimer's disease. <b>2012</b> , 65, 329-52	176
1987	Effects of amyloid- $\beta$ plaque proximity on the axon initial segment of pyramidal cells. <b>2012</b> , 29, 841-52	16
1986	The frontal assessment battery in the differential diagnosis of dementia. <b>2012</b> , 25, 201-7	16
1985	Pittsburgh compound B and the postmortem diagnosis of Alzheimer disease. <b>2012</b> , 72, 564-70	27
1984	Relation of neuropathology to cognition in persons without cognitive impairment. <b>2012</b> , 72, 599-609	153
1983	[(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid $\beta$ detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies. <b>2012</b> , 124, 833-45	63
1982	Early-onset Alzheimer's disease: nonamnestic subtypes and type 2 AD. <b>2012</b> , 43, 677-85	96
1981	Amyloid imaging in dementias with atypical presentation. <b>2012</b> , 8, 389-98	43
1980	National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. <b>2012</b> , 8, 1-13	1396
1979	The need to unify neuropathological assessments of vascular alterations in the ageing brain: multicentre survey by the BrainNet Europe consortium. <b>2012</b> , 47, 825-33	50
1978	Decrease of the immunophilin FKBP52 accumulation in human brains of Alzheimer's disease and FTDP-17. <b>2012</b> , 29, 471-83	23
1977	The French series of autosomal dominant early onset Alzheimer's disease cases: mutation spectrum and cerebrospinal fluid biomarkers. <b>2012</b> , 30, 847-56	94

1976	Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. <b>2012</b> , 33, 215-25	108
1975	BDNF increases with behavioral enrichment and an antioxidant diet in the aged dog. <b>2012</b> , 33, 546-54	73
1974	Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. <b>2012</b> , 33, 198.e1-14	103
1973	White matter hyperintensities predict amyloid increase in Alzheimer's disease. <b>2012</b> , 33, 2766-73	91
1972	Prediction of Alzheimer's disease using individual structural connectivity networks. <b>2012</b> , 33, 2756-65	46
1971	Preclinical studies of potential amyloid binding PET/SPECT ligands in Alzheimer's disease. <b>2012</b> , 39, 484-501	23
1970	Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia. <b>2012</b> , 97, 38-51	127
1969	The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions. <b>2012</b> , 135, 723-35	226
1968	Spinal cord lesions in sporadic Parkinson's disease. <b>2012</b> , 124, 643-64	113
1967	Should Alzheimer's disease be equated with human brain ageing? A maladaptive interaction between brain evolution and senescence. <b>2012</b> , 11, 104-22	16
1966	Sparse learning and stability selection for predicting MCI to AD conversion using baseline ADNI data. <b>2012</b> , 12, 46	103
1965	Pick's pathology in Parkinson's disease with dementia. <b>2012</b> , 38, 737-43	3
1964	Vascular dementia: different forms of vessel disorders contribute to the development of dementia in the elderly brain. <b>2012</b> , 47, 816-24	134
1963	The epidemiological neuropathology of dementia and the implications for drug development. <b>2012</b> , 2, 471-482	7
1962	Florbetapir PET analysis of amyloid- $\beta$ deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. <b>2012</b> , 11, 1057-65	178
1961	Inflammation-induced dysfunction of the low-density lipoprotein receptor-related protein-1 at the blood-brain barrier: protection by the antioxidant N-acetylcysteine. <b>2012</b> , 26, 1085-94	70
1960	Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. <b>2012</b> , 59, 1152-60	116
1959	Imaging brain amyloid deposition using grating-based differential phase contrast tomography. <b>2012</b> , 61, 1336-46	62

1958	In vitro characterization of [18F]-florbetaben, an A $\beta$ imaging radiotracer. <b>2012</b> , 39, 1042-8	45
1957	Cognitive decline and amyloid accumulation in patients with mild cognitive impairment. <b>2012</b> , 34, 31-7	9
1956	Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer's disease and other neurodegenerative dementias. <b>2012</b> , 262 Suppl 2, S71-7	19
1955	Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. <b>2012</b> , 69, 198-207	288
1954	Long night's journey into the day: amyloid- $\beta$ imaging in Alzheimer's disease. <b>2013</b> , 33 Suppl 1, S349-59	19
1953	3xTg-AD mice exhibit an activated central stress axis during early-stage pathology. <b>2013</b> , 33, 407-22	37
1952	Striatal amyloid plaque density predicts Braak neurofibrillary stage and clinicopathological Alzheimer's disease: implications for amyloid imaging. <b>2012</b> , 28, 869-76	54
1951	Neocortical-hippocampal dynamics of working memory in healthy and diseased brain states based on functional connectivity. <b>2012</b> , 6, 36	21
1950	Measurement of altered A $\beta$ P isoform expression in frontal cortex of patients with Alzheimer's disease by absolute quantification real-time PCR. <b>2012</b> , 29, 449-57	11
1949	The neuropathology of genetic Parkinson's disease. <b>2012</b> , 27, 831-42	184
1948	Nigral Tau pathology and striatal amyloid- $\beta$ deposition does not correlate with striatal dopamine deficit in Alzheimer's disease. <b>2012</b> , 119, 1545-9	2
1947	Interaction between pathogenic proteins in neurodegenerative disorders. <b>2012</b> , 16, 1166-83	89
1946	Dimebon slows progression of proteinopathy in $\beta$ -synuclein transgenic mice. <b>2012</b> , 22, 33-42	35
1945	Cerebrospinal fluid levels of A $\beta$ 2 relationship with cholinergic cortical activity in Alzheimer's disease patients. <b>2012</b> , 119, 771-8	24
1944	Unusual clinical presentation and neuropathology in two subjects with fused-in sarcoma (FUS) positive inclusions. <b>2012</b> , 32, 60-8	1
1943	Post-mortem findings in 10 patients with presumed normal-pressure hydrocephalus and review of the literature. <b>2012</b> , 38, 72-86	64
1942	High-molecular weight A $\beta$ oligomers and protofibrils are the predominant A $\beta$ species in the native soluble protein fraction of the AD brain. <b>2012</b> , 16, 287-95	50
1941	Neurogenic abnormalities in Alzheimer's disease differ between stages of neurogenesis and are partly related to cholinergic pathology. <b>2012</b> , 47, 155-62	117

1940	Parietal cortex matters in Alzheimer's disease: an overview of structural, functional and metabolic findings. <b>2012</b> , 36, 297-309	149
1939	Prevalence and severity of cerebral amyloid angiopathy: a population-based study on very elderly Finns (Vantaa 85+). <b>2012</b> , 38, 329-36	25
1938	Cerebral amyloid (A $\beta$ ) deposits and microvascular pathology in ageing baboons. <b>2012</b> , 38, 487-99	26
1937	Atheromatous disease in small intracerebral vessels, microinfarcts and dementia. <b>2012</b> , 38, 505-8	17
1936	Neuroimaging results impose new views on Alzheimer's disease--the role of amyloid revised. <b>2012</b> , 45, 153-72	38
1935	Amyloid pathway-based candidate gene analysis of [(11)C]PiB-PET in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. <b>2012</b> , 6, 1-15	39
1934	AIImaging: feasible, pertinent, and vital to progress in Alzheimer's disease. <b>2012</b> , 39, 209-19	46
1933	Mild cognitive impairment: pathology and mechanisms. <b>2012</b> , 123, 13-30	150
1932	National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. <b>2012</b> , 123, 1-11	1425
1931	Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis. <b>2012</b> , 123, 395-407	80
1930	Asymmetry of neurodegenerative disease-related pathologies: a cautionary note. <b>2012</b> , 123, 449-52	24
1929	Memory performance and fMRI signal in presymptomatic familial Alzheimer's disease. <b>2013</b> , 34, 3308-19	7
1928	Alterations of central insulin-like growth factor-1 sensitivity in APP/PS1 transgenic mice and neuronal models. <b>2013</b> , 91, 717-25	20
1927	Amyloid- $\beta$ may be released from non-junctional varicosities of axons generated from abnormal tau-containing brainstem nuclei in sporadic Alzheimer's disease: a hypothesis. <b>2013</b> , 126, 303-6	31
1926	Cognitive decline and cerebrospinal fluid biomarkers: a close relationship. <b>2013</b> , 8, 403-406	1
1925	Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. <b>2013</b> , 126, 365-84	207
1924	Amyloid or tau: the chicken or the egg?. <b>2013</b> , 126, 609-13	30
1923	The influence of Apolipoprotein E genotype on regional pathology in Alzheimer's disease. <b>2013</b> , 13, 44	16

1922	Topography of FUS pathology distinguishes late-onset BIBD from aFTLD-U. <b>2013</b> , 1, 1-11	11
1921	Semiquantitative proteomic analysis of human hippocampal tissues from Alzheimer's disease and age-matched control brains. <b>2013</b> , 10, 5	43
1920	Study into possible molecular targets of a neuroprotective compound dimebon using a transgenic mouse line. <b>2013</b> , 7, 154-159	
1919	<sup>3</sup> H-deprenyl and <sup>3</sup> H-PIB autoradiography show different laminar distributions of astroglia and fibrillar $\beta$ amyloid in Alzheimer brain. <b>2013</b> , 10, 90	38
1918	A canine model of human aging and Alzheimer's disease. <b>2013</b> , 1832, 1384-9	75
1917	Distinct patterns of medial temporal impairment in degenerative dementia: a brain SPECT perfusion study in Alzheimer's disease and frontotemporal dementia. <b>2013</b> , 40, 932-42	3
1916	Globular glial-like inclusions in a patient with advanced Alzheimer's disease. <b>2013</b> , 126, 155-7	8
1915	Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. <b>2013</b> , 501, 45-51	1033
1914	Non-invasive infra-red therapy (1072 nm) reduces $\beta$ amyloid protein levels in the brain of an Alzheimer's disease mouse model, TASTPM. <b>2013</b> , 123, 13-22	55
1913	Tissue transglutaminase colocalizes with extracellular matrix proteins in cerebral amyloid angiopathy. <b>2013</b> , 34, 1159-69	30
1912	Striatal morphology in early-onset and late-onset Alzheimer's disease: a preliminary study. <b>2013</b> , 34, 1728-39	36
1911	Primary progressive aphasia with parkinsonism. <b>2013</b> , 28, 741-6	3
1910	Amyloid $\beta$ precursor protein as a molecular target for amyloid $\beta$ induced neuronal degeneration in Alzheimer's disease. <b>2013</b> , 34, 2525-37	33
1909	The relationship between cerebral amyloid angiopathy and cortical microinfarcts in brain ageing and Alzheimer's disease. <b>2013</b> , 39, 498-509	71
1908	Magnetic resonance imaging of fixed post mortem brains reliably reflects subcortical vascular pathology of frontal, parietal and occipital white matter. <b>2013</b> , 39, 485-97	18
1907	Pathology of clinical and preclinical Alzheimer's disease. <b>2013</b> , 263 Suppl 2, S137-45	39
1906	Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases. <b>2013</b> , 521, 4339-55	41
1905	Cerebral amyloid PET imaging in Alzheimer's disease. <b>2013</b> , 126, 643-57	79

1904	Molecular mechanism for age-related memory loss: the histone-binding protein RbAp48. <b>2013</b> , 5, 200ra115	80
1903	Amyloid PET Imaging: MCI and AD. <b>2013</b> , 8, 431-45	2
1902	Can infections cause Alzheimer's disease?. <b>2013</b> , 35, 161-80	65
1901	Meta-analysis of functional network alterations in Alzheimer's disease: toward a network biomarker. <b>2013</b> , 37, 753-65	81
1900	Synthesis and biological evaluation of novel styryl benzimidazole derivatives as probes for imaging of neurofibrillary tangles in Alzheimer's disease. <b>2013</b> , 21, 3356-62	24
1899	Rapidly progressive dementia with thalamic degeneration and peculiar cortical prion protein immunoreactivity, but absence of proteinase K resistant PrP: a new disease entity?. <b>2013</b> , 1, 72	10
1898	Early molecular changes in Alzheimer disease: can we catch the disease in its presymptomatic phase?. <b>2014</b> , 38, 719-40	36
1897	The receiver operational characteristic for binary classification with multiple indices and its application to the neuroimaging study of Alzheimer's disease. <b>2013</b> , 10, 173-80	19
1896	Caspase-6 as a novel early target in the treatment of Alzheimer's disease. <b>2013</b> , 37, 2005-18	45
1895	Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents. <b>2013</b> , 34, 22-34	48
1894	Liraglutide protects against amyloid- $\beta$ protein-induced impairment of spatial learning and memory in rats. <b>2013</b> , 34, 576-88	96
1893	MAPT H1 haplotype is associated with enhanced $\beta$ synuclein deposition in dementia with Lewy bodies. <b>2013</b> , 34, 936-42	39
1892	Time-of-flight secondary ion mass spectrometry (TOF-SIMS) imaging reveals cholesterol overload in the cerebral cortex of Alzheimer disease patients. <b>2013</b> , 125, 133-44	97
1891	Tau pathology in frontotemporal lobar degeneration with C9ORF72 hexanucleotide repeat expansion. <b>2013</b> , 125, 289-302	75
1890	Extracellular matrix modulator lysyl oxidase colocalizes with amyloid-beta pathology in Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis--Dutch type. <b>2013</b> , 48, 109-14	12
1889	Dose-dependent improvements in learning and memory deficits in APPPS1-21 transgenic mice treated with the orally active A $\beta$ toxicity inhibitor SEN1500. <b>2013</b> , 75, 458-66	11
1888	TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT. <b>2013</b> , 34, 2889.e5-9	33
1887	Disclosure of amyloid imaging results to research participants: has the time come?. <b>2013</b> , 9, 741-744.e2	34

1886	Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease. <b>2013</b> , 2, 497-511	74
1885	Regional brain volume differences in symptomatic and presymptomatic carriers of familial Alzheimer's disease mutations. <b>2013</b> , 84, 154-62	41
1884	Calcium-sensing receptor antagonist (calcilytic) NPS 2143 specifically blocks the increased secretion of endogenous A $\beta$ 2 prompted by exogenous fibrillary or soluble A $\beta$ 5-35 in human cortical astrocytes and neurons-therapeutic relevance to Alzheimer's disease. <b>2013</b> , 1832, 1634-52	43
1883	Drain of the brain: low-affinity p75 neurotrophin receptor affords a molecular sink for clearance of cortical amyloid by the cholinergic modulator system. <b>2013</b> , 34, 2517-24	15
1882	Tauroursodeoxycholic acid (TUDCA) supplementation prevents cognitive impairment and amyloid deposition in APP/PS1 mice. <b>2013</b> , 50, 21-9	63
1881	Sex steroid levels and AD-like pathology in 3xTgAD mice. <b>2013</b> , 25, 131-144	30
1880	Sequence variants in eukaryotic translation initiation factor 4-gamma (eIF4G1) are associated with Lewy body dementia. <b>2013</b> , 125, 425-38	16
1879	Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. <b>2013</b> , 12, 443-53	472
1878	Neurodegenerative Diseases. <b>2013</b> , 151-173	1
1877	Clathrin adaptor CALM/PICALM is associated with neurofibrillary tangles and is cleaved in Alzheimer's brains. <b>2013</b> , 125, 861-78	88
1876	Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study. <b>2013</b> , 19, 717-24	104
1875	Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid- $\beta$ changes occur before increases of tau in cerebrospinal fluid. <b>2013</b> , 126, 631-41	103
1874	Brain regional correlation of amyloid- $\beta$ with synapses and apolipoprotein E in non-demented individuals: potential mechanisms underlying regional vulnerability to amyloid- $\beta$ accumulation. <b>2013</b> , 125, 535-47	42
1873	C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. <b>2013</b> , 126, 845-57	225
1872	Prospective flutemetamol positron emission tomography and histopathology in normal pressure hydrocephalus. <b>2014</b> , 13, 237-45	16
1871	Amyloid- $\beta$ positron emission tomography imaging probes: a critical review. <b>2013</b> , 36, 613-31	56
1870	Progressive amnesic dementia, hippocampal sclerosis, and mutation in C9ORF72. <b>2013</b> , 126, 545-54	22
1869	Induced pluripotent stem cells as tools for disease modelling and drug discovery in Alzheimer's disease. <b>2013</b> , 120, 103-11	37



1868	The Arctic A $\beta$ P mutation leads to Alzheimer's disease pathology with highly variable topographic deposition of differentially truncated A $\beta$ <b>2013</b> , 1, 60	27
1867	In vivo characterization of the early states of the amyloid-beta network. <b>2013</b> , 136, 2239-52	84
1866	Comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology. <i>Neurology</i> , <b>2013</b> , 80, 2121-9	6.5 37
1865	Making the diagnosis of frontotemporal lobar degeneration. <b>2013</b> , 137, 314-25	22
1864	Confluence of $\beta$ -synuclein, tau, and $\beta$ -amyloid pathologies in dementia with Lewy bodies. <b>2013</b> , 72, 1203-12	106
1863	The interest of amyloid PET imaging in the diagnosis of Alzheimer's disease. <b>2013</b> , 26, 646-55	16
1862	Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center. <b>2013</b> , 72, 1182-92	72
1861	Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson's disease-related dementia. <b>2013</b> , 84, 774-83	148
1860	Amyloid imaging in dementia. <b>2013</b> , 23, 43-60	
1859	Changes in brain function occur years before the onset of cognitive impairment. <b>2013</b> , 33, 18008-14	120
1858	Amyloid- $\beta$ load predicts medial temporal lobe dysfunction in Alzheimer dementia. <b>2013</b> , 54, 1909-14	18
1857	Positron emission tomography with [18F]flutemetamol and [11C]PiB for in vivo detection of cerebral cortical amyloid in normal pressure hydrocephalus patients. <b>2013</b> , 20, 1043-52	33
1856	Molecular Pathology of Alzheimer's Disease. <b>2013</b> , 1, 1-91	1
1855	Val $\beta$ GLP-1 remodels synaptic activity and intracellular calcium homeostasis impaired by amyloid $\beta$ peptide in rats. <b>2013</b> , 91, 568-77	19
1854	In vivo assessment of amyloid- $\beta$ deposition in nondemented very elderly subjects. <b>2013</b> , 73, 751-61	80
1853	Loss of deep cerebellar nuclei neurons in the 3xTg-AD mice and protection by an anti-amyloid $\beta$ antibody fragment. <b>2013</b> , 5, 660-4	20
1852	Alzheimer's disease: the downside of a highly evolved parietal lobe?. <b>2013</b> , 35, 227-40	59
1851	What can we learn from regional vulnerability to amyloid- $\beta$ accumulation in nondemented individuals?. <b>2013</b> , 3, 187-189	2

1850	Increased apolipoprotein D dimer formation in Alzheimer's disease hippocampus is associated with lipid conjugated diene levels. <b>2013</b> , 35, 475-86	19
1849	Postmortem 3-D brain hemisphere cortical tau and amyloid- $\beta$ pathology mapping and quantification as a validation method of neuropathology imaging. <b>2013</b> , 36, 261-74	26
1848	[Amyloid aggregates: role in Protein Misfolding Disorders]. <b>2013</b> , 141, 495-505	3
1847	Hereditary and sporadic beta-amyloidoses. <b>2013</b> , 18, 1202-26	6
1846	MR microscopy of human amyloid- $\beta$ deposits: characterization of parenchymal amyloid, diffuse plaques, and vascular amyloid. <b>2013</b> , 34, 1037-49	15
1845	Perspectives in molecular imaging using staging biomarkers and immunotherapies in Alzheimer's disease. <b>2013</b> , 2013, 589308	7
1844	Immunolocalization of Kisspeptin Associated with Amyloid- $\beta$ Deposits in the Pons of an Alzheimer's Disease Patient. <b>2013</b> , 2013, 879710	3
1843	Cholesterol and copper affect learning and memory in the rabbit. <b>2013</b> , 2013, 518780	11
1842	Neuropathology of Alzheimer's Disease. <b>2014</b> , 2014-2020	0
1841	MR-less surface-based amyloid assessment based on $^{11}\text{C}$ PiB PET. <b>2014</b> , 9, e84777	29
1840	Amyloid beta: multiple mechanisms of toxicity and only some protective effects?. <b>2014</b> , 2014, 795375	75
1839	Prevention approaches in a preclinical canine model of Alzheimer's disease: benefits and challenges. <b>2014</b> , 5, 47	20
1838	What is the role of spatial processing in the decline of episodic memory in Alzheimer's disease? The "mental frame syncing" hypothesis. <b>2014</b> , 6, 33	14
1837	Meta-Review of CSF Core Biomarkers in Alzheimer's Disease: The State-of-the-Art after the New Revised Diagnostic Criteria. <b>2014</b> , 6, 47	74
1836	Aging reduces glial uptake and promotes extracellular accumulation of A $\beta$ from a lentiviral vector. <b>2014</b> , 6, 210	19
1835	Why looking at the whole hippocampus is not enough-a critical role for anteroposterior axis, subfield and activation analyses to enhance predictive value of hippocampal changes for Alzheimer's disease diagnosis. <b>2014</b> , 8, 95	73
1834	Positive florbetapir PET amyloid imaging in a subject with frequent cortical neuritic plaques and frontotemporal lobar degeneration with TDP43-positive inclusions. <b>2014</b> , 42, 813-21	20
1833	Neuropathology of Dementia Disorders. <b>2014</b> , 04,	7

1832	Models of Amyloid induced Tau-pathology: the long and "folded" road to understand the mechanism. <b>2014</b> , 9, 51		172
1831	Extracellular monomeric tau protein is sufficient to initiate the spread of tau protein pathology. <b>2014</b> , 289, 956-67		111
1830	Amyloid induces a dying-back process and remote trans-synaptic alterations in a microfluidic-based reconstructed neuronal network. <b>2014</b> , 2, 145		28
1829	A platelet protein biochip rapidly detects an Alzheimer's disease-specific phenotype. <b>2014</b> , 128, 665-77		31
1828	Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease. <b>2014</b> , 2, 135		175
1827	The hippocampus in neurodegenerative disease. <b>2014</b> , 34, 95-108		65
1826	Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology. <i>Neurology</i> , <b>2014</b> , 83, 434-40	6.5	51
1825	Atypical Alzheimer's disease in an elderly United States resident with amyotrophic lateral sclerosis and pathological tau in spinal motor neurons. <b>2014</b> , 15, 466-72		1
1824	Protective effect of pranlukast on Aβ-induced cognitive deficits associated with downregulation of cysteinyl leukotriene receptor 1. <b>2014</b> , 17, 581-92		31
1823	Amyloid deposition is decreasing in aging brains: an autopsy study of 1,599 older people. <i>Neurology</i> , <b>2014</b> , 82, 326-31	6.5	28
1822	Regional neuronal network failure and cognition in late-onset sporadic Alzheimer disease. <b>2014</b> , 35, S18-30		8
1821	A theoretical framework for cognitive and non-cognitive interventions for older adults: stimulation versus compensation. <b>2014</b> , 18, 304-15		22
1820	Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer's disease: association with cognitive impairment. <b>2014</b> , 35, 2836-2844		74
1819	Amyloid is transmitted via neuronal connections along axonal membranes. <b>2014</b> , 75, 88-97		71
1818	Phosphatidylinositol-4,5-bisphosphate is enriched in granulovacuolar degeneration bodies and neurofibrillary tangles. <b>2014</b> , 40, 489-501		19
1817	Morphometry of the hippocampal microvasculature in post-stroke and age-related dementias. <b>2014</b> , 40, 284-95		36
1816	Cerebrospinal fluid biomarker and brain biopsy findings in idiopathic normal pressure hydrocephalus. <b>2014</b> , 9, e91974		66
1815	Prevalence of mixed pathologies in the aging brain. <b>2014</b> , 6, 82		158

1814	TDP-43 pathology in the basal forebrain and hypothalamus of patients with amyotrophic lateral sclerosis. <b>2014</b> , 2, 171	51
1813	Theoretical impact of Florbetapir (18F) amyloid imaging on diagnosis of Alzheimer's dementia and detection of preclinical cortical amyloid. <b>2014</b> , 73, 948-53	25
1812	Alzheimer disease and cellular mechanisms of memory storage. <b>2014</b> , 73, 192-205	16
1811	Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates. <b>2014</b> , 73, 72-80	31
1810	Alzheimer's Disease. <b>2014</b> , 122-127	5
1809	Emerging amyloid pathology and accelerated cortical atrophy. <b>2014</b> , 71, 725-34	43
1808	Concomitant progressive supranuclear palsy and chronic traumatic encephalopathy in a boxer. <b>2014</b> , 2, 24	16
1807	Dynamin protein in stroke and vascular dementia. <b>2014</b> , 563, 118-22	3
1806	Alzheimer's disease-related plaques in nondemented subjects. <b>2014</b> , 10, 522-9	6
1805	Involvement of cysteinyl leukotriene receptor 1 in A $\beta$ -42-induced neurotoxicity in vitro and in vivo. <b>2014</b> , 35, 590-9	50
1804	Diagnosticare la malattia di Alzheimer. <b>2014</b> , 14, 1-14	
1803	Linking pathways in the developing and aging brain with neurodegeneration. <b>2014</b> , 269, 152-72	42
1802	Olfactory bulb involvement in neurodegenerative diseases. <b>2014</b> , 127, 459-75	183
1801	Lesion of the subiculum reduces the spread of amyloid beta pathology to interconnected brain regions in a mouse model of Alzheimer's disease. <b>2014</b> , 2, 17	13
1800	Reduced sphingosine kinase-1 and enhanced sphingosine 1-phosphate lyase expression demonstrate deregulated sphingosine 1-phosphate signaling in Alzheimer's disease. <b>2014</b> , 2, 12	80
1799	Distinct patterns of sirtuin expression during progression of Alzheimer's disease. <b>2014</b> , 16, 405-14	76
1798	Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease. <b>2014</b> , 88, 508-16	153
1797	The complexities of the pathology-pathogenesis relationship in Alzheimer disease. <b>2014</b> , 88, 671-6	69

1796	Ceramides and sphingomyelinases in senile plaques. <b>2014</b> , 65, 193-201	36
1795	Early detection of Alzheimer's disease using PiB and FDG PET. <b>2014</b> , 72 Pt A, 117-22	131
1794	Understanding the cause of sporadic Alzheimer's disease. <b>2014</b> , 14, 621-30	31
1793	Region-specific expression of tau, amyloid- $\beta$ protein precursor, and synaptic proteins at physiological condition or under endoplasmic reticulum stress in rats. <b>2014</b> , 41, 1149-63	20
1792	Cerebrospinal fluid $\beta$ amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. <b>2014</b> , 76, 223-30	88
1791	Human APOE genotype affects intraneuronal A $\beta$ -42 accumulation in a lentiviral gene transfer model. <b>2014</b> , 23, 1365-75	26
1790	First patho-anatomical investigation of the brain of a SCA19 patient. <b>2014</b> , 40, 640-4	7
1789	Up-regulation of $\beta$ amyloidogenesis in neuron-like human cells by both 24- and 27-hydroxycholesterol: protective effect of N-acetyl-cysteine. <b>2014</b> , 13, 561-72	40
1788	Regional analysis of striatal and cortical amyloid deposition in patients with Alzheimer's disease. <b>2014</b> , 40, 2701-6	20
1787	Unilateral injection of A $\beta$ in the hippocampus reduces the number of dendritic spines in hyperglycemic rats. <b>2014</b> , 68, 585-594	20
1786	Are cases with tau pathology occurring in the absence of A $\beta$ deposits part of the AD-related pathological process?. <b>2014</b> , 128, 767-72	66
1785	Cerebral microbleeds: Spatial distribution implications. <b>2014</b> , 5,	3
1784	Aging in the canine and feline brain. <b>2014</b> , 44, 1113-29	37
1783	Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations. <b>2014</b> , 20, 1009-14	31
1782	Enhancement of binding affinity for amyloid aggregates by multivalent interactions of <sup>99m</sup> Tc-hydroxamamide complexes. <b>2014</b> , 11, 1132-9	20
1781	Pin1 promotes degradation of Smad proteins and their interaction with phosphorylated tau in Alzheimer's disease. <b>2014</b> , 40, 815-32	10
1780	Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. <b>2014</b> , 20, 130-8	422
1779	CSF in Alzheimer's disease. <b>2014</b> , 65, 143-72	18

1778	Flow cytometry analysis of synaptosomes from post-mortem human brain reveals changes specific to Lewy body and Alzheimer's disease. <b>2014</b> , 94, 1161-72	24
1777	Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias. <b>2014</b> , 6, 1	110
1776	Soluble amyloid beta levels are elevated in the white matter of Alzheimer's patients, independent of cortical plaque severity. <b>2014</b> , 2, 83	29
1775	Protease-resistant SOD1 aggregates in amyotrophic lateral sclerosis demonstrated by paraffin-embedded tissue (PET) blot. <b>2014</b> , 2, 130	6
1774	Intracellular amyloid and the neuronal origin of Alzheimer neuritic plaques. <b>2014</b> , 71, 53-61	57
1773	Pyroglutamylated amyloid- $\beta$ s associated with hyperphosphorylated tau and severity of Alzheimer's disease. <b>2014</b> , 128, 67-79	48
1772	TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord. <b>2014</b> , 128, 423-37	143
1771	Diagnostic effectiveness of quantitative [ $^{18}$ F]flutemetamol PET imaging for detection of fibrillar amyloid $\beta$ using cortical biopsy histopathology as the standard of truth in subjects with idiopathic normal pressure hydrocephalus. <b>2014</b> , 2, 46	16
1770	Biochemical stages of amyloid- $\beta$ peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease. <b>2014</b> , 137, 887-903	109
1769	Serial propagation of distinct strains of A $\beta$ prions from Alzheimer's disease patients. <b>2014</b> , 111, 10323-8	214
1768	Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer's disease. <b>2014</b> , 137, 1533-49	83
1767	Network dysfunction in Alzheimer's disease: refining the disconnection hypothesis. <b>2014</b> , 4, 299-311	100
1766	White matter hyperintensities are positively associated with cortical thickness in Alzheimer's disease. <b>2014</b> , 39, 409-22	23
1765	Myeloid microvesicles in cerebrospinal fluid are associated with myelin damage and neuronal loss in mild cognitive impairment and Alzheimer disease. <b>2014</b> , 76, 813-25	62
1764	Lixisenatide rescues spatial memory and synaptic plasticity from amyloid $\beta$ protein-induced impairments in rats. <b>2014</b> , 277, 6-13	56
1763	A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. <b>2014</b> , 10, 477-484.e1	118
1762	SET translocation is associated with increase in caspase cleaved amyloid precursor protein in CA1 of Alzheimer and Down syndrome patients. <b>2014</b> , 35, 958-68	11
1761	LRP-1 polymorphism is associated with global and regional amyloid load in Alzheimer's Disease in humans in-vivo. <b>2014</b> , 4, 411-6	14

1760	Basal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjects. <b>2014</b> , 10, S344-53	58
1759	Redox proteomics and the dynamic molecular landscape of the aging brain. <b>2014</b> , 13, 75-89	50
1758	Montelukast targeting the cysteinyl leukotriene receptor 1 ameliorates A $\beta$ -42-induced memory impairment and neuroinflammatory and apoptotic responses in mice. <b>2014</b> , 79, 707-14	62
1757	Loss of Calbindin immunoreactivity in the dentate gyrus distinguishes Alzheimer's disease from other neurodegenerative dementias. <b>2014</b> , 566, 137-41	17
1756	Disrupted cross-laminar cortical processing in $\beta$ amyloid pathology precedes cell death. <b>2014</b> , 63, 62-73	16
1755	Cortical phase changes in Alzheimer's disease at 7T MRI: a novel imaging marker. <b>2014</b> , 10, e19-26	35
1754	Cholinergic basal forebrain atrophy predicts amyloid burden in Alzheimer's disease. <b>2014</b> , 35, 482-91	77
1753	A comparison of A $\beta$ amyloid pathology staging systems and correlation with clinical diagnosis. <b>2014</b> , 128, 543-50	18
1752	Firing properties of entorhinal cortex neurons and early alterations in an Alzheimer's disease transgenic model. <b>2014</b> , 466, 1437-50	25
1751	The intersection of amyloid beta and tau at synapses in Alzheimer's disease. <b>2014</b> , 82, 756-71	610
1750	The role of egocentric and allocentric abilities in Alzheimer's disease: a systematic review. <b>2014</b> , 16, 32-44	71
1749	Patterns of cerebral amyloid angiopathy define histopathological phenotypes in Alzheimer's disease. <b>2014</b> , 40, 136-48	34
1748	Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. <b>2014</b> , 5, 88	413
1747	Conventional brain imaging of white matter lesions. 117-128	
1746	The co-occurrence of Alzheimer's disease and Huntington's disease: a neuropathological study of 15 elderly Huntington's disease subjects. <b>2014</b> , 3, 209-17	32
1745	Spreading of amyloid, tau, and microvascular pathology in Alzheimer's disease: findings from neuropathological and neuroimaging studies. <b>2014</b> , 42 Suppl 4, S421-9	60
1744	Cerebral small vessel disease: cerebrospinal fluid aspects. 200-216	
1743	Retrograde memory for public events in mild cognitive impairment and its relationship to anterograde memory and neuroanatomy. <b>2014</b> , 28, 959-72	6

1742	Use of magnetization transfer contrast MRI to detect early molecular pathology in Alzheimer's disease. <b>2014</b> , 71, 333-8	17
1741	Cardiorespiratory Fitness Attenuates the Influence of Amyloid on Cognition. <b>2015</b> , 21, 841-50	37
1740	Controlling the Regional Identity of hPSC-Derived Neurons to Uncover Neuronal Subtype Specificity of Neurological Disease Phenotypes. <b>2015</b> , 5, 1010-1022	66
1739	Neuropsychological Markers of Cognitive Decline in Persons With Alzheimer Disease Neuropathology. <b>2015</b> , 74, 1086-92	19
1738	Neuropathologic features of suicide victims who presented with acute poststroke depression: significance of association with neurodegenerative disorders. <b>2015</b> , 74, 401-10	9
1737	Quantitative phosphoproteomic analyses of the inferior parietal lobule from three different pathological stages of Alzheimer's disease. <b>2016</b> , 49, 45-62	23
1736	Projecting Burden of Dementia in Spain, 2010-2050: Impact of Modifying Risk Factors. <b>2015</b> , 48, 721-30	19
1735	Tau and Amyloid- $\beta$ Cerebrospinal Fluid Biomarkers have Differential Relationships with Cognition in Mild Cognitive Impairment. <b>2015</b> , 47, 965-75	16
1734	Identification of neurotoxic cytokines by profiling Alzheimer's disease tissues and neuron culture viability screening. <b>2015</b> , 5, 16622	40
1733	String Vessel Formation is Increased in the Brain of Parkinson Disease. <b>2015</b> , 5, 821-36	27
1732	Decreased Levels of VAMP2 and Monomeric Alpha-Synuclein Correlate with Duration of Dementia. <b>2016</b> , 50, 101-10	18
1731	Neuronal activity and amyloid plaque pathology: an update. <b>2016</b> , 49, 13-9	22
1730	Cortical tau load is associated with white matter hyperintensities. <b>2015</b> , 3, 60	73
1729	Distribution of $\beta$ -Synuclein in the spinal cord and dorsal root ganglia in an autopsy cohort of elderly persons. <b>2015</b> , 3, 57	41
1728	Lovastatin Differentially Affects Neuronal Cholesterol and Amyloid- $\beta$ Production in vivo and in vitro. <b>2015</b> , 21, 631-41	10
1727	Patterns of Tau and $\beta$ -Synuclein Pathology in the Visual System. <b>2015</b> , 5, 333-40	9
1726	Neurodegeneration and sport. <b>2015</b> , 76, 643-55; discussion 655-6	28
1725	Post-Mortem evaluation of amyloid-dopamine terminal positron emission tomography dementia classifications. <b>2015</b> , 78, 824-30	8



1724	Relationship of medial temporal lobe atrophy, APOE genotype, and cognitive reserve in preclinical Alzheimer's disease. <b>2015</b> , 36, 2826-41	68
1723	Autopsy case of spinocerebellar ataxia type 31 with severe dementia at the terminal stage. <b>2015</b> , 35, 273-9	7
1722	An autopsy case of hemiconvulsion-hemiplegia-epilepsy syndrome manifesting as cerebral hemiatrophy in an elderly man. <b>2015</b> , 35, 592-8	2
1721	Multimodality Imaging Approaches in Alzheimer's disease. Part II: 1H MR spectroscopy, FDG PET and Amyloid PET. <b>2015</b> , 9, 330-342	3
1720	Hierarchical Distribution of the Tau Cytoskeletal Pathology in the Thalamus of Alzheimer's Disease Patients. <b>2016</b> , 49, 905-15	14
1719	Role of Different Alpha-Synuclein Strains in Synucleinopathies, Similarities with other Neurodegenerative Diseases. <b>2015</b> , 5, 217-27	87
1718	I716F A $\beta$ P mutation associates with the deposition of oligomeric pyroglutamate amyloid- $\beta$ and Synucleinopathy with Lewy bodies. <b>2015</b> , 44, 103-14	9
1717	Modeling clustered activity increase in amyloid-beta positron emission tomographic images with statistical descriptors. <b>2015</b> , 10, 759-70	4
1716	Neurodegenerative changes in the brainstem and olfactory bulb in people older than 50 years old: a descriptive study. <b>2015</b> , 73, 569-77	2
1715	Olfactory bulb proteome dynamics during the progression of sporadic Alzheimer's disease: identification of common and distinct olfactory targets across Alzheimer-related co-pathologies. <b>2015</b> , 6, 39437-56	50
1714	Clearance of amyloid $\beta$ protein and its role in the spreading of Alzheimer's disease pathology. <b>2015</b> , 7, 25	19
1713	Dissecting Alzheimer disease in Down syndrome using mouse models. <b>2015</b> , 9, 268	29
1712	PET Imaging of Tau Pathology in Alzheimer's Disease and Tauopathies. <b>2015</b> , 6, 38	65
1711	Abnormal Paraplegin Expression in Swollen Neurites, $\beta$ and Synuclein Pathology in a Case of Hereditary Spastic Paraplegia SPG7 with an Ala510Val Mutation. <b>2015</b> , 16, 25050-66	11
1710	Turning on the Light Within: Subcortical Nuclei of the Isodentric Core and their Role in Alzheimer's Disease Pathogenesis. <b>2015</b> , 46, 17-34	49
1709	A reduced astrocyte response to $\beta$ amyloid plaques in the ageing brain associates with cognitive impairment. <b>2015</b> , 10, e0118463	36
1708	Neuroimaging in Dementias. <b>2015</b> , 107-118	
1707	Integrating retrogenesis theory to Alzheimer's disease pathology: insight from DTI-TBSS investigation of the white matter microstructural integrity. <b>2015</b> , 2015, 291658	42

1706	Oxidative Stress and Protein Quality Control Systems in the Aged Canine Brain as a Model for Human Neurodegenerative Disorders. <b>2015</b> , 2015, 940131		18
1705	Systems biology of neurodegenerative diseases. <b>2015</b> , 7, 758-75		32
1704	Loss of endophilin-B1 exacerbates Alzheimer's disease pathology. <b>2015</b> , 138, 2005-19		21
1703	Near infrared light mitigates cerebellar pathology in transgenic mouse models of dementia. <b>2015</b> , 591, 155-159		42
1702	Cortical laminar binding of PET amyloid and tau tracers in Alzheimer disease. <b>2015</b> , 56, 270-3		18
1701	Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program. <b>2015</b> , 35, 354-89		211
1700	Mitochondrial targeting sequence variants of the CHCHD2 gene are a risk for Lewy body disorders. <i>Neurology</i> , <b>2015</b> , 85, 2016-25	6.5	40
1699	Roles of LIM kinases in central nervous system function and dysfunction. <b>2015</b> , 589, 3795-806		28
1698	Chronic traumatic encephalopathy pathology in a neurodegenerative disorders brain bank. <b>2015</b> , 130, 877-89		176
1697	[(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid- $\beta$ pathology. <b>2015</b> , 11, 975-85		93
1696	Prion Disease Induces Alzheimer Disease-Like Neuropathologic Changes. <b>2015</b> , 74, 873-88		25
1695	Correlations between mini-mental state examination score, cerebrospinal fluid biomarkers, and pathology observed in brain biopsies of patients with normal-pressure hydrocephalus. <b>2015</b> , 74, 470-9		40
1694	Computer-aided discovery of novel non-peptide inhibitors against amyloid-beta (A $\beta$ ) peptide aggregation for treating Alzheimer's disease. <b>2015</b> , 41, 622-632		5
1693	The role of telomerase protein TERT in Alzheimer's disease and in tau-related pathology in vitro. <b>2015</b> , 35, 1659-74		80
1692	Progression of Seed-Induced A $\beta$ Deposition within the Limbic Connectome. <b>2015</b> , 25, 743-52		38
1691	Brain amyloid-beta fragment signatures in pathological ageing and Alzheimer's disease by hybrid immunoprecipitation mass spectrometry. <b>2015</b> , 15, 50-7		33
1690	Protein aggregation in Alzheimer's disease: A $\beta$ and $\tau$ and their potential roles in the pathogenesis of AD. <b>2015</b> , 129, 163-5		37
1689	APOE $\epsilon$ 2 is associated with milder clinical and pathological Alzheimer disease. <b>2015</b> , 77, 917-29		82

1688	Degree of abnormality is associated with rate of change in measures of beta-amyloid, glucose metabolism and cognition in an autopsy-verified Alzheimer's disease case. <b>2015</b> , 21, 738-47	
1687	Diagnostic differentiation of mild cognitive impairment due to Alzheimer's disease using a hippocampus-dependent test of spatial memory. <b>2015</b> , 25, 939-51	42
1686	Spreading of pathology in neurodegenerative diseases: a focus on human studies. <b>2015</b> , 16, 109-20	484
1685	Relevance of parahippocampal-locus coeruleus connectivity to memory in early dementia. <b>2015</b> , 36, 618-26	41
1684	Drug access to the central nervous system in Alzheimer's disease: preclinical and clinical insights. <b>2015</b> , 32, 819-39	27
1683	PART is part of Alzheimer disease. <b>2015</b> , 129, 749-56	198
1682	Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes. <b>2015</b> , 129, 729-48	120
1681	Scanning ultrasound removes amyloid- $\beta$ and restores memory in an Alzheimer's disease mouse model. <b>2015</b> , 7, 278ra33	292
1680	Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. <b>2015</b> , 138, 1370-81	224
1679	NEURODEGENERATION. Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled A $\beta$ tau, and $\beta$ synuclein. <b>2015</b> , 349, 1255555	564
1678	Cerebral amyloid angiopathy and its co-occurrence with Alzheimer's disease and other cerebrovascular neuropathologic changes. <b>2015</b> , 36, 2702-8	73
1677	Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging. <b>2015</b> , 42, 1492-506	9
1676	When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients. <i>Neurology</i> , <b>2015</b> , 85, 4046-53	182
1675	The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. <b>2015</b> , 138, 2732-49	275
1674	Lipidomics of human brain aging and Alzheimer's disease pathology. <b>2015</b> , 122, 133-89	86
1673	Analyzing dendritic spine pathology in Alzheimer's disease: problems and opportunities. <b>2015</b> , 130, 1-19	106
1672	Screening for $\beta$ synuclein immunoreactive neuronal inclusions in the hippocampus allows identification of atypical MSA (FTLD-synuclein). <b>2015</b> , 130, 299-301	20
1671	Loss of lysosome-associated membrane protein 3 (LAMP3) enhances cellular vulnerability against proteasomal inhibition. <b>2015</b> , 94, 148-61	17

1670	Brain collection, standardized neuropathologic assessment, and comorbidity in Alzheimer's Disease Neuroimaging Initiative 2 participants. <b>2015</b> , 11, 815-22	23
1669	Analysis of calretinin early expression in the rat hippocampus after beta amyloid (1-42) peptide injection. <b>2015</b> , 1610, 89-97	8
1668	Pathological features of preclinical or early clinical stages of corticobasal degeneration: a comparison with advanced cases. <b>2015</b> , 41, 893-905	16
1667	Fitting the epidemiology and neuropathology of the early stages of Alzheimer's disease to prevent dementia. <b>2015</b> , 7, 2	17
1666	Early neurone loss in Alzheimer's disease: cortical or subcortical?. <b>2015</b> , 3, 10	101
1665	A novel mutation P112H in the TARDBP gene associated with frontotemporal lobar degeneration without motor neuron disease and abundant neuritic amyloid plaques. <b>2015</b> , 3, 19	37
1664	Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer's disease. <b>2015</b> , 3, 14	122
1663	Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 $\beta$ Amyloid Measures Across the Spectrum of Alzheimer Disease. <b>2015</b> , 72, 571-81	73
1662	Atypical sporadic CJD-MM phenotype with white matter kuru plaques associated with intranuclear inclusion body and argyrophilic grain disease. <b>2015</b> , 35, 336-42	8
1661	Atypical multiple system atrophy is a new subtype of frontotemporal lobar degeneration: frontotemporal lobar degeneration associated with $\beta$ synuclein. <b>2015</b> , 130, 93-105	51
1660	Acute amnesic encephalopathy in amyloid- $\beta$ oligomer-injected mice is due to their widespread diffusion in vivo. <b>2015</b> , 36, 2043-52	16
1659	Amyloid polymorphism: structural basis and neurobiological relevance. <b>2015</b> , 86, 632-45	257
1658	Olfactory dysfunction: its early temporal relationship and neural correlates in the pathogenesis of Alzheimer's disease. <b>2015</b> , 122, 1475-97	38
1657	PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. <b>2015</b> , 129, 757-62	109
1656	Neuroinflammatory signals in Alzheimer disease and APP/PS1 transgenic mice: correlations with plaques, tangles, and oligomeric species. <b>2015</b> , 74, 319-44	86
1655	Staging of cognitive deficits and neuropathological and ultrastructural changes in streptozotocin-induced rat model of Alzheimer's disease. <b>2015</b> , 122, 577-92	63
1654	Accelerating Alzheimer's research through 'natural' animal models. <b>2015</b> , 28, 155-64	30
1653	Combined Alzheimer's disease and cerebrovascular staging explains advanced dementia cognition. <b>2015</b> , 11, 1358-66	10

1652	Microglial malfunction: the third rail in the development of Alzheimer's disease. <b>2015</b> , 38, 621-636	85
1651	Beta Amyloid Hallmarks: From Intrinsically Disordered Proteins to Alzheimer's Disease. <b>2015</b> , 870, 401-21	19
1650	A Recurrent Mutation in CACNA1G Alters Cav3.1 T-Type Calcium-Channel Conduction and Causes Autosomal-Dominant Cerebellar Ataxia. <b>2015</b> , 97, 726-37	72
1649	Stereological estimation of neuron number and plaque load in the hippocampal region of a transgenic rat model of Alzheimer's disease. <b>2015</b> , 41, 1245-62	34
1648	Assessment of the degree of asymmetry of pathological features in neurodegenerative diseases. What is the significance for brain banks?. <b>2015</b> , 122, 1499-508	8
1647	No neuropathological evidence for a direct topographical relation between microbleeds and cerebral amyloid angiopathy. <b>2015</b> , 3, 49	18
1646	Regional mosaic genomic heterogeneity in the elderly and in Alzheimer's disease as a correlate of neuronal vulnerability. <b>2015</b> , 130, 501-10	31
1645	The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data. <b>2015</b> , 11, 1050-68	79
1644	Parametric imaging and quantitative analysis of the PET amyloid ligand [(18)F]flutemetamol. <b>2015</b> , 121, 184-92	17
1643	The preclinical phase of the pathological process underlying sporadic Alzheimer's disease. <b>2015</b> , 138, 2814-33	260
1642	Asymmetries of amyloid- $\beta$ burden and neuronal dysfunction are positively correlated in Alzheimer's disease. <b>2015</b> , 138, 3089-99	39
1641	$\beta$ Amyloid binding in elderly subjects with declining or stable episodic memory function measured with PET and [ <sup>11</sup> C]AZD2184. <b>2015</b> , 42, 1507-11	4
1640	Persistence of A $\beta$ seeds in APP null mouse brain. <b>2015</b> , 18, 1559-61	45
1639	Heroin abuse exaggerates age-related deposition of hyperphosphorylated tau and p62-positive inclusions. <b>2015</b> , 36, 3100-3107	37
1638	Evidence for human transmission of amyloid- $\beta$ pathology and cerebral amyloid angiopathy. <b>2015</b> , 525, 247-50	311
1637	Episodic memory in normal aging and Alzheimer disease: Insights from imaging and behavioral studies. <b>2015</b> , 24, 232-62	171
1636	Stereotactic brain injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: A phase 1 clinical trial. <b>2015</b> , 1, 95-102	88
1635	Locus Coeruleus, norepinephrine and A $\beta$ peptides in Alzheimer's disease. <b>2015</b> , 2, 73-84	41

1634	Parenchymal cystatin C focal deposits and glial scar formation around brain arteries in Hereditary Cystatin C Amyloid Angiopathy. <b>2015</b> , 1622, 149-62	4
1633	Neuropathology and biochemistry of A $\beta$ and its aggregates in Alzheimer's disease. <b>2015</b> , 129, 167-82	141
1632	Neuroanatomy and Pathology of Sporadic Alzheimer's Disease. <b>2015</b> ,	13
1631	White matter changes in dementia: role of impaired drainage of interstitial fluid. <b>2015</b> , 25, 63-78	105
1630	Entorhinal cortical defects in Tg2576 mice are present as early as 2-4 months of age. <b>2015</b> , 36, 134-48	24
1629	Emerging concepts in Alzheimer's disease. <b>2015</b> , 10, 291-319	152
1628	Challenges of multimorbidity of the aging brain: a critical update. <b>2015</b> , 122, 505-21	91
1627	Novel therapeutic strategy for neurodegeneration by blocking A $\beta$ seeding mediated aggregation in models of Alzheimer's disease. <b>2015</b> , 74, 144-57	21
1626	At the interface of sensory and motor dysfunctions and Alzheimer's disease. <b>2015</b> , 11, 70-98	271
1625	Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias. <b>2015</b> , 25, 401-8	115
1624	Detection of changes in the locus coeruleus in patients with mild cognitive impairment and Alzheimer's disease: high-resolution fast spin-echo T1-weighted imaging. <b>2015</b> , 15, 334-40	54
1623	Amyloid-beta immunotherapy: the hope for Alzheimer disease?. <b>2016</b> , 203-212	37
1622	Cytokines and Cytokine Receptors Involved in the Pathogenesis of Alzheimer's Disease. <b>2016</b> , 7,	10
1621	The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease. <b>2016</b> , 53, 1523-38	40
1620	Neuropsychiatric Disturbances in Alzheimer's Disease: What Have We Learned from Neuropathological Studies?. <b>2016</b> , 13, 1145-64	36
1619	Metals and Neuronal Metal Binding Proteins Implicated in Alzheimer's Disease. <b>2016</b> , 2016, 9812178	89
1618	Hippocampal Injections of Oligomeric Amyloid $\beta$ peptide (1-42) Induce Selective Working Memory Deficits and Long-lasting Alterations of ERK Signaling Pathway. <b>2015</b> , 7, 245	53
1617	Olfactory Receptors in Non-Chemosensory Organs: The Nervous System in Health and Disease. <b>2016</b> , 8, 163	58

1616	CB2 Cannabinoid Receptor As Potential Target against Alzheimer's Disease. <b>2016</b> , 10, 243	78
1615	Telomerase Activity is Downregulated Early During Human Brain Development. <b>2016</b> , 7,	20
1614	Molecular Pathological Classification of Neurodegenerative Diseases: Turning towards Precision Medicine. <b>2016</b> , 17,	163
1613	Heterogeneity of cerebral TDP-43 pathology in sporadic amyotrophic lateral sclerosis: Evidence for clinico-pathologic subtypes. <b>2016</b> , 4, 61	30
1612	Competitive Mirror Image Phage Display Derived Peptide Modulates Amyloid Beta Aggregation and Toxicity. <b>2016</b> , 11, e0147470	7
1611	Assessing the Effects of Acute Amyloid $\beta$ Oligomer Exposure in the Rat. <b>2016</b> , 17,	10
1610	In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. <b>2016</b> , 80, 247-58	266
1609	Applicability of digital analysis and imaging technology in neuropathology assessment. <b>2016</b> , 36, 270-82	9
1608	Changes to the lateral geniculate nucleus in Alzheimer's disease but not dementia with Lewy bodies. <b>2016</b> , 42, 366-76	17
1607	TDP-43 in the olfactory bulb in Alzheimer's disease. <b>2016</b> , 42, 390-3	6
1606	Beer Drinking Associates with Lower Burden of Amyloid Beta Aggregation in the Brain: Helsinki Sudden Death Series. <b>2016</b> , 40, 1473-8	11
1605	Cerebellar ataxia in progressive supranuclear palsy: An autopsy study of PSP-C. <b>2016</b> , 31, 653-62	43
1604	Calcium channel blockade attenuates abnormal synaptic transmission in the dentate gyrus elicited by entorhinal amyloidopathy. <b>2016</b> , 70, 408-17	10
1603	Precortical Phase of Alzheimer's Disease (AD)-Related Tau Cytoskeletal Pathology. <b>2016</b> , 26, 371-86	79
1602	Unfolded protein response is activated in Lewy body dementias. <b>2016</b> , 42, 352-65	32
1601	Lewy- and Alzheimer-type pathologies in midbrain and cerebellum across the Lewy body disorders spectrum. <b>2016</b> , 42, 451-62	19
1600	First magnetic resonance imaging studies on aluminium maltolate-treated aged New Zealand rabbits: an Alzheimer's animal model. <b>2016</b> , 16, 263-7	3
1599	Spatial Navigation in Preclinical Alzheimer's Disease. <b>2016</b> , 52, 77-90	101

- 1598 The Role of Cerebrovascular Disease in Amyloid Deposition. **2016**, 54, 1015-1026 8
- 1597 Cross-Sectional and Longitudinal Cognitive Correlates of FDDNP PET and CSF Amyloid- $\beta$  and Tau in Parkinson's Disease. **2017**, 55, 1261-1272 13
- 1596 Neuronal network disintegration: common pathways linking neurodegenerative diseases. **2016**, 87, 1234-1241 69
- 1595 A Theoretical Analysis of the Synergy of Amyloid and Tau in Alzheimer's Disease. **2016**, 52, 1461-70 8
- 1594 Low episodic memory performance in cognitively normal elderly subjects is associated with increased posterior cingulate gray matter N-acetylaspartate: a H MRSI study at 7 Tesla. **2016**, 48, 195-203 15
- 1593 Neuropathological assessment and validation of mouse models for Alzheimer's disease: applying NIA-AA guidelines. **2016**, 6, 32397 13
- 1592 An autopsy-confirmed case of progressive supranuclear palsy with predominant postural instability. **2016**, 4, 120 12
- 1591 The Brain's Structural Connectome Mediates the Relationship between Regional Neuroimaging Biomarkers in Alzheimer's Disease. **2017**, 55, 1639-1657 13
- 1590 Analysis of primary visual cortex in dementia with Lewy bodies indicates GABAergic involvement associated with recurrent complex visual hallucinations. **2016**, 4, 66 42
- 1589 Heterogeneity of neuroanatomical patterns in prodromal Alzheimer's disease: links to cognition, progression and biomarkers. **2017**, 140, 735-747 80
- 1588 Tau Platelets Correlate with Regional Brain Atrophy in Patients with Alzheimer's Disease. **2017**, 55, 1595-1603 14
- 1587 Region-Specific Vulnerability to Oxidative Stress, Neuroinflammation, and Tau Hyperphosphorylation in Experimental Diabetes Mellitus Mice. **2016**, 51, 1209-24 25
- 1586 Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease. **2016**, 22, 978-990 13
- 1585 Neutrophil Gelatinase-Associated Lipocalin and its Receptors in Alzheimer's Disease (AD) Brain Regions: Differential Findings in AD with and without Depression. **2017**, 55, 763-776 22
- 1584 Computerized Cognitive Tests Are Associated with Biomarkers of Alzheimer's Disease in Cognitively Normal Individuals 10 Years Prior. **2016**, 22, 968-977 11
- 1583 P3-253: Performance of [18F]Flutemetamol Amyloid Imaging Against the Current (2012) NIA-AA Recommendations for the Neuropathological Diagnosis of Alzheimer's Disease. **2016**, 12, P926-P926
- 1582 Dogs with Cognitive Dysfunction as a Spontaneous Model for Early Alzheimer's Disease: A Translational Study of Neuropathological and Inflammatory Markers. **2016**, 52, 433-49 43
- 1581 Dura mater is a potential source of A $\beta$  seeds. **2016**, 131, 911-23 72



1580	Reduced fibrillar $\beta$ amyloid in subcortical structures in a butyrylcholinesterase-knockout Alzheimer disease mouse model. <b>2016</b> , 259, 307-312	34
1579	(11)C-PBR28 binding to translocator protein increases with progression of Alzheimer's disease. <b>2016</b> , 44, 53-61	104
1578	Pathological tau deposition in Motor Neuron Disease and frontotemporal lobar degeneration associated with TDP-43 proteinopathy. <b>2016</b> , 4, 33	26
1577	Molecular and cellular pathophysiology of preclinical Alzheimer's disease. <b>2016</b> , 311, 54-69	71
1576	Effects of rs3846662 Variants on HMGR mRNA and Protein Levels and on Markers of Alzheimer's Disease Pathology. <b>2016</b> , 58, 109-19	7
1575	Multisite assessment of NIA-AA guidelines for the neuropathologic evaluation of Alzheimer's disease. <b>2016</b> , 12, 164-169	62
1574	Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. <b>2016</b> , 139, 1539-50	275
1573	Chotosan improves A $\beta$ -42-induced cognitive impairment and neuroinflammatory and apoptotic responses through the inhibition of TLR-4/NF- $\kappa$ B signaling in mice. <b>2016</b> , 191, 398-407	28
1572	Differential Functional Connectivity Correlates of Cerebrospinal Fluid Biomarkers in Dementia of the Alzheimer's Type. <b>2016</b> , 16, 147-51	10
1571	Immunotherapy and Biomarkers in Neurodegenerative Disorders. <b>2016</b> ,	3
1570	Reference tissue normalization in longitudinal (18)F-florbetapir positron emission tomography of late mild cognitive impairment. <b>2016</b> , 8, 2	31
1569	Monitoring the progression of Alzheimer's disease with $\beta$ PET. <b>2016</b> , 139, 1318-20	4
1568	Thal Amyloid Stages Do Not Significantly Impact the Correlation Between Neuropathological Change and Cognition in the Alzheimer Disease Continuum. <b>2016</b> , 75, 516-26	33
1567	Automated quantification of amyloid positron emission tomography: a comparison of PMOD and MIMneuro. <b>2016</b> , 30, 682-689	19
1566	Cerebellar Amyloid- $\beta$ Plaques: How Frequent Are They, and Do They Influence 18F-Florbetaben SUV Ratios?. <b>2016</b> , 57, 1740-1745	42
1565	Magnetic Resonance Spectroscopy in Dementia. <b>2016</b> , 55-70	
1564	Insights into White Matter Damage in Alzheimer's Disease: From Postmortem to in vivo Diffusion Tensor MRI Studies. <b>2016</b> , 16, 26-33	32
1563	Can Creutzfeldt-Jakob disease unravel the mysteries of Alzheimer's?. <b>2016</b> , 10, 369-376	5

1562	Alzheimer's disease, apolipoprotein E and hormone replacement therapy. <b>2016</b> , 94, 98-105	34
1561	Amyloid- $\beta$ Precursor Protein Modulates the Sorting of Testican-1 and Contributes to Its Accumulation in Brain Tissue and Cerebrospinal Fluid from Patients with Alzheimer Disease. <b>2016</b> , 75, 903-16	12
1560	Atypical Alzheimer's disease. <b>2016</b> , 17-29	3
1559	Animal Models of Behavior Genetics. <b>2016</b> ,	
1558	Striatal and Cortical $\beta$ Amyloidopathy and Cognition in Parkinson's Disease. <b>2016</b> , 31, 111-7	42
1557	The identification of raft-derived tau-associated vesicles that are incorporated into immature tangles and paired helical filaments. <b>2016</b> , 42, 639-653	12
1556	Progressive supranuclear palsy and Parkinson's disease overlap: A clinicopathological case report. <b>2016</b> , 36, 187-91	4
1555	Behavioral variant of frontotemporal dementia: Fundamental clinical issues associated with prediction of pathological bases. <b>2016</b> , 36, 388-404	7
1554	Altered memory-related functional connectivity of the anterior and posterior hippocampus in older adults at increased genetic risk for Alzheimer's disease. <b>2016</b> , 37, 366-80	21
1553	Globular Glial Mixed Four Repeat Tau and TDP-43 Proteinopathy with Motor Neuron Disease and Frontotemporal Dementia. <b>2016</b> , 26, 82-94	19
1552	An MRI-Based Atlas for Correlation of Imaging and Pathologic Findings in Alzheimer's Disease. <b>2016</b> , 26, 264-8	2
1551	Clinicopathological description of two cases with SQSTM1 gene mutation associated with frontotemporal dementia. <b>2016</b> , 36, 27-38	25
1550	Magnetic Resonance Spectroscopy of Degenerative Brain Diseases. <b>2016</b> ,	0
1549	Quantification of immunohistochemical findings of neurofibrillary tangles and senile plaques for a diagnosis of dementia in forensic autopsy cases. <b>2016</b> , 22, 82-9	1
1548	The effect of $\beta$ amyloid positivity on cerebral metabolism in cognitively normal seniors. <b>2016</b> , 12, 1250-1258	8
1547	Chronic Traumatic Encephalopathy Pathology in Multiple System Atrophy. <b>2016</b> , 75, 963-970	45
1546	Clinical Diagnosis of Alzheimer's Disease. <b>2016</b> , 27-48	2
1545	Convergent and divergent intranetwork and internetwork connectivity patterns in patients with remitted late-life depression and amnesic mild cognitive impairment. <b>2016</b> , 83, 194-211	33

1544	An early dysregulation of FAK and MEK/ERK signaling pathways precedes the $\beta$ amyloid deposition in the olfactory bulb of APP/PS1 mouse model of Alzheimer's disease. <b>2016</b> , 148, 149-58	36
1543	Pathogenic mechanisms of prion protein, amyloid- $\beta$ and $\beta$ synuclein misfolding: the prion concept and neurotoxicity of protein oligomers. <b>2016</b> , 139, 162-180	59
1542	An autoradiographic evaluation of AV-1451 Tau PET in dementia. <b>2016</b> , 4, 58	305
1541	Detection of Striatal Amyloid Plaques with [18F]flutemetamol: Validation with Postmortem Histopathology. <b>2016</b> , 52, 863-73	40
1540	Neuropathology of supercentenarians - four autopsy case studies. <b>2016</b> , 4, 97	16
1539	Argyrophilic Grain Disease: Demographics, Clinical, and Neuropathological Features From a Large Autopsy Study. <b>2016</b> , 75, 628-35	38
1538	Tau PET in Alzheimer disease and mild cognitive impairment. <i>Neurology</i> , <b>2016</b> , 87, 375-83	6.5 175
1537	NEUROPATOLOGÍA DE LAS DEMENCIAS NEURODEGENERATIVAS. <b>2016</b> , 27, 297-308	1
1536	Neuroimaging Advances in Alzheimer's Disease. <b>2016</b> , 263-282	0
1535	Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between $\beta$ Amyloid and Tauopathy. <b>2016</b> , 73, 1070-7	179
1534	In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain. <b>2016</b> , 36, 7364-74	109
1533	Assessment of neuroinflammation in a mouse model of obesity and $\beta$ amyloidosis using PET. <b>2016</b> , 13, 221	18
1532	The road to restoring neural circuits for the treatment of Alzheimer's disease. <b>2016</b> , 539, 187-196	280
1531	Gd-nanoparticles functionalization with specific peptides for $\beta$ amyloid plaques targeting. <b>2016</b> , 14, 60	40
1530	Tau and A $\beta$ imaging, CSF measures, and cognition in Alzheimer's disease. <b>2016</b> , 8, 338ra66	418
1529	Quinolinic acid injection in mouse medial prefrontal cortex affects reversal learning abilities, cortical connectivity and hippocampal synaptic plasticity. <b>2016</b> , 6, 36489	34
1528	Soluble pre-fibrillar tau and $\beta$ amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline. <b>2016</b> , 132, 875-895	66
1527	Human Central Nervous System (CNS) ApoE Isoforms Are Increased by Age, Differentially Altered by Amyloidosis, and Relative Amounts Reversed in the CNS Compared with Plasma. <b>2016</b> , 291, 27204-27218	27

1526	Association of Plasma A $\beta$ 0 Peptides, But Not A $\beta$ 2, with Coronary Artery Disease and Diabetes Mellitus. <b>2016</b> , 52, 161-9	10
1525	Neuritic and Diffuse Plaque Associations with Memory in Non-Cognitively Impaired Elderly. <b>2016</b> , 53, 1641-52	35
1524	A Mathematical Model for the Proliferation, Accumulation and Spread of Pathogenic Proteins Along Neuronal Pathways with Locally Anomalous Trapping. <b>2016</b> , 11, 142-156	2
1523	Imaging of Cerebral Amyloid Angiopathy with Bivalent (99m)Tc-Hydroxamamide Complexes. <b>2016</b> , 6, 25990	16
1522	Reduction of Amyloid- $\beta$ Plasma Levels by Hemodialysis: An Anti-Amyloid Treatment Strategy?. <b>2016</b> , 50, 791-6	12
1521	Post-mortem assessment in vascular dementia: advances and aspirations. <b>2016</b> , 14, 129	73
1520	Post-mortem histopathology underlying $\beta$ amyloid PET imaging following flutemetamol F 18 injection. <b>2016</b> , 4, 130	57
1519	Hippocampal phospho-tau/MAPT neuropathology in the fornix in Alzheimer disease: an immunohistochemical autopsy study. <b>2016</b> , 4, 114	9
1518	Extranodal NK/T-cell lymphoma, nasal type, manifesting as rapidly progressive dementia without any mass or enhancing brain lesion. <b>2016</b> , 36, 456-463	7
1517	PET Imaging as a Diagnostic Tool in Alzheimer's Disease. <b>2016</b> , 199-213	
1516	The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. <b>2016</b> , 139, 2249-60	125
1515	Level of PICALM, a key component of clathrin-mediated endocytosis, is correlated with levels of phosphotau and autophagy-related proteins and is associated with tau inclusions in AD, PSP and Pick disease. <b>2016</b> , 94, 32-43	45
1514	Anti-Amyloid- $\beta$ Immunotherapy for Alzheimer's Disease. <b>2016</b> , 193-226	6
1513	Inhibition of Tau Aggregation as a Basis for Treatment and Prevention of Alzheimer's Disease. <b>2016</b> , 385-436	1
1512	The Prion-Like Properties of Amyloid- $\beta$ Assemblies: Implications for Alzheimer's Disease. <b>2016</b> , 6,	49
1511	Amyloid and Amyloid Fibrils. <b>2016</b> , 1-30	
1510	Disrupted Network Topology in Patients with Stable and Progressive Mild Cognitive Impairment and Alzheimer's Disease. <b>2016</b> , 26, 3476-3493	71
1509	Malattie da prioni o encefalopatie spongiformi trasmissibili. <b>2016</b> , 16, 1-21	

1508	Epidemiological pathology of Tau in the ageing brain: application of staging for neuropil threads (BrainNet Europe protocol) to the MRC cognitive function and ageing brain study. <b>2016</b> , 4, 11	32
1507	Amyloid- $\beta$ plaque deposition measured using propagation-based X-ray phase contrast CT imaging. <b>2016</b> , 23, 813-9	16
1506	Apomorphine: A potential modifier of amyloid deposition in Parkinson's disease?. <b>2016</b> , 31, 668-75	23
1505	Regional $\beta$ amyloid burden does not correlate with cognitive or language deficits in Alzheimer's disease presenting as aphasia. <b>2016</b> , 23, 313-9	12
1504	The Ubiquitin-Proteasome System and Molecular Chaperone Deregulation in Alzheimer's Disease. <b>2016</b> , 53, 905-931	61
1503	Amnesia in frontotemporal dementia: shedding light on the Geneva historical data. <b>2016</b> , 263, 657-64	5
1502	Distinct prion-like strains of amyloid beta implicated in phenotypic diversity of Alzheimer's disease. <b>2016</b> , 10, 9-17	46
1501	Cascading network failure across the Alzheimer's disease spectrum. <b>2016</b> , 139, 547-62	265
1500	The pattern of amyloid accumulation in the brains of adults with Down syndrome. <b>2016</b> , 12, 538-45	101
1499	Stereological approaches to dementia research using human brain tissue. <b>2016</b> , 76, 73-81	5
1498	Amyloid- $\beta$ dimers in the absence of plaque pathology impair learning and synaptic plasticity. <b>2016</b> , 139, 509-25	54
1497	Modulation effect of the SORL1 gene on functional connectivity density in healthy young adults. <b>2016</b> , 221, 4103-4110	1
1496	Altered Proteins in the Aging Brain. <b>2016</b> , 75, 316-25	109
1495	Characterization of tau positron emission tomography tracer [ $^{18}$ F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias. <b>2016</b> , 12, 1116-1124	139
1494	The Cellular Phase of Alzheimer's Disease. <b>2016</b> , 164, 603-15	849
1493	Pathology of the Aging Brain in Domestic and Laboratory Animals, and Animal Models of Human Neurodegenerative Diseases. <b>2016</b> , 53, 327-48	74
1492	The rise and fall of insulin signaling in Alzheimer's disease. <b>2016</b> , 31, 497-515	33
1491	Symptomatic and preclinical Alzheimer's disease: Neuropathology and imaging. <b>2016</b> , 22, 127-131	1

1490	Amyloid pathology and axonal injury after brain trauma. <i>Neurology</i> , <b>2016</b> , 86, 821-8	6.5	86
1489	Local and distributed PiB accumulation associated with development of preclinical Alzheimer's disease. <b>2016</b> , 38, 104-111		10
1488	Exome sequencing in dementia with Lewy bodies. <b>2016</b> , 6, e728		30
1487	Axonal transport and secretion of fibrillar forms of $\beta$ synuclein, A $\beta$ 2 peptide and HTTExon 1. <b>2016</b> , 131, 539-48		98
1486	Relationships between sleep quality and brain volume, metabolism, and amyloid deposition in late adulthood. <b>2016</b> , 41, 107-114		102
1485	PPAR $\alpha$ agonist GW0742 ameliorates A $\beta$ -42-induced hippocampal neurotoxicity in mice. <b>2016</b> , 31, 663-71		9
1484	Dendritic Spine Pathology in Neurodegenerative Diseases. <b>2016</b> , 11, 221-50		104
1483	Pathological $\beta$ synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology. <b>2016</b> , 131, 393-409		93
1482	Synaptic Amyloid- $\beta$ Oligomers Precede p-Tau and Differentiate High Pathology Control Cases. <b>2016</b> , 186, 185-98		68
1481	Neuroprotective effects of ginseng protein on PI3K/Akt signaling pathway in the hippocampus of D-galactose/AlCl $_3$ inducing rats model of Alzheimer's disease. <b>2016</b> , 179, 162-9		74
1480	Propagation of A $\beta$ pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. <b>2016</b> , 131, 5-25		54
1479	Heterotypic seeding of Tau fibrillization by pre-aggregated Abeta provides potent seeds for prion-like seeding and propagation of Tau-pathology in vivo. <b>2016</b> , 131, 549-69		95
1478	Mixed tau and TDP-43 pathology in a patient with unclassifiable primary progressive aphasia. <b>2016</b> , 22, 55-9		8
1477	Tissue Transglutaminase and Its Product Isopeptide Are Increased in Alzheimer's Disease and APP $_{swe}$ /PS1 $_{dE9}$ Double Transgenic Mice Brains. <b>2016</b> , 53, 5066-78		17
1476	Physiological fluctuations in white matter are increased in Alzheimer's disease and correlate with neuroimaging and cognitive biomarkers. <b>2016</b> , 37, 12-18		34
1475	Why therapies for Alzheimer's disease do not work: Do we have consensus over the path to follow?. <b>2016</b> , 25, 70-84		19
1474	Deposition of amyloid $\beta$ in the walls of human leptomenigeal arteries in relation to perivascular drainage pathways in cerebral amyloid angiopathy. <b>2016</b> , 1862, 1037-46		94
1473	Protocols for Monitoring the Development of Tau Pathology in Alzheimer's Disease. <b>2016</b> , 1303, 143-60		2

1472	Alzheimer's disease drug development based on Computer-Aided Drug Design. <b>2016</b> , 121, 851-863	30
1471	Imaging $\beta$ amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis. <b>2016</b> , 43, 362-373	28
1470	The Relationship Between Development of Neuronal and Astrocytic Tau Pathologies in Subcortical Nuclei and Progression of Argyrophilic Grain Disease. <b>2016</b> , 26, 488-505	16
1469	Advanced Neuroimaging Methods Towards Characterization of Early Stages of Alzheimer's Disease. <b>2016</b> , 1303, 509-19	7
1468	Systems Biology of Alzheimer's Disease. <b>2016</b> ,	4
1467	A neuronal aging pattern unique to humans and common chimpanzees. <b>2016</b> , 221, 647-64	13
1466	Early changes in extracellular matrix in Alzheimer's disease. <b>2017</b> , 43, 167-182	85
1465	Amyloid- $\beta$ and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease. <b>2017</b> , 22, 306-311	86
1464	Monoaminergic neuropathology in Alzheimer's disease. <b>2017</b> , 151, 101-138	137
1463	Clusterin levels are increased in Alzheimer's disease and influence the regional distribution of A $\beta$ . <b>2017</b> , 27, 305-313	41
1462	Neural Correlates of Self-Reference Effect in Early Alzheimer's Disease. <b>2017</b> , 56, 717-731	4
1461	Incipient progressive supranuclear palsy is more common than expected and may comprise clinicopathological subtypes: a forensic autopsy series. <b>2017</b> , 133, 809-823	39
1460	Pathology of Neurodegenerative Diseases. <b>2017</b> , 9,	360
1459	Specific patterns of neuronal loss in the pulvinar nucleus in dementia with lewy bodies. <b>2017</b> , 32, 414-422	19
1458	Tau interactome mapping based identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo. <b>2017</b> , 133, 731-749	49
1457	Chronic Sleep Restriction Induces Cognitive Deficits and Cortical Beta-Amyloid Deposition in Mice via BACE1-Antisense Activation. <b>2017</b> , 23, 233-240	26
1456	Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). <b>2017</b> , 133, 705-715	91
1455	Case 1-2017. A 70-Year-Old Woman with Gradually Progressive Loss of Language. <b>2017</b> , 376, 158-167	16

1454	Selecting A $\beta$ isoforms for an Alzheimer's disease cerebrospinal fluid biomarker panel. <b>2017</b> , 11, 169-178	10
1453	Locus coeruleus at asymptomatic early and middle Braak stages of neurofibrillary tangle pathology. <b>2017</b> , 43, 373-392	45
1452	What can the topology of white matter structural networks tell us about mild cognitive impairment?. <b>2017</b> , 12, 35-50	1
1451	Tau and $\beta$ Amyloid Are Associated with Medial Temporal Lobe Structure, Function, and Memory Encoding in Normal Aging. <b>2017</b> , 37, 3192-3201	77
1450	Reduction of RPT6/S8 (a Proteasome Component) and Proteasome Activity in the Cortex is Associated with Cognitive Impairment in Lewy Body Dementia. <b>2017</b> , 57, 373-386	13
1449	A Combination of Resveratrol and Curcumin is Effective Against Aluminum Chloride-Induced Neuroinflammation in Rats. <b>2017</b> , 60, S221-S235	30
1448	Alzheimer's disease neuropathologic change, Lewy body disease, and vascular brain injury in clinic- and community-based samples. <b>2017</b> , 53, 83-92	45
1447	Neuronal Loss and $\beta$ Synuclein Pathology in the Superior Colliculus and Its Relationship to Visual Hallucinations in Dementia with Lewy Bodies. <b>2017</b> , 25, 595-604	21
1446	Optimal Reference Region to Measure Longitudinal Amyloid- $\beta$ Change with F-Florbetaben PET. <b>2017</b> , 58, 1300-1306	34
1445	Neurodegenerative Disease Transmission and Transgenesis in Mice. <b>2017</b> , 9,	9
1444	Mixed pathologies including chronic traumatic encephalopathy account for dementia in retired association football (soccer) players. <b>2017</b> , 133, 337-352	128
1443	Cortical laminar tau deposits and activated astrocytes in Alzheimer's disease visualised by H-THK5117 and H-deprenyl autoradiography. <b>2017</b> , 7, 45496	29
1442	Diagnosing the frontal variant of Alzheimer's disease: a clinician's yellow brick road. <b>2017</b> , 4, 2	17
1441	Interactions of pathological proteins in neurodegenerative diseases. <b>2017</b> , 134, 187-205	193
1440	Preclinical models of Alzheimer's disease for identification and preclinical validation of therapeutic targets: from fine-tuning strategies for validated targets to new venues for therapy. <b>2017</b> , 115-156	1
1439	Effect of aging and Alzheimer's disease-like pathology on brain monoamines in mice. <b>2017</b> , 108, 238-245	27
1438	Neuronal tetraploidization in the cerebral cortex correlates with reduced cognition in mice and precedes and recapitulates Alzheimer's-associated neuropathology. <b>2017</b> , 56, 50-66	17
1437	Enhanced Tau Aggregation in the Presence of Amyloid $\beta$ <b>2017</b> , 187, 1601-1612	106



1436	Use of Analgesics (Opioids and Nonsteroidal Anti-Inflammatory Drugs) and Dementia-Related Neuropathology in a Community-Based Autopsy Cohort. <b>2017</b> , 58, 435-448	6
1435	Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to $\beta$ -synuclein pathology. <b>2017</b> , 32, 884-892	39
1434	Clinical Amyloid Imaging. <b>2017</b> , 47, 31-43	44
1433	Traumatic brain injury history is associated with earlier age of onset of Alzheimer disease. <b>2017</b> , 31, 85-98	51
1432	Regional Overlap of Pathologies in Lewy Body Disorders. <b>2017</b> , 76, 216-224	34
1431	Longitudinal changes in amyloid positron emission tomography and volumetric magnetic resonance imaging in the nondemented Down syndrome population. <b>2017</b> , 9, 1-9	42
1430	Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia. <b>2017</b> , 140, 1987-2001	76
1429	Re-imagining Alzheimer's disease - the diminishing importance of amyloid and a glimpse of what lies ahead. <b>2017</b> , 143, 432-444	57
1428	Hierarchical Organization of Tau and Amyloid Deposits in the Cerebral Cortex. <b>2017</b> , 74, 813-820	44
1427	Alzheimer Disease: Scientific Breakthroughs and Translational Challenges. <b>2017</b> , 92, 978-994	45
1426	Amyloid positron emission tomography in sporadic cerebral amyloid angiopathy: A systematic critical update. <b>2017</b> , 15, 247-263	40
1425	Multisite Assessment of Aging-Related Tau Astrogliaopathy (ARTAG). <b>2017</b> , 76, 605-619	28
1424	PE859, A Novel Curcumin Derivative, Inhibits Amyloid- $\beta$ and Tau Aggregation, and Ameliorates Cognitive Dysfunction in Senescence-Accelerated Mouse Prone 8. <b>2017</b> , 59, 313-328	28
1423	Evaluating the Patterns of Aging-Related Tau Astrogliaopathy Unravels Novel Insights Into Brain Aging and Neurodegenerative Diseases. <b>2017</b> , 76, 270-288	71
1422	The cerebellum shrinks faster than normal ageing in Alzheimer's disease but not in mild cognitive impairment. <b>2017</b> , 38, 3141-3150	33
1421	Cryptic exon incorporation occurs in Alzheimer's brain lacking TDP-43 inclusion but exhibiting nuclear clearance of TDP-43. <b>2017</b> , 133, 923-931	31
1420	IRE1 signaling exacerbates Alzheimer's disease pathogenesis. <b>2017</b> , 134, 489-506	93
1419	Absence of Alzheimer Disease Neuropathologic Changes in Eyes of Subjects With Alzheimer Disease. <b>2017</b> , 76, 376-383	36

1418	Alzheimer's senile plaque as shown by microcryodissection, a new technique for dissociating tissue structures. <b>2017</b> , 124, 685-694	3
1417	Functional neuroimaging findings in healthy middle-aged adults at risk of Alzheimer's disease. <b>2017</b> , 36, 88-104	28
1416	Amyloid- $\beta$ accumulation in the CNS in human growth hormone recipients in the UK. <b>2017</b> , 134, 221-240	67
1415	Immunological memory to hyperphosphorylated tau in asymptomatic individuals. <b>2017</b> , 133, 767-783	31
1414	Quantitative neuropathology: an update on automated methodologies and implications for large scale cohorts. <b>2017</b> , 124, 671-683	16
1413	Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. <b>2017</b> , 52, 214-227	52
1412	The biomarker-based diagnosis of Alzheimer's disease. 2-lessons from oncology. <b>2017</b> , 52, 141-152	33
1411	Distribution and characteristics of transactive response DNA binding protein 43 kDa pathology in progressive supranuclear palsy. <b>2017</b> , 32, 246-255	34
1410	Alzheimer's disease: experimental models and reality. <b>2017</b> , 133, 155-175	274
1409	Brain tau deposition linked to systemic causes of death in normal elderly. <b>2017</b> , 50, 163-166	2
1408	Neurophysiological assessment of neural network plasticity and connectivity: Progress towards early functional biomarkers for disease interception therapies in Alzheimer's disease. <b>2017</b> , 73, 340-358	20
1407	Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global $\beta$ Amyloid Burden. <b>2017</b> , 74, 1455-1463	90
1406	Earliest accumulation of $\beta$ Amyloid occurs within the default-mode network and concurrently affects brain connectivity. <b>2017</b> , 8, 1214	348
1405	Cognitive impairment in progressive supranuclear palsy is associated with tau burden. <b>2017</b> , 32, 1772-1779	30
1404	Altered neurovascular coupling as measured by optical imaging: a biomarker for Alzheimer's disease. <b>2017</b> , 7, 12906	44
1403	Brain Aging in the Dog. <b>2017</b> , 93-102	
1402	Canine and Feline Dementia. <b>2017</b> ,	4
1401	Regional analysis and genetic association of nigrostriatal degeneration in Lewy body disease. <b>2017</b> , 32, 1584-1593	11

1400	Heterogeneous Association of Alzheimer's Disease-Linked Amyloid- $\beta$ and Amyloid- $\beta$ Protein Precursor with Synapses. <b>2017</b> , 60, 511-524		11
1399	Using induced pluripotent stem cells to explore genetic and epigenetic variation associated with Alzheimer's disease. <b>2017</b> , 9, 1455-1468		13
1398	Amyloid PET scan: Staging beyond reading?. <i>Neurology</i> , <b>2017</b> , 89, 2029-2030	6.5	6
1397	In vivo staging of regional amyloid deposition. <i>Neurology</i> , <b>2017</b> , 89, 2031-2038	6.5	190
1396	Amyloid-PET in sporadic cerebral amyloid angiopathy: A diagnostic accuracy meta-analysis. <i>Neurology</i> , <b>2017</b> , 89, 1490-1498	6.5	35
1395	Parkinson's disease susceptibility variants and severity of Lewy body pathology. <b>2017</b> , 44, 79-84		10
1394	Comparison of symptomatic and asymptomatic persons with primary age-related tauopathy. <i>Neurology</i> , <b>2017</b> , 89, 1707-1715	6.5	30
1393	Quantitative susceptibility mapping to evaluate the early stage of Alzheimer's disease. <b>2017</b> , 16, 429-438		55
1392	A Cytomic Approach Towards Genomic Individuality of Neurons. <b>2017</b> , 81-106		1
1391	Seed-induced acceleration of amyloid- $\beta$ -mediated neurotoxicity in vivo. <b>2017</b> , 8, 512		40
1390	Near-infrared spectroscopy (NIRS) and vagus somatosensory evoked potentials (VSEP) in the early diagnosis of Alzheimer's disease: rationale, design, methods, and first baseline data of the Vogel study. <b>2017</b> , 124, 1473-1488		11
1389	Olfactory bulb neuroproteomics reveals a chronological perturbation of survival routes and a disruption of prohibitin complex during Alzheimer's disease progression. <b>2017</b> , 7, 9115		44
1388	Guide à la lecture et interprétation de l'imagerie PET des plaques amyloïdes. <b>2017</b> , 41, 299-306		2
1387	A Review of Biomarkers for Neurodegenerative Disease: Will They Swing Us Across the Valley?. <b>2017</b> , 6, 5-13		22
1386	Assessment of amyloid $\beta$ in pathologically confirmed frontotemporal dementia syndromes. <b>2017</b> , 9, 10-20		29
1385	Genetic Comparison of Symptomatic and Asymptomatic Persons With Alzheimer Disease Neuropathology. <b>2017</b> , 31, 232-238		12
1384	Knowing your enemy: from post-mortem scene reconstruction to real-time monitoring of the spread of tau and amyloid. <b>2017</b> , 140, 1179-1182		
1383	Pick's disease with neuronal four-repeat tau accumulation in the basal ganglia, brain stem nuclei and cerebellum. <b>2017</b> , 37, 544-559		4

1382	An autopsy case of Creutzfeldt-Jakob disease with a prion protein gene codon 180 mutation presenting with pathological laughing and an exaggerated startle reaction. <b>2017</b> , 37, 575-581	7
1381	Performance of [F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease. <b>2017</b> , 9, 25-34	40
1380	Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents. <b>2017</b> , 139, 153-167	97
1379	Aged chimpanzees exhibit pathologic hallmarks of Alzheimer's disease. <b>2017</b> , 59, 107-120	63
1378	The diagnostic value of FDG and amyloid PET in Alzheimer's disease-A systematic review. <b>2017</b> , 94, 16-24	79
1377	Decreased Glutamate Levels in Patients with Amnesic Mild Cognitive Impairment: An sLASER Proton MR Spectroscopy and PiB-PET Study. <b>2017</b> , 27, 630-636	20
1376	Protein astrogliopathies in human neurodegenerative diseases and aging. <b>2017</b> , 27, 675-690	56
1375	Amygdala TDP-43 Pathology in Frontotemporal Lobar Degeneration and Motor Neuron Disease. <b>2017</b> , 76, 800-812	10
1374	Alzheimer's Disease: Characterization of the Brain Sites of the Initial Tau Cytoskeletal Pathology Will Improve the Success of Novel Immunological Anti-Tau Treatment Approaches. <b>2017</b> , 57, 683-696	16
1373	Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature. <b>2017</b> , 32, 1504-1523	152
1372	Novel intracytoplasmic inclusions immunoreactive for phosphorylated-TDP43 and cystatin C in anterior horn cells in a case of sporadic amyotrophic lateral sclerosis. <b>2017</b> , 37, 526-534	2
1371	Parietal white matter lesions in Alzheimer's disease are associated with cortical neurodegenerative pathology, but not with small vessel disease. <b>2017</b> , 134, 459-473	120
1370	How Does the P7C3-Series of Neuroprotective Small Molecules Prevent Membrane Disruption?. <b>2017</b> , 57, 2009-2019	2
1369	A clinicopathological approach to the diagnosis of dementia. <b>2017</b> , 13, 457-476	138
1368	Biomarkers in Neurodegenerative Diseases. <b>2017</b> , 15, 491-528	32
1367	Radiosynthesis of [F]AV1451 in pharmaceutical conditions and its biological characteristics. <b>2017</b> , 128, 101-107	5
1366	YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer's disease and other tauopathies. <b>2017</b> , 14, 118	69
1365	Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression. <b>2017</b> , 9, 17	19

1364	Optimized classification of F-Florbetaben PET scans as positive and negative using an SUVR quantitative approach and comparison to visual assessment. <b>2017</b> , 15, 325-332	62
1363	Quantification of Butyrylcholinesterase Activity as a Sensitive and Specific Biomarker of Alzheimer's Disease. <b>2017</b> , 58, 491-505	36
1362	Association of cortical microinfarcts and cerebral small vessel pathology in the ageing brain. <b>2017</b> , 43, 505-513	26
1361	Brain imaging evidence of early involvement of subcortical regions in familial and sporadic Alzheimer's disease. <b>2017</b> , 1655, 23-32	21
1360	Biomarkers for the Early Detection and Progression of Alzheimer's Disease. <b>2017</b> , 14, 35-53	78
1359	In Vivo Comparison of Tau Radioligands F-THK-5351 and F-THK-5317. <b>2017</b> , 58, 996-1002	43
1358	Profile of cognitive impairment and underlying pathology in multiple system atrophy. <b>2017</b> , 32, 405-413	68
1357	Mixed neuropathologies and estimated rates of clinical progression in a large autopsy sample. <b>2017</b> , 13, 654-662	53
1356	eEF2K inhibition blocks A $\beta$ 2 neurotoxicity by promoting an NRF2 antioxidant response. <b>2017</b> , 133, 101-119	30
1355	Pathological TDP-43 changes in Betz cells differ from those in bulbar and spinal Motoneurons in sporadic amyotrophic lateral sclerosis. <b>2017</b> , 133, 79-90	45
1354	Alzheimer's Disease. <b>2017</b> , 83-118	1
1353	Lixisenatide attenuates the detrimental effects of amyloid $\beta$ protein on spatial working memory and hippocampal neurons in rats. <b>2017</b> , 318, 28-35	26
1352	TDP-43 pathology in Alzheimer's disease, dementia with Lewy bodies and ageing. <b>2017</b> , 27, 472-479	107
1351	Systems proteomic analysis reveals that clusterin and tissue inhibitor of metalloproteinases 3 increase in leptomenigeal arteries affected by cerebral amyloid angiopathy. <b>2017</b> , 43, 492-504	41
1350	Inhomogeneous distribution of Alzheimer pathology along the isocortical relief. Are cortical convolutions an Achilles heel of evolution?. <b>2017</b> , 27, 603-611	9
1349	Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development. <b>2017</b> , 3, 83-91	57
1348	Does neuroinflammation drive the relationship between tau hyperphosphorylation and dementia development following traumatic brain injury?. <b>2017</b> , 60, 369-382	47
1347	Tau pathology in Creutzfeldt-Jakob disease revisited. <b>2017</b> , 27, 332-344	38

1346	Alzheimer-Like Pattern of Hypometabolism Emerges with Elevated Amyloid- $\beta$ Burden in Down Syndrome. <b>2018</b> , 61, 631-644	21
1345	Distinct spatiotemporal accumulation of N-truncated and full-length amyloid- $\beta$ 2 in Alzheimer's disease. <b>2017</b> , 140, 3301-3316	10
1344	Neuropathology of dementia. 94-122	1
1343	Transactive DNA Binding Protein 43 Rather Than Other Misfolded Proteins in the Brain is Associated with Islet Amyloid Polypeptide in Pancreas in Aged Subjects with Diabetes Mellitus. <b>2017</b> , 59, 43-56	6
1342	What is the evidence that tau pathology spreads through prion-like propagation?. <b>2017</b> , 5, 99	168
1341	Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases. <b>2017</b> , 18,	111
1340	Subcortical Shape Changes, Hippocampal Atrophy and Cortical Thinning in Future Alzheimer's Disease Patients. <b>2017</b> , 9, 38	26
1339	The Neuroanatomy of the Reticular Nucleus Locus Coeruleus in Alzheimer's Disease. <b>2017</b> , 11, 80	31
1338	Dementia with Lewy Bodies: Molecular Pathology in the Frontal Cortex in Typical and Rapidly Progressive Forms. <b>2017</b> , 8, 89	21
1337	Analysis of Amyloid- $\beta$ Pathology Spread in Mouse Models Suggests Spread Is Driven by Spatial Proximity, Not Connectivity. <b>2017</b> , 8, 653	15
1336	Hippocampal Neurodegenerative Pathology in Post-stroke Dementia Compared to Other Dementias and Aging Controls. <b>2017</b> , 11, 717	25
1335	Hippocampal activation is associated with longitudinal amyloid accumulation and cognitive decline. <b>2017</b> , 6,	67
1334	Neuropathological and transcriptomic characteristics of the aged brain. <b>2017</b> , 6,	50
1333	Can brain impermeable BACE1 inhibitors serve as anti-CAA medicine?. <b>2017</b> , 17, 163	5
1332	Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson's case. <b>2017</b> , 5, 75	60
1331	Centiloid method evaluation for amyloid PET of subcortical vascular dementia. <b>2017</b> , 7, 16322	7
1330	Regional Differences in Amyloid Deposition between 11C-Pib PET Positive Patients with and without Elevated Striatal Amyloid Uptake. <b>2017</b> , 07,	3
1329	Proposal Guidelines for Standardized Operating Procedures of Brain Autopsy: Brain Bank in South Korea. <b>2017</b> , 58, 1055-1060	10

1328	Progressive modulation of the human olfactory bulb transcriptome during Alzheimer's disease evolution: novel insights into the olfactory signaling across proteinopathies. <b>2017</b> , 8, 69663-69679	16
1327	Phenotypic Variability in Autosomal Dominant Familial Alzheimer Disease due to the S170F Mutation of Presenilin-1. <b>2018</b> , 18, 57-68	3
1326	Imaging of Brain Amyloid Load in Early Alzheimer's Disease. <b>2018</b> , 149-156	
1325	Brain insulin signalling, glucose metabolism and females' reproductive aging: A dangerous triad in Alzheimer's disease. <b>2018</b> , 136, 223-242	26
1324	Biomarkers for Preclinical Alzheimer's Disease. <b>2018</b> ,	
1323	A method for inferring regional origins of neurodegeneration. <b>2018</b> , 141, 863-876	24
1322	Progression of Alzheimer's Disease-Related Pathology and Cell Counts in a Patient with Idiopathic Normal Pressure Hydrocephalus. <b>2018</b> , 61, 1451-1462	7
1321	Integrated neurodegenerative disease autopsy diagnosis. <b>2018</b> , 135, 643-646	7
1320	Visualization of Altered Hippocampal Connectivity in an Animal Model of Alzheimer's Disease. <b>2018</b> , 55, 7886-7899	10
1319	Fatal Alzheimer's cerebral amyloid angiopathy 4 decades after a dural graft at the age of 27 years. <b>2018</b> , 135, 801-803	37
1318	Lysosomal response in relation to synuclein pathology differs between Parkinson's disease and multiple system atrophy. <b>2018</b> , 114, 140-152	12
1317	An autopsy case of globular glial tauopathy presenting with clinical features of motor neuron disease with dementia and iron deposition in the motor cortex. <b>2018</b> , 38, 372	9
1316	Predicted sequence of cortical tau and amyloid- $\beta$ deposition in Alzheimer disease spectrum. <b>2018</b> , 68, 76-84	24
1315	Subthreshold Amyloid Predicts Tau Deposition in Aging. <b>2018</b> , 38, 4482-4489	73
1314	New Beginnings in Alzheimer's Disease: The Most Prevalent Tauopathy. <b>2018</b> , 64, S529-S534	4
1313	Low Cerebrospinal Fluid A $\beta$ 2 and A $\beta$ 0 are Related to White Matter Lesions in Cognitively Normal Elderly. <b>2018</b> , 62, 1877-1886	9
1312	Molecular changes in the absence of severe pathology in the pulvinar in dementia with Lewy bodies. <b>2018</b> , 33, 982-991	14
1311	Amyloid assembly and disassembly. <b>2018</b> , 131,	91

1310	TDP-43 pathology in multiple system atrophy: colocalization of TDP-43 and $\beta$ -synuclein in glial cytoplasmic inclusions. <b>2018</b> , 44, 707-721		19
1309	Topographic staging of tau positron emission tomography images. <b>2018</b> , 10, 221-231		23
1308	Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease. <b>2018</b> , 62, 1815-1826		8
1307	$\beta$ Amyloid accumulation in the human brain after one night of sleep deprivation. <b>2018</b> , 115, 4483-4488		333
1306	A Novel Therapeutic Approach to Treat Alzheimer's Disease by Neurotrophic Support During the Period of Synaptic Compensation. <b>2018</b> , 62, 1211-1218		23
1305	Doublecortin expression in CD8+ T-cells and microglia at sites of amyloid- $\beta$ plaques: A potential role in shaping plaque pathology?. <b>2018</b> , 14, 1022-1037		22
1304	Negative $^{11}\text{C}$ -PIB PET Predicts Lack of Alzheimer's Disease Pathology in Postmortem Examination. <b>2018</b> , 63, 79-85		1
1303	Evidence of amyloid- $\beta$ cerebral amyloid angiopathy transmission through neurosurgery. <b>2018</b> , 135, 671-679		59
1302	Early vs late age at onset frontotemporal dementia and frontotemporal lobar degeneration. <i>Neurology</i> , <b>2018</b> , 90, e1047-e1056	6.5	25
1301	Protein kinase C activity is a protective modifier of Purkinje neuron degeneration in cerebellar ataxia. <b>2018</b> , 27, 1396-1410		22
1300	Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease. <b>2018</b> , 45, 1021-1030		20
1299	Region- and Cell-specific Aneuploidy in Brain Aging and Neurodegeneration. <b>2018</b> , 374, 326-334		16
1298	Cerebrospinal Fluid Biomarkers are Differentially Related to Structural and Functional Changes in Dementia of the Alzheimer's Type. <b>2018</b> , 62, 417-427		4
1297	Purine-related metabolites and their converting enzymes are altered in frontal, parietal and temporal cortex at early stages of Alzheimer's disease pathology. <b>2018</b> , 28, 933-946		33
1296	Activated forms of astrocytes with higher GLT-1 expression are associated with cognitive normal subjects with Alzheimer pathology in human brain. <b>2018</b> , 8, 1712		48
1295	Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy: A meta-analysis. <i>Neurology</i> , <b>2018</b> , 90, e754-e762	6.5	44
1294	Sleep and cognitive decline: A prospective nondemented elderly cohort study. <b>2018</b> , 83, 472-482		49
1293	Evidence-based Interpretation of Amyloid- $\beta$ PET Results: A Clinician's Tool. <b>2018</b> , 32, 28-34		21



1292	Multimodal Characterization of the Late Effects of Traumatic Brain Injury: A Methodological Overview of the Late Effects of Traumatic Brain Injury Project. <b>2018</b> , 35, 1604-1619	23
1291	Multiple system atrophy and apolipoprotein E. <b>2018</b> , 33, 647-650	11
1290	Neuropathology correlates of cognitive assessments. <b>2018</b> , 187, 835-844	
1289	Clinicopathological and I-FP-CIT SPECT correlations in patients with dementia. <b>2018</b> , 5, 376-381	8
1288	Biopsy Pathology of Neurodegenerative Disorders in Adults. <b>2018</b> , 659-680	2
1287	Aging African green monkeys manifest transcriptional, pathological, and cognitive hallmarks of human Alzheimer's disease. <b>2018</b> , 64, 92-106	25
1286	BACE1 inhibition more effectively suppresses initiation than progression of Amyloid pathology. <b>2018</b> , 135, 695-710	43
1285	Networks of tau distribution in Alzheimer's disease. <b>2018</b> , 141, 568-581	80
1284	The Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative Diseases. <b>2018</b> , 77, 2-20	40
1283	Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration. <b>2018</b> , 10, 31	29
1282	Neuronal sphingosine kinase 2 subcellular localization is altered in Alzheimer's disease brain. <b>2018</b> , 6, 25	23
1281	Extended FTLD pedigree segregating a Belgian GRN-null mutation: neuropathological heterogeneity in one family. <b>2018</b> , 10, 7	6
1280	Improving the identification of dementia with Lewy bodies in the context of an Alzheimer's-type dementia. <b>2018</b> , 10, 27	29
1279	Prion-like propagation of Amyloid aggregates in the absence of APP overexpression. <b>2018</b> , 6, 26	32
1278	Alzheimer disease. <b>2017</b> , 145, 325-337	62
1277	Prions, prionoids and protein misfolding disorders. <b>2018</b> , 19, 405-418	138
1276	Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. <b>2018</b> , 136, 363-376	83
1275	Amyloid Network Topology Characterizes the Progression of Alzheimer's Disease During the Predementia Stages. <b>2018</b> , 28, 340-349	18

1274	Amyloid- $\beta$ Increases Tau by Mediating Sirtuin 3 in Alzheimer's Disease. <b>2018</b> , 55, 8592-8601	36
1273	Hallmarks of Alzheimer disease are evolving relentlessly in Metropolitan Mexico City infants, children and young adults. APOE4 carriers have higher suicide risk and higher odds of reaching NFT stage V at $\geq$ 40 years of age. <b>2018</b> , 164, 475-487	64
1272	Potential Novel Approaches to Understand the Pathogenesis and Treat Alzheimer's Disease. <b>2018</b> , 64, S299-S312	18
1271	Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis. <b>2018</b> , 10, 172-181	13
1270	Capillary cerebral amyloid angiopathy in Alzheimer's disease: association with allocortical/hippocampal microinfarcts and cognitive decline. <b>2018</b> , 135, 681-694	42
1269	Pedunculopontine Nucleus Cholinergic Deficiency in Cervical Dystonia. <b>2018</b> , 33, 827-834	10
1268	The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases. <b>2018</b> , 109, 226-248	136
1267	Self-reported confusion is related to global and regional $\beta$ amyloid: data from the Women's healthy ageing project. <b>2018</b> , 12, 78-86	3
1266	$\beta$ Amyloid Prions and the Pathobiology of Alzheimer's Disease. <b>2018</b> , 8,	44
1265	Transcriptional network analysis in frontal cortex in Lewy body diseases with focus on dementia with Lewy bodies. <b>2018</b> , 28, 315-333	20
1264	Reduced TRPC6 mRNA levels in the blood cells of patients with Alzheimer's disease and mild cognitive impairment. <b>2018</b> , 23, 767-776	28
1263	The cerebellum in Alzheimer's disease: evaluating its role in cognitive decline. <b>2018</b> , 141, 37-47	113
1262	The hypothalamus as the primary brain region of metabolic abnormalities in APP/PS1 transgenic mouse model of Alzheimer's disease. <b>2018</b> , 1864, 263-273	25
1261	Amyloid-PET burden and regional distribution in cerebral amyloid angiopathy: a systematic review and meta-analysis of biomarker performance. <b>2018</b> , 89, 410-417	24
1260	Early Alzheimer-type lesions in cognitively normal subjects. <b>2018</b> , 62, 34-44	24
1259	Alzheimer's disease. <b>2018</b> , 25, 59-70	846
1258	Anxiety-like behavior as an early endophenotype in the TgF344-AD rat model of Alzheimer's disease. <b>2018</b> , 61, 169-176	29
1257	Gray matter network measures are associated with cognitive decline in mild cognitive impairment. <b>2018</b> , 61, 198-206	25

1256	Validation of Noninvasive Tracer Kinetic Analysis of F-Florbetaben PET Using a Dual-Time-Window Acquisition Protocol. <b>2018</b> , 59, 1104-1110	17
1255	Whole-exome sequencing of the BDR cohort: evidence to support the role of the PILRA gene in Alzheimer's disease. <b>2018</b> , 44, 506-521	27
1254	The limbic and neocortical contribution of $\beta$ -synuclein, tau, and amyloid $\beta$ to disease duration in dementia with Lewy bodies. <b>2018</b> , 14, 330-339	40
1253	Frontotemporal lobar degeneration due to P301L tau mutation showing apathy and severe frontal atrophy but lacking other behavioral changes: A case report and literature review. <b>2018</b> , 38, 268-280	5
1252	Treated hypothyroidism is associated with cerebrovascular disease but not Alzheimer's disease pathology in older adults. <b>2018</b> , 62, 64-71	11
1251	Imaging microglial activation and amyloid burden in amnesic mild cognitive impairment. <b>2018</b> , 38, 1885-1895	20
1250	Spatiotemporal Distribution of $\beta$ Amyloid in Alzheimer Disease Is the Result of Heterogeneous Regional Carrying Capacities. <b>2018</b> , 59, 822-827	26
1249	Neuroimaging and other modalities to assess Alzheimer's disease in Down syndrome. <b>2018</b> , 17, 263-271	42
1248	Comparison of olfactory and gustatory disorders in Alzheimer's disease. <b>2018</b> , 39, 321-328	17
1247	Application of the condensed protocol for the NIA-AA guidelines for the neuropathological assessment of Alzheimer's disease in an academic clinical practice. <b>2018</b> , 72, 433-440	4
1246	Stress induced neural reorganization: A conceptual framework linking depression and Alzheimer's disease. <b>2018</b> , 85, 136-151	33
1245	When pitch adds to volume: coregulation of transcript diversity predicts gene function. <b>2018</b> , 19, 926	
1244	Antemortem CSF A42/A40 ratio predicts Alzheimer's disease pathology better than A42 in rapidly progressive dementias. <b>2019</b> , 6, 263-273	19
1243	3 .Neuropathologie und molekulare Mechanismen. <b>2018</b> , 35-122	0
1242	Autopsied centenarian case of Alzheimer's disease combined with hippocampal sclerosis, TDP-43, and $\beta$ -synuclein pathologies. <b>2018</b> , 38, 653-659	
1241	Non-Phosphorylated Tau in Cerebrospinal Fluid is a Marker of Alzheimer's Disease Continuum in Young Urbanites Exposed to Air Pollution. <b>2018</b> , 66, 1437-1451	9
1240	Microglial activation occurs late during preclinical Alzheimer's disease. <b>2018</b> , 66, 2550-2562	38
1239	The Brain Donation Program in South Korea. <b>2018</b> , 59, 1197-1204	4

1238	Endothelial damage, vascular bagging and remodeling of the microvascular bed in human microangiopathy with deep white matter lesions. <b>2018</b> , 6, 128	16
1237	Progressive impairment of directional and spatially precise trajectories by TgF344-Alzheimer's disease rats in the Morris Water Task. <b>2018</b> , 8, 16153	26
1236	Toxic Protein Spread in Neurodegeneration: Reality versus Fantasy. <b>2018</b> , 24, 1007-1020	17
1235	Jowiseungchungtang Inhibits Amyloid- $\beta$ Aggregation and Amyloid- $\beta$ Mediated Pathology in 5XFAD Mice. <b>2018</b> , 19,	6
1234	Cerebral Corpora amylacea are dense membranous labyrinths containing structurally preserved cell organelles. <b>2018</b> , 8, 18046	13
1233	Amyloid, tau, pathogen infection and antimicrobial protection in Alzheimer's disease -conformist, nonconformist, and realistic prospects for AD pathogenesis. <b>2018</b> , 7, 34	52
1232	Can 11C-PiB-PET Relative Delivery R1 or 11C-PiB-PET Perfusion Replace 18F-FDG-PET in the Assessment of Brain Neurodegeneration?. <b>2018</b> , 65, 89-97	13
1231	MR approaches in neurodegenerative disorders. <b>2018</b> , 108, 1-16	10
1230	Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders. <b>2019</b> , 85, 259-271	41
1229	Genetic characterization of amyloid- $\beta$ and tau network spread. <b>2018</b> , 24, 1790-1792	1
1228	Prediction of Autopsy Verified Neuropathological Change of Alzheimer's Disease Using Machine Learning and MRI. <b>2018</b> , 10, 406	10
1227	Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches. <b>2018</b> , 29, 3937-3966	15
1226	Al $\beta$ and the dementia syndrome: Simple versus complex perspectives. <b>2018</b> , 48, e13025	8
1225	Chronic Traumatic Encephalopathy Within an Amyotrophic Lateral Sclerosis Brain Bank Cohort. <b>2018</b> , 77, 1091-1100	19
1224	Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease. <b>2018</b> , 14, 1505-1521	97
1223	The Early Events That Initiate $\beta$ Amyloid Aggregation in Alzheimer's Disease. <b>2018</b> , 10, 359	47
1222	APOE $\epsilon$ is associated with increased tau pathology in primary tauopathy. <b>2018</b> , 9, 4388	68
1221	Evidence of intraneuronal A $\beta$ accumulation preceding tau pathology in the entorhinal cortex. <b>2018</b> , 136, 901-917	36

1220	Neurogenetic contributions to amyloid beta and tau spreading in the human cortex. <b>2018</b> , 24, 1910-1918	80
1219	Alzheimer's Disease Biomarkers Have Distinct Associations with Specific Hippocampal Subfield Volumes. <b>2018</b> , 66, 811-823	5
1218	Optimizing Longitudinal Amyloid- $\beta$ PET Measurement: The Challenges of Intensity Normalization. <b>2018</b> , 59, 1581-1582	3
1217	Sex and age interact to determine clinicopathologic differences in Alzheimer's disease. <b>2018</b> , 136, 873-885	36
1216	Dynactin is involved in Lewy body pathology. <b>2018</b> , 38, 583-590	7
1215	Imaging Protein Misfolding in the Brain Using $\beta$ Sheet Ligands. <b>2018</b> , 12, 585	21
1214	Autopsy case of V180I genetic Creutzfeldt-Jakob disease presenting with early disease pathology. <b>2018</b> , 38, 638-645	7
1213	Nuclear poly(ADP-ribose) activity is a therapeutic target in amyotrophic lateral sclerosis. <b>2018</b> , 6, 84	54
1212	Neural correlates of episodic memory in the Memento cohort. <b>2018</b> , 4, 224-233	10
1211	Patterns and severity of vascular amyloid in Alzheimer's disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimer's disease. <b>2018</b> , 136, 569-587	35
1210	Amyloid Accumulation and Cognitive Decline in Clinically Normal Older Individuals: Implications for Aging and Early Alzheimer's Disease. <b>2018</b> , 64, S633-S646	27
1209	PET staging of amyloidosis using striatum. <b>2018</b> , 14, 1281-1292	62
1208	Emergence of exosomal DNA in molecular neuropathology. <b>2018</b> , 42, 9-22	1
1207	Lysosomes, autophagosomes and Alzheimer pathology in dementia with Lewy body disease. <b>2018</b> , 38, 347	4
1206	Staging of amyloid $\beta$ -tau, regional atrophy rates, and cognitive change in a nondemented cohort: Results of serial mediation analyses. <b>2018</b> , 10, 382-393	13
1205	Evidence of altered depression and dementia-related proteins in the brains of young rats after ovariectomy. <b>2018</b> , 146, 703-721	27
1204	EEG and ERP biomarkers of Alzheimer's disease: a critical review. <b>2018</b> , 23, 183-220	68
1203	Alzheimer's disease and alpha-synuclein pathology in the olfactory bulbs of infants, children, teens and adults $\geq$ 40 years in Metropolitan Mexico City. APOE4 carriers at higher risk of suicide accelerate their olfactory bulb pathology. <b>2018</b> , 166, 348-362	47

1202	Amyotrophic lateral sclerosis and non-tau frontotemporal lobar degeneration. <b>2017</b> , 145, 369-381	13
1201	Comorbidities. <b>2017</b> , 145, 573-577	3
1200	The Revised National Alzheimer's Coordinating Center's Neuropathology Form-Available Data and New Analyses. <b>2018</b> , 77, 717-726	55
1199	Mitochondrial dysfunction and altered ribostasis in hippocampal neurons with cytoplasmic inclusions of multiple system atrophy. <b>2018</b> , 38, 361	3
1198	Translational opportunities for amyloid-targeting fluorophores. <b>2018</b> , 54, 9107-9118	20
1197	Brain donation procedures in the Sudden Death Brain Bank in Edinburgh. <b>2018</b> , 150, 17-27	2
1196	The Role of Immunosenescence in Neurodegenerative Diseases. <b>2018</b> , 2018, 6039171	68
1195	Early stage memory impairment, visual hallucinations, and myoclonus combined with temporal lobe atrophy predict Alzheimer's disease pathology in corticobasal syndrome. <b>2018</b> , 24, 145-150	3
1194	The age of onset and evolution of Braak tangle stage and Thal amyloid pathology of Alzheimer's disease in individuals with Down syndrome. <b>2018</b> , 6, 56	48
1193	Neonatal Neurodegeneration in Alzheimer's Disease Transgenic Mouse Model. <b>2018</b> , 2, 79-91	5
1192	Phosphorylation of different tau sites during progression of Alzheimer's disease. <b>2018</b> , 6, 52	124
1191	Oligodendrogliopathy in neurodegenerative diseases with abnormal protein aggregates: The forgotten partner. <b>2018</b> , 169, 24-54	33
1190	Autopsied case of non-plaque-type dura mater graft-associated Creutzfeldt-Jakob disease presenting with extensive amyloid- $\beta$ deposition. <b>2018</b> , 38, 549-556	8
1189	Sequential stages and distribution patterns of aging-related tau astrogliopathy (ARTAG) in the human brain. <b>2018</b> , 6, 50	49
1188	Epigenetic regulation of brain region-specific microglia clearance activity. <b>2018</b> , 21, 1049-1060	189
1187	DNA methylation analysis on purified neurons and glia dissects age and Alzheimer's disease-specific changes in the human cortex. <b>2018</b> , 11, 41	96
1186	Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model. <b>2018</b> , 10, 54	19
1185	Diffuse Amyloid- $\beta$ Plaques, Neurofibrillary Tangles, and the Impact of APOE in Elderly Persons' Brains Lacking Neuritic Amyloid Plaques. <b>2018</b> , 64, 1307-1324	19

1184	Neuropathology and cognitive performance in self-reported cognitively healthy centenarians. <b>2018</b> , 6, 64	24
1183	Infrequent false positive [F]ludemetamol PET signal is resolved by combined histological assessment of neuritic and diffuse plaques. <b>2018</b> , 10, 60	19
1182	Use of Peptides for the Management of Alzheimer's Disease: Diagnosis and Inhibition. <b>2018</b> , 10, 21	40
1181	Glutamate Transporter GLT1 Expression in Alzheimer Disease and Dementia With Lewy Bodies. <b>2018</b> , 10, 122	22
1180	Altered Regulation of KIAA0566, and Katanin Signaling Expression in the Locus Coeruleus With Neurofibrillary Tangle Pathology. <b>2018</b> , 12, 131	6
1179	Perspectives on How Human Simultaneous Multi-Modal Imaging Adds Directionality to Spread Models of Alzheimer's Disease. <b>2018</b> , 9, 26	3
1178	Mathematical Modeling of Protein Misfolding Mechanisms in Neurological Diseases: A Historical Overview. <b>2018</b> , 9, 37	25
1177	Synaptic Tau Seeding Precedes Tau Pathology in Human Alzheimer's Disease Brain. <b>2018</b> , 12, 267	115
1176	Multimodal Discrimination between Normal Aging, Mild Cognitive Impairment and Alzheimer's Disease and Prediction of Cognitive Decline. <b>2018</b> , 8,	15
1175	Amyloid involvement in subcortical regions predicts cognitive decline. <b>2018</b> , 45, 2368-2376	25
1174	What Happens with the Circuit in Alzheimer's Disease in Mice and Humans?. <b>2018</b> , 41, 277-297	83
1173	MK-0677, a Ghrelin Agonist, Alleviates Amyloid Beta-Related Pathology in 5XFAD Mice, an Animal Model of Alzheimer's Disease. <b>2018</b> , 19,	19
1172	Proteomics analysis identifies new markers associated with capillary cerebral amyloid angiopathy in Alzheimer's disease. <b>2018</b> , 6, 46	39
1171	Molecular imaging in dementia: Past, present, and future. <b>2018</b> , 14, 1522-1552	40
1170	Modified amyloid variants in pathological subgroups of -amyloidosis. <b>2018</b> , 5, 815-831	14
1169	The presubiculum is preserved from neurodegenerative changes in Alzheimer's disease. <b>2018</b> , 6, 62	3
1168	Molecular properties underlying regional vulnerability to Alzheimer's disease pathology. <b>2018</b> , 141, 2755-2771	65
1167	Large inter- and intra-case variability of first generation tau PET ligand binding in neurodegenerative dementias. <b>2018</b> , 6, 34	20

1166	Tau seeding activity begins in the transentorhinal/entorhinal regions and anticipates phospho-tau pathology in Alzheimer's disease and PART. <b>2018</b> , 136, 57-67		105
1165	The correlation between striatal and cortical binding ratio of C-PiB-PET in amyloid-uptake-positive patients. <b>2018</b> , 32, 398-403		5
1164	Brainstem tau pathology in Alzheimer's disease is characterized by increase of three repeat tau and independent of amyloid $\beta$ <b>2018</b> , 6, 1		47
1163	Iatrogenic Creutzfeldt-Jakob disease with Amyloid- $\beta$ pathology: an international study. <b>2018</b> , 6, 5		55
1162	Creutzfeldt-Jakob disease with Alzheimer pathology, presenting with status epilepticus following repeated partial seizures: a case report and literature review. <b>2018</b> , 18, 54		5
1161	An inorganic overview of natural A $\beta$ fragments: Copper(II) and zinc(II)-mediated pathways. <b>2018</b> , 369, 1-14		11
1160	A common antigenic motif recognized by naturally occurring human V5-51/V4-1 anti-tau antibodies with distinct functionalities. <b>2018</b> , 6, 43		10
1159	Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer's disease brains: Implications for in-vivo diagnostics. <b>2018</b> , 6, 75		30
1158	$\beta$ is associated with severity of Lewy body pathology independent of Alzheimer pathology. <i>Neurology</i> , <b>2018</b> , 91, e1182-e1195	6.5	77
1157	Distinctive temporal profiles of detergent-soluble and -insoluble tau and A $\beta$ species in human Alzheimer's disease. <b>2018</b> , 1699, 121-134		9
1156	Dysregulation of Neuronal Iron Homeostasis as an Alternative Unifying Effect of Mutations Causing Familial Alzheimer's Disease. <b>2018</b> , 12, 533		25
1155	Different patterns of hippocampal tau pathology in Alzheimer's disease and PART. <b>2018</b> , 136, 811-813		21
1154	Neuroinflammation is increased in the parietal cortex of atypical Alzheimer's disease. <b>2018</b> , 15, 170		17
1153	Estimation of amyloid distribution by [ $^{18}$ F]flutemetamol PET predicts the neuropathological phase of amyloid $\beta$ protein deposition. <b>2018</b> , 136, 557-567		29
1152	[ $^{18}$ F]-Flutemetamol Uptake in Cortex and White Matter: Comparison with Cerebrospinal Fluid Biomarkers and [ $^{18}$ F]-Fludeoxyglucose. <b>2018</b> , 62, 1595-1607		13
1151	A simple and clinically relevant combination of neuroimaging and functional indexes for the identification of those at highest risk of Alzheimer's disease. <b>2018</b> , 69, 102-110		7
1150	Alzheimer's disease pathology propagation by exosomes containing toxic amyloid-beta oligomers. <b>2018</b> , 136, 41-56		216
1149	Diffuse Lewy body disease manifesting as corticobasal syndrome: A rare form of Lewy body disease. <i>Neurology</i> , <b>2018</b> , 91, e268-e279	6.5	30



1148	Update on biomarkers for amyloid pathology in Alzheimer's disease. <b>2018</b> , 12, 799-812	39
1147	Old Gray Mouse Lemur Behavior, Cognition, and Neuropathology. <b>2018</b> , 287-300	2
1146	Nuclear medicine of the cerebellum. <b>2018</b> , 154, 251-266	4
1145	Pathological Correlates of Cognitive Impairment in The University of Manchester Longitudinal Study of Cognition in Normal Healthy Old Age. <b>2018</b> , 64, 483-496	19
1144	Stereological Quantification of Plaques and Tangles in Neocortex from Alzheimer's Disease Patients. <b>2018</b> , 64, 723-734	3
1143	Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype. <b>2018</b> , 136, 389-404	27
1142	Detection of Changes in Immunohistochemical Stains Caused by Postmortem Delay and Fixation Time. <b>2019</b> , 27, 238-245	11
1141	Spatial Patterns of Hypometabolism and Amyloid Deposition in Variants of Alzheimer's Disease Corresponding to Brain Networks: a Prospective Cohort Study. <b>2019</b> , 21, 140-148	9
1140	Lysosomal cathepsin D is upregulated in Alzheimer's disease neocortex and may be a marker for neurofibrillary degeneration. <b>2019</b> , 29, 63-74	27
1139	Differential insular cortex subregional vulnerability to $\beta$ -synuclein pathology in Parkinson's disease and dementia with Lewy bodies. <b>2019</b> , 45, 262-277	19
1138	In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand F-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls. <b>2019</b> , 60, 93-99	106
1137	Cortical Network Topology in Prodromal and Mild Dementia Due to Alzheimer's Disease: Graph Theory Applied to Resting State EEG. <b>2019</b> , 32, 127-141	20
1136	Spatially Adaptive Varying Correlation Analysis for Multimodal Neuroimaging Data. <b>2019</b> , 38, 113-123	2
1135	Distinct Interplay Between Atrophy and Hypometabolism in Alzheimer's Versus Semantic Dementia. <b>2019</b> , 29, 1889-1899	18
1134	The basis of cellular and regional vulnerability in Alzheimer's disease. <b>2019</b> , 138, 729-749	31
1133	Clinicopathologic subtype of Alzheimer's disease presenting as corticobasal syndrome. <b>2019</b> , 15, 1218-1228	20
1132	Aging, Metabolism, Synaptic Activity, and A $\beta$ in Alzheimer's Disease. <b>2019</b> , 11, 185	4
1131	A $\beta$ -induced acceleration of Alzheimer-related $\beta$ -pathology spreading and its association with prion protein. <b>2019</b> , 138, 913-941	48

1130	Microglia Express Insulin-Like Growth Factor-1 in the Hippocampus of Aged APP/PS1 Transgenic Mice. <b>2019</b> , 13, 308	10
1129	Linking Molecular Pathways and Large-Scale Computational Modeling to Assess Candidate Disease Mechanisms and Pharmacodynamics in Alzheimer's Disease. <b>2019</b> , 13, 54	30
1128	Molecular pathology of neurodegenerative diseases: principles and practice. <b>2019</b> , 72, 725-735	58
1127	Neuropathology of dementia in patients with Parkinson's disease: a systematic review of autopsy studies. <b>2019</b> , 90, 1234-1243	37
1126	The neuropathological diagnosis of Alzheimer's disease. <b>2019</b> , 14, 32	554
1125	LATE to the PART-y. <b>2019</b> , 142, e47	25
1124	Comparison of neurodegenerative types using different brain MRI analysis metrics in older adults with normal cognition, mild cognitive impairment, and Alzheimer's dementia. <b>2019</b> , 14, e0220739	6
1123	Neuropathological correlates of amyloid PET imaging in Down syndrome. <b>2019</b> , 79, 750-766	25
1122	Optimized dual-time-window protocols for quantitative [F]flutemetamol and [F]florbetaben PET studies. <b>2019</b> , 9, 32	19
1121	Contextualizing the pathology in the essential tremor cerebellar cortex: a patholog-omics approach. <b>2019</b> , 138, 859-876	27
1120	Brain Molecular Connectivity in Neurodegenerative Diseases: Recent Advances and New Perspectives Using Positron Emission Tomography. <b>2019</b> , 13, 617	29
1119	Alzheimer Disease Pathogenesis: Insights From Molecular and Cellular Biology Studies of Oligomeric A $\beta$ and Tau Species. <b>2019</b> , 13, 659	122
1118	Staging $\beta$ Amyloid Pathology With Amyloid Positron Emission Tomography. <b>2019</b> , 76, 1319-1329	71
1117	Quantitative Brain Amyloid Measures Predict Time-to-Progression from Amnesic Mild Cognitive Impairment to Alzheimer's Disease. <b>2019</b> , 70, 477-486	4
1116	Early Electrophysiological Disintegration of Hippocampal Neural Networks in a Novel Locus Coeruleus Tau-Seeding Mouse Model of Alzheimer's Disease. <b>2019</b> , 2019, 6981268	11
1115	Relationships Between Diffusion Tensor Imaging and Cerebrospinal Fluid Metrics in Early Stages of the Alzheimer's Disease Continuum. <b>2019</b> , 70, 965-981	10
1114	Associations among amyloid status, age, and longitudinal regional brain atrophy in cognitively unimpaired older adults. <b>2019</b> , 82, 110-119	4
1113	Impact of TREM2 risk variants on brain region-specific immune activation and plaque microenvironment in Alzheimer's disease patient brain samples. <b>2019</b> , 138, 613-630	35

1112	Neuropathological Changes in Dementia With Lewy Bodies and the Cingulate Island Sign. <b>2019,</b>	6
1111	Subcortical amyloid relates to cortical morphology in cognitively normal individuals. <b>2019, 46, 2358-2369</b>	3
1110	Topographical Heterogeneity of Alzheimer's Disease Based on MR Imaging, Tau PET, and Amyloid PET. <b>2019, 11, 211</b>	14
1109	Tauopathy in basal ganglia involvement is exacerbated in a subset of patients with Alzheimer's disease: The Hisayama study. <b>2019, 11, 415-423</b>	8
1108	Amyloid Beta 25-35 induces blood-brain barrier disruption in vitro. <b>2019, 34, 1365-1374</b>	23
1107	Combustion- and friction-derived magnetic air pollution nanoparticles in human hearts. <b>2019, 176, 108567</b>	66
1106	Microstates as Disease and Progression Markers in Patients With Mild Cognitive Impairment. <b>2019, 13, 563</b>	28
1105	Associations of Neprilysin Activity in CSF with Biomarkers for Alzheimer's Disease. <b>2019, 19, 43-50</b>	4
1104	Neuropathologic correlates of amyloid and dopamine transporter imaging in Lewy body disease. <i>Neurology</i> , <b>2019, 93, e476-e484</b>	6.5 15
1103	Evaluation of Associations of Alzheimer's Disease Risk Variants that Are Highly Expressed in Microglia with Neuropathological Outcome Measures. <b>2019, 70, 659-666</b>	5
1102	Association between brain amyloid accumulation and neuropsychological characteristics in elders with depression and mild cognitive impairment. <b>2019, 34, 1907-1915</b>	8
1101	Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment. <b>2019, 40, 5424-5442</b>	57
1100	Biological, Diagnostic and Therapeutic Advances in Alzheimer's Disease. <b>2019,</b>	0
1099	Prognostic plasma protein panel for A $\beta$ deposition in the brain in Alzheimer's disease. <b>2019, 183, 101690</b>	10
1098	Lower nucleus accumbens $\beta$ synuclein load and D3 receptor levels in Parkinson's disease with impulsive compulsive behaviours. <b>2019, 142, 3580-3591</b>	6
1097	Mutations in CHCHD2 cause $\beta$ synuclein aggregation. <b>2019, 28, 3895-3911</b>	22
1096	Topographical Visualization of the Reciprocal Projection between the Medial Septum and the Hippocampus in the 5XFAD Mouse Model of Alzheimer's Disease. <b>2019, 20,</b>	8
1095	Future horizons in Alzheimer's disease research. <b>2019, 168, 223-241</b>	10

1094	Cerebrovascular pathology presenting as corticobasal syndrome: An autopsy case series of "vascular CBS". <b>2019</b> , 68, 79-84	10
1093	Heat Shock Proteins in Neuroscience. <b>2019</b> ,	
1092	From molecules to system failure: translational frontiers of multimodal imaging in neurodegenerative diseases. <b>2019</b> , 46, 2816-2818	
1091	Tau and Amyloid- $\beta$ Pathology in Japanese Forensic Autopsy Series Under 40 Years of Age: Prevalence and Association with APOE Genotype and Suicide Risk. <b>2019</b> , 72, 641-652	2
1090	AD molecular: Imaging tau aggregates with positron emissions tomography. <b>2019</b> , 165, 107-138	7
1089	Hibernation Impairs Odor Discrimination - Implications for Alzheimer's Disease. <b>2019</b> , 13, 69	2
1088	Overview of Transgenic Mouse Models for Alzheimer's Disease. <b>2019</b> , 89, e81	37
1087	Neuropathologic basis of frontotemporal dementia in progressive supranuclear palsy. <b>2019</b> , 34, 1655-1662	8
1086	Samung Fan-out Panel Level Package Solutions. <b>2019</b> ,	0
1085	Kallikrein-related peptidases 6 and 10 are elevated in cerebrospinal fluid of patients with Alzheimer's disease and associated with CSF-TAU and FDG-PET. <b>2019</b> , 8, 25	6
1084	Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities. <b>2019</b> , 8, 28	42
1083	AD molecular: PET amyloid imaging across the Alzheimer's disease spectrum: From disease mechanisms to prevention. <b>2019</b> , 165, 63-106	4
1082	Late-onset unexplained epilepsy: What are we missing?. <b>2019</b> , 99, 106478	9
1081	Aggregation States of A $\beta$ , A $\beta$ and A $\beta$ Amyloid Beta Peptides: A SANS Study. <b>2019</b> , 20,	9
1080	Altered microglia and neurovasculature in the Alzheimer's disease cerebellum. <b>2019</b> , 132, 104589	15
1079	Do Alzheimer's and Lewy body disease have discrete pathological signatures of gait?. <b>2019</b> , 15, 1367-1377	20
1078	Braak neurofibrillary tangle staging prediction from in vivo MRI metrics. <b>2019</b> , 11, 599-609	1
1077	Condensing the A $\beta$ protocol to reduce the effort and cost of NIA-AA guidelines for neuropathologic assessment of Alzheimer disease. <b>2019</b> , 78, 975-977	1

1076	Comorbidity of age-related macular degeneration with Alzheimer's disease: A histopathologic case-control study. <b>2019</b> , 14, e0223199	2
1075	Neuroglia in Neurodegenerative Diseases. <b>2019</b> ,	7
1074	3D mapping reveals network-specific amyloid progression and subcortical susceptibility in mice. <b>2019</b> , 2, 360	22
1073	Regional brain atrophy predicts time to conversion to Alzheimer's disease, dependent on baseline volume. <b>2019</b> , 83, 86-94	12
1072	ApoE attenuates unresolvable inflammation by complex formation with activated C1q. <b>2019</b> , 25, 496-506	107
1071	Clinical diagnoses among individuals with primary age-related tauopathy versus Alzheimer's neuropathology. <b>2019</b> , 99, 1049-1055	12
1070	Aggregated Tau activates NLRP3-ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo. <b>2019</b> , 137, 599-617	129
1069	The Promises and Challenges of Erythropoietin for Treatment of Alzheimer's Disease. <b>2019</b> , 21, 12-24	22
1068	Characteristics of the tissue section that influence the staining outcome in immunohistochemistry. <b>2019</b> , 151, 91-96	16
1067	Association of MAPT H1 subhaplotypes with neuropathology of lewy body disease. <b>2019</b> , 34, 1325-1332	6
1066	Assessing Neuroprotective Agents for A $\beta$ Induced Neurotoxicity. <b>2019</b> , 25, 685-695	10
1065	Diffuse Lewy Body Disease and Alzheimer Disease: Neuropathologic Phenotype Associated With the PSEN1 p.A396T Mutation. <b>2019</b> , 78, 585-594	6
1064	Modeling and Inference of Spatio-Temporal Protein Dynamics Across Brain Networks. <b>2019</b> , 57-69	4
1063	Mild Chronic Traumatic Encephalopathy Neuropathology in People With No Known Participation in Contact Sports or History of Repetitive Neurotrauma. <b>2019</b> , 78, 615-625	25
1062	Resistance and resilience to Alzheimer's disease pathology are associated with reduced cortical pTau and absence of limbic-predominant age-related TDP-43 encephalopathy in a community-based cohort. <b>2019</b> , 7, 91	30
1061	Tau Protein is Associated with Longitudinal Memory Decline in Cognitively Healthy Subjects with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels. <b>2019</b> , 70, 211-225	6
1060	APOE Effect on Amyloid- $\beta$ PET Spatial Distribution, Deposition Rate, and Cut-Points. <b>2019</b> , 69, 783-793	7
1059	Increased prevalence of granulovacuolar degeneration in C9orf72 mutation. <b>2019</b> , 138, 783-793	13

1058	Subcortical amyloid load is associated with shape and volume in cognitively normal individuals. <b>2019</b> , 40, 3951-3965	6
1057	Alzheimer's disease neuropathological change and loss of matrix/neuropil in patients with idiopathic Normal Pressure Hydrocephalus, a model of Alzheimer's disease. <b>2019</b> , 7, 98	8
1056	Optimization of solid-phase extraction (SPE) in the preparation of [F]D3FSP: A new PET imaging agent for mapping A $\beta$ plaques. <b>2019</b> , 71, 54-64	2
1055	Gray matter T1-w/T2-w ratios are higher in Alzheimer's disease. <b>2019</b> , 40, 3900-3909	10
1054	Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease. <b>2019</b> , 15, 927-939	30
1053	Chronic traumatic encephalopathy is a common co-morbidity, but less frequent primary dementia in former soccer and rugby players. <b>2019</b> , 138, 389-399	55
1052	Cholinesterase Inhibitors May Not Benefit Mild Cognitive Impairment and Mild Alzheimer Disease Dementia. <b>2019</b> , 33, 87-94	25
1051	The standardization of cerebrospinal fluid markers and neuropathological diagnoses brings to light the frequent complexity of concomitant pathology in Alzheimer's disease: The next challenge for biochemical markers?. <b>2019</b> , 72, 15-23	3
1050	Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer's disease. <b>2019</b> , 130, 104509	25
1049	Developing a Spatial Navigation Screening Tool Sensitive to the Preclinical Alzheimer Disease Continuum. <b>2019</b> , 34, 1138-1155	7
1048	Medial Temporal Lobe Disconnection and Hyperexcitability Across Alzheimer's Disease Stages. <b>2019</b> , 3, 103-112	24
1047	Network Patterns of Beta-Amyloid Deposition in Parkinson's Disease. <b>2019</b> , 56, 7731-7740	9
1046	Exploring the Pathogenesis of Alzheimer Disease in Basal Forebrain Cholinergic Neurons: Converging Insights From Alternative Hypotheses. <b>2019</b> , 13, 446	68
1045	Comparison of F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL approaches: Validation against histopathology. <b>2019</b> , 15, 807-816	26
1044	The interplay of biochemical and biomechanical degeneration in Alzheimer's disease. <b>2019</b> , 352, 369-388	16
1043	Interpretable classification of Alzheimer's disease pathologies with a convolutional neural network pipeline. <b>2019</b> , 10, 2173	53
1042	Abnormal Amyloid Load in Mild Cognitive Impairment: The Effect of Reducing the PiB-PET Threshold. <b>2019</b> , 29, 499-505	7
1041	Peripheral administration of human recombinant ApoJ/clusterin modulates brain beta-amyloid levels in APP23 mice. <b>2019</b> , 11, 42	15

1040	Biopathological Significance of Early-Phase Amyloid Imaging in the Spectrum of Alzheimer's Disease. <b>2019</b> , 69, 529-538	2
1039	Neurochemical Aspects of Alzheimer's Type of Dementia. <b>2019</b> , 73-112	0
1038	Age, but Not Amyloidosis, Induced Changes in Global Levels of Histone Modifications in Susceptible and Disease-Resistant Neurons in Alzheimer's Disease Model Mice. <b>2019</b> , 11, 68	3
1037	Brain atrophy in primary age-related tauopathy is linked to transactive response DNA-binding protein of 43 kDa. <b>2019</b> , 15, 799-806	11
1036	Aβ and tau prion-like activities decline with longevity in the Alzheimer's disease human brain. <b>2019</b> , 11,	55
1035	No association between head injury with loss of consciousness and Alzheimer disease pathology-Findings from the University of Manchester Longitudinal Study of Cognition in Normal Healthy Old Age. <b>2019</b> , 34, 1262-1266	1
1034	Bridging the Gap between Alzheimer's Disease and Alzheimer's-like Diseases in Animals. <b>2019</b> , 20,	10
1033	Amyloid-β PET Imaging in Aging and Dementia. <b>2019</b> , 119-129	
1032	Association of MAPT Subhaplotypes With Risk of Progressive Supranuclear Palsy and Severity of Tau Pathology. <b>2019</b> , 76, 710-717	23
1031	Is there a difference in regional read [F]flutemetamol amyloid patterns between end-of-life subjects and those with amnesic mild cognitive impairment?. <b>2019</b> , 46, 1299-1308	9
1030	Validation of the Erlangen Score Algorithm for Differential Dementia Diagnosis in Autopsy-Confirmed Subjects. <b>2019</b> , 68, 1151-1159	6
1029	Development of Radioiodinated Benzofuran Derivatives for Imaging of Prion Deposits in the Brain. <b>2019</b> , 5, 2003-2013	2
1028	Neurodegenerative Diseases and Ageing. <b>2019</b> , 91, 75-106	5
1027	PET/CT in Brain Disorders. <b>2019</b> ,	1
1026	Pathogenic tau modifications occur in axons before the somatodendritic compartment in mossy fiber and Schaffer collateral pathways. <b>2019</b> , 7, 29	7
1025	Are comorbidities compatible with a molecular pathological classification of neurodegenerative diseases?. <b>2019</b> , 32, 279-291	20
1024	The Dichotomy of Alzheimer's Disease Pathology: Amyloid-β and Tau. <b>2019</b> , 68, 77-83	8
1023	Young adult-onset, very slowly progressive cognitive decline with spastic paraparesis in Alzheimer's disease with cotton wool plaques due to a novel presenilin1 G417S mutation. <b>2019</b> , 7, 19	6

1022	Normal Aging Brain Collection Amsterdam (NABCA): A comprehensive collection of postmortem high-field imaging, neuropathological and morphometric datasets of non-neurological controls. <b>2019</b> , 22, 101698	9
1021	Putative Survival Advantages in Young Apolipoprotein e4 Carriers are Associated with Increased Neural Stress. <b>2019</b> , 68, 885-923	18
1020	Hippocampal Gene Expression is Increased in Late-Stage Alzheimer's Disease. <b>2019</b> , 20,	5
1019	Understanding the Amyloid Hypothesis in Alzheimer's Disease. <b>2019</b> , 68, 493-510	33
1018	A cortical microvascular structure in vascular dementia, Alzheimer's disease, frontotemporal lobar degeneration and nondemented controls: a sign of angiogenesis due to brain ischaemia?. <b>2019</b> , 45, 557-569	7
1017	Alzheimer's Disease Including Focal Presentations. <b>2019</b> , 39, 213-226	33
1016	Heterogeneous drug tissue binding in brain regions of rats, Alzheimer's patients and controls: impact on translational drug development. <b>2019</b> , 9, 5308	11
1015	ApoE4 lowers age at onset in patients with frontotemporal dementia and tauopathy independent of amyloid- $\beta$ pathology. <b>2019</b> , 11, 277-280	16
1014	Ethnoracial differences in Alzheimer's disease from the FLorida Autopsied Multi-Ethnic (FLAME) cohort. <b>2019</b> , 15, 635-643	17
1013	Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study. <b>2019</b> , 11, 15	17
1012	Beta-amyloid pathology in human brain microvessel extracts from the parietal cortex: relation with cerebral amyloid angiopathy and Alzheimer's disease. <b>2019</b> , 137, 801-823	35
1011	A walk through tau therapeutic strategies. <b>2019</b> , 7, 22	133
1010	Impaired Glucose Tolerance and Reduced Plasma Insulin Precede Decreased AKT Phosphorylation and GLUT3 Translocation in the Hippocampus of Old 3xTg-AD Mice. <b>2019</b> , 68, 809-837	18
1009	Brain and cognitive correlates of sleep fragmentation in elderly subjects with and without cognitive deficits. <b>2019</b> , 11, 142-150	17
1008	The relationship between the morphological subtypes of microglia and Alzheimer's disease neuropathology. <b>2019</b> , 29, 726-740	34
1007	A distinct brain beta amyloid signature in cerebral amyloid angiopathy compared to Alzheimer's disease. <b>2019</b> , 701, 125-131	25
1006	Pyroglutamation of amyloid- $\beta$ -42 (A $\beta$ -42) followed by A $\beta$ -40 deposition underlies plaque polymorphism in progressing Alzheimer's disease pathology. <b>2019</b> , 294, 6719-6732	30
1005	Neuropathological Diagnoses of Demented Hispanic, Black, and Non-Hispanic White Decedents Seen at an Alzheimer's Disease Center. <b>2019</b> , 68, 145-158	29



1004	Deep White Matter Lesions Are Associated with Early Recognition of Dementia in Alzheimer's Disease. <b>2019</b> , 68, 797-808	4
1003	Fact, Fiction, or Evolution: Mechanism Hypothesis of Alzheimer's Disease. <b>2019</b> ,	
1002	Optimization of the k <sub>2</sub> Parameter Estimation for the Pharmacokinetic Modeling of Dynamic PIB PET Scans Using SRTM2. <b>2019</b> , 7,	4
1001	Alzheimer's-like pathology in aging rhesus macaques: Unique opportunity to study the etiology and treatment of Alzheimer's disease. <b>2019</b> ,	23
1000	Deterioration from healthy to mild cognitive impairment and Alzheimer's disease mirrored in corresponding loss of centrality in directed brain networks. <b>2019</b> , 6, 8	5
999	Association Between Hippocampus, Thalamus, and Caudate in Mild Cognitive Impairment APOE $\epsilon$ Carriers: A Structural Covariance MRI Study. <b>2019</b> , 10, 1303	9
998	Neuropathology-driven Whole-genome Sequencing Study Points to Novel Candidate Genes for Healthy Brain Aging. <b>2019</b> , 33, 7-14	1
997	Different aspects of Alzheimer's disease-related amyloid $\beta$ peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia. <b>2019</b> , 7, 178	16
996	Alzheimer's disease. <b>2019</b> , 167, 231-255	128
995	Subregional Density of Neurons, Neurofibrillary Tangles and Amyloid Plaques in the Hippocampus of Patients With Alzheimer's Disease. <b>2019</b> , 13, 99	16
994	Selective memory and behavioral alterations after ambient ultrafine particulate matter exposure in aged 3xTgAD Alzheimer's disease mice. <b>2019</b> , 16, 45	16
993	Aberrant Accumulation of BRCA1 in Alzheimer Disease and Other Tauopathies. <b>2020</b> , 79, 22-33	10
992	Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments. <b>2019</b> , 7, 313	49
991	Epidemiological pathology of A $\beta$ deposition in the ageing brain in CFAS: addition of multiple A $\beta$ -derived measures does not improve dementia assessment using logistic regression and machine learning approaches. <b>2019</b> , 7, 198	7
990	QUINT: Workflow for Quantification and Spatial Analysis of Features in Histological Images From Rodent Brain. <b>2019</b> , 13, 75	13
989	Decreased Vascular Pulsatility in Alzheimer's Disease Dementia Measured by Transcranial Color-Coded Duplex Sonography. <b>2019</b> , 15, 3487-3499	3
988	Lewy body pathology in Alzheimer's disease: A clinicopathological prospective study. <b>2019</b> , 139, 76-81	19
987	A protocol for precise comparisons of small vessel disease lesions between ex vivo magnetic resonance imaging and histopathology. <b>2019</b> , 14, 310-320	10

986	Astrocytic changes with aging and Alzheimer's disease-type pathology in chimpanzees. <b>2019</b> , 527, 1179-1195	20
985	Comparison of Amyloid and Tau Spread Models in Alzheimer's Disease. <b>2019</b> , 29, 4291-4302	10
984	Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease. <b>2019</b> , 97, 3-17	51
983	Influence of hypertension on brain amyloid deposition and Alzheimer's disease signature neurodegeneration. <b>2019</b> , 75, 62-70	15
982	Neuropathologic, genetic, and longitudinal cognitive profiles in primary age-related tauopathy (PART) and Alzheimer's disease. <b>2019</b> , 15, 8-16	46
981	Neuroinflammation in mild cognitive impairment and Alzheimer's disease: A meta-analysis. <b>2019</b> , 50, 1-8	76
980	Luminex-based quantification of Alzheimer's disease neuropathologic change in formalin-fixed post-mortem human brain tissue. <b>2019</b> , 99, 1056-1067	6
979	Early functional connectivity deficits and progressive microstructural alterations in the TgF344-AD rat model of Alzheimer's Disease: A longitudinal MRI study. <b>2019</b> , 124, 93-107	24
978	A nonhuman primate model of early Alzheimer's disease pathologic change: Implications for disease pathogenesis. <b>2019</b> , 15, 93-105	44
977	Intracranial vascular calcification with extensive white matter changes in an autopsy case of pseudopseudohypoparathyroidism. <b>2019</b> , 39, 39-46	9
976	Sleep-wake regulation and the hallmarks of the pathogenesis of Alzheimer's disease. <b>2019</b> , 42,	17
975	Prognosis and Neuropathologic Correlation of Clinical Subtypes of Parkinson Disease. <b>2019</b> , 76, 470-479	118
974	Amyloid- $\beta$ immunotherapy for alzheimer disease: Is it now a long shot?. <b>2019</b> , 85, 303-315	87
973	Beyond the neuron-cellular interactions early in Alzheimer disease pathogenesis. <b>2019</b> , 20, 94-108	142
972	Multisite study of the relationships between antemortem [C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. <b>2019</b> , 15, 205-216	82
971	A physics-based model explains the prion-like features of neurodegeneration in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. <b>2019</b> , 124, 264-281	45
970	Whole brain imaging reveals distinct spatial patterns of amyloid beta deposition in three mouse models of Alzheimer's disease. <b>2019</b> , 527, 2122-2145	37
969	Amyotrophic lateral sclerosis of long clinical course clinically presenting with progressive muscular atrophy. <b>2019</b> , 39, 47-53	1

968	Extravascular fibrinogen in the white matter of Alzheimer's disease and normal aged brains: implications for fibrinogen as a biomarker for Alzheimer's disease. <b>2019</b> , 29, 414-424	19
967	The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer's disease. <b>2019</b> , 137, 89-102	47
966	Fucosterol exerts protection against amyloid $\beta$ -induced neurotoxicity, reduces intracellular levels of amyloid $\beta$ and enhances the mRNA expression of neuroglobin in amyloid $\beta$ -induced SH-SY5Y cells. <b>2019</b> , 121, 207-213	18
965	Pathology, Prevention and Therapeutics of Neurodegenerative Disease. <b>2019</b> ,	1
964	Targeting Glucocorticoid Receptors: A New Avenue for Alzheimer's Disease Therapy. <b>2019</b> , 173-183	2
963	Can Animal Models Inform on the Relationship between Depression and Alzheimer Disease?. <b>2019</b> , 64, 18-29	4
962	Intrinsic connectivity identifies the sensory-motor network as a main cross-network between remitted late-life depression- and amnesic mild cognitive impairment-targeted networks. <b>2020</b> , 14, 1130-1142	4
961	Variability and Coupling of Olfactory Identification and Episodic Memory in Older Adults. <b>2020</b> , 75, 577-584	1
960	Association of anxiety with subcortical amyloidosis in cognitively normal older adults. <b>2020</b> , 25, 2599-2607	14
959	Noradrenergic pathways of locus coeruleus in Parkinson's and Alzheimer's pathology. <b>2020</b> , 130, 251-261	1
958	Cholinergic deficits and galaninergic hyperinnervation of the nucleus basalis of Meynert in Alzheimer's disease and Lewy body disorders. <b>2020</b> , 46, 264-278	8
957	The Molecular Misreading of APP and UBB Induces a Humoral Immune Response in Alzheimer's Disease Patients with Diagnostic Ability. <b>2020</b> , 57, 1009-1020	8
956	Neuronal loss without amyloid- $\beta$ deposits in the thalamus and hippocampus in the late period after middle cerebral artery occlusion in cynomolgus monkeys. <b>2020</b> , 30, 165-178	5
955	Neuropathologic basis of in vivo cortical atrophy in the aphasic variant of Alzheimer's disease. <b>2020</b> , 30, 332-344	5
954	Saliva, an easily accessible fluid as diagnostic tool and potent stem cell source for Alzheimer's Disease: Present and future applications. <b>2020</b> , 1727, 146535	11
953	The puzzle of preserved cognition in the oldest old. <b>2020</b> , 41, 441-447	3
952	Evaluation of the effect of aroma oil as a bath salt on cognitive function. <b>2020</b> , 20, 163-171	2
951	Selective Vulnerability of the Nucleus Basalis of Meynert Among Neuropathologic Subtypes of Alzheimer Disease. <b>2020</b> , 77, 225-233	26

950	Analysis of brain sub regions using optimization techniques and deep learning method in Alzheimer disease. <b>2020</b> , 86, 105857	30
949	G protein-coupled receptors in neurodegenerative diseases. <b>2020</b> , 335-365	
948	Chemical imaging of evolving amyloid plaque pathology and associated A $\beta$ peptide aggregation in a transgenic mouse model of Alzheimer's disease. <b>2020</b> , 152, 602-616	8
947	Resistance, vulnerability and resilience: A review of the cognitive cerebellum in aging and neurodegenerative diseases. <b>2020</b> , 170, 106981	26
946	From the Entorhinal Region via the Prosubiculum to the Dentate Fascia: Alzheimer Disease-Related Neurofibrillary Changes in the Temporal Allocortex. <b>2020</b> , 79, 163-175	10
945	Receptors for pro-resolving mediators are increased in Alzheimer's disease brain. <b>2020</b> , 30, 614-640	17
944	Staging of tau distribution by positron emission tomography may be useful in clinical staging of Alzheimer disease. <b>2020</b> , 8, 61-67	3
943	Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age. <b>2020</b> , 143, 320-335	56
942	To stage, or not to stage. <b>2020</b> , 61, 10-22	14
941	Cerebrospinal fluid progranulin is associated with increased cortical thickness in early stages of Alzheimer's disease. <b>2020</b> , 88, 61-70	7
940	Staging and quantification of florbetaben PET images using machine learning: impact of predicted regional cortical tracer uptake and amyloid stage on clinical outcomes. <b>2020</b> , 47, 1971-1983	6
939	The Spatial-Temporal Ordering of Amyloid Pathology and Opportunities for PET Imaging. <b>2020</b> , 61, 166-171	18
938	Binding of [F]AV1451 in post mortem brain slices of semantic variant primary progressive aphasia patients. <b>2020</b> , 47, 1949-1960	6
937	Limbic Predominant Age-Related TDP-43 Encephalopathy (LATE): Clinical and Neuropathological Associations. <b>2020</b> , 79, 305-313	25
936	Distance disintegration delineates the brain connectivity failure of Alzheimer's disease. <b>2020</b> , 88, 51-60	5
935	The search for a unique Raman signature of amyloid-beta plaques in human brain tissue from Alzheimer's disease patients. <b>2020</b> , 145, 1724-1736	13
934	Normal brain aging and Alzheimer's disease are associated with lower cerebral pH: an in vivo histidine H-MR spectroscopy study. <b>2020</b> , 87, 60-69	15
933	Clinical significance of focal $\beta$ amyloid deposition measured by F-flutemetamol PET. <b>2020</b> , 12, 6	4

932	A Comparative Study of Pathological Outcomes in The University of Manchester Longitudinal Study of Cognition in Normal Healthy Old Age and Brains for Dementia Research Cohorts. <b>2020</b> , 73, 619-632	5
931	Human subiculo-fornico-mamillary system in Alzheimer's disease: Tau seeding by the pillar of the fornix. <b>2020</b> , 139, 443-461	5
930	Brain imaging measurements of fibrillar amyloid-burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE $\epsilon$ allele. <b>2020</b> , 16, 598-609	10
929	Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. <b>2020</b> , 16, 30-42	171
928	Amyloid-Independent regulators of tau pathology in Alzheimer disease. <b>2020</b> , 21, 21-35	176
927	Necrosome complex detected in granulovacuolar degeneration is associated with neuronal loss in Alzheimer's disease. <b>2020</b> , 139, 463-484	38
926	Medial temporal lobe white matter pathway variability is associated with individual differences in episodic memory in cognitively normal older adults. <b>2020</b> , 87, 78-88	3
925	$\beta$ Amyloid PET and neuropathology in dementia with Lewy bodies. <i>Neurology</i> , <b>2020</b> , 94, e282-e291	6.5 31
924	Invited Review: The role of prion-like mechanisms in neurodegenerative diseases. <b>2020</b> , 46, 522-545	46
923	Aging and Alzheimer's disease pathology. <b>2020</b> , 40, 22-29	75
922	Sowing the Seeds of Discovery: Tau-Propagation Models of Alzheimer's Disease. <b>2020</b> , 11, 3499-3509	2
921	Amyloid-IPET and CSF in an autopsy-confirmed cohort. <b>2020</b> , 7, 2150-2160	10
920	Local Sleep and Alzheimer's Disease Pathophysiology. <b>2020</b> , 14, 525970	10
919	Derivation and utility of an A $\beta$ PET pathology accumulation index to estimate A $\beta$ load. <i>Neurology</i> , <b>2020</b> , 95, e2834-e2844	6.5 3
918	Mixed Brain Pathology Is the Most Common Cause of Cognitive Impairment in the Elderly. <b>2020</b> , 78, 453-465	7
917	Bridging the Gap Between Fluid Biomarkers for Alzheimer's Disease, Model Systems, and Patients. <b>2020</b> , 12, 272	3
916	Quadruple abnormal protein aggregates in brainstem pathology and exogenous metal-rich magnetic nanoparticles (and engineered Ti-rich nanorods). The substantia nigrae is a very early target in young urbanites and the gastrointestinal tract a key brainstem portal. <b>2020</b> , 191, 110139	20
915	Globular glial tauopathy Type I presenting with behavioral variant frontotemporal dementia. <b>2020</b> , 40, 515-525	5

914	Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer's Disease. <b>2020</b> , 182, 976-991.e19	164
913	Integrated Metabolomic and Lipidomic Analysis Reveals the Neuroprotective Mechanisms of Bushen Tiansui Formula in an A1-42-Induced Rat Model of Alzheimer's Disease. <b>2020</b> , 2020, 5243453	5
912	Complex I reductions in the nucleus basalis of Meynert in Lewy body dementia: the role of Lewy bodies. <b>2020</b> , 8, 103	2
911	Primary Age-Related Tauopathy (PART): Addressing the Spectrum of Neuronal Tauopathic Changes in the Aging Brain. <b>2020</b> , 20, 39	10
910	Multitracer model for staging cortical amyloid deposition using PET imaging. <i>Neurology</i> , <b>2020</b> , 95, e15386-15530	6.5
909	Relationship between Amyloid and structural network topology in decedents without dementia. <i>Neurology</i> , <b>2020</b> , 95, e532-e544	3
908	Passive immunotherapies targeting A $\beta$ and tau in Alzheimer's disease. <b>2020</b> , 144, 105010	27
907	An Overview on the Differential Interplay Among Neurons-Astrocytes-Microglia in CA1 and CA3 Hippocampus in Hypoxia/Ischemia. <b>2020</b> , 14, 585833	10
906	Pathological Correlations of Neuropsychiatric Symptoms in Institutionalized People with Dementia. <b>2020</b> , 78, 1731-1741	6
905	Comparison of ELISA- and SIMOA-based quantification of plasma A $\beta$ ratios for early detection of cerebral amyloidosis. <b>2020</b> , 12, 162	21
904	Accuracy of Biomarker Testing for Neuropathologically Defined Alzheimer Disease in Older Adults With Dementia. <b>2020</b> , 172, 669-677	17
903	Feasibility studies of radioiodinated pyridyl benzofuran derivatives as potential SPECT imaging agents for prion deposits in the brain. <b>2020</b> , 90-91, 41-48	1
902	Cerebral Amyloid Angiopathy Presenting as Massive Subarachnoid Haemorrhage: A Case Study and Review of Literature. <b>2020</b> , 12, 538456	1
901	Advanced Glycation End Product Formation in Human Cerebral Cortex Increases With Alzheimer-Type Neuropathologic Changes but Is Not Independently Associated With Dementia in a Population-Derived Aging Brain Cohort. <b>2020</b> , 79, 950-958	5
900	Microglia depletion diminishes key elements of the leukotriene pathway in the brain of Alzheimer's Disease mice. <b>2020</b> , 8, 129	9
899	Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers. <b>2020</b> , 61, 1413-1418	6
898	The Neuropathological Diagnosis of Alzheimer's Disease-The Challenges of Pathological Mimics and Concomitant Pathology. <b>2020</b> , 10,	12
897	The existence of A $\beta$ trains and their potential for driving phenotypic heterogeneity in Alzheimer's disease. <b>2021</b> , 142, 17-39	18

896	Neuropathological assessment of the Alzheimer spectrum. <b>2020</b> , 127, 1229-1256	13
895	JBPOS0101 regulates amyloid beta, tau, and glial cells in an Alzheimer's disease model. <b>2020</b> , 15, e0237153	1
894	Exploring Beyond the DNA Sequence: A Review of Epigenomic Studies of DNA and Histone Modifications in Dementia. <b>2020</b> , 8, 79-92	6
893	Prion-Like Propagation Mechanisms in Tauopathies and Traumatic Brain Injury: Challenges and Prospects. <b>2020</b> , 10,	2
892	Concomitant LATE-NC in Alzheimer's disease is not associated with increased tau or amyloid- $\beta$ pathological burden. <b>2020</b> , 46, 722-734	2
891	Association of ABI3 and PLCG2 missense variants with disease risk and neuropathology in Lewy body disease and progressive supranuclear palsy. <b>2020</b> , 8, 172	3
890	Neuroimaging in dementias. <b>2020</b> , 187-197	
889	Denser brain capillary network with preserved pericytes in Alzheimer's disease. <b>2020</b> , 30, 1071-1086	8
888	The two faces of synaptic failure in App knock-in mice. <b>2020</b> , 12, 100	8
887	Sensitivity-Specificity of Tau and Amyloid $\beta$ Positron Emission Tomography in Frontotemporal Lobar Degeneration. <b>2020</b> , 88, 1009-1022	9
886	Unclassified four-repeat tauopathy associated with familial parkinsonism and progressive respiratory failure. <b>2020</b> , 8, 148	1
885	The Contribution of Vascular Pathology Toward Cognitive Impairment in Older Individuals with Intermediate Braak Stage Tau Pathology. <b>2020</b> , 77, 1005-1015	1
884	Neuron loss associated with age but not Alzheimer's disease pathology in the chimpanzee brain. <b>2020</b> , 375, 20190619	8
883	Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease. <b>2020</b> , 15, 55	38
882	4 Pathology of the Brainstem. <b>2020</b> ,	
881	Clinician-judged hearing impairment and associations with neuropathologic burden. <i>Neurology</i> , <b>2020</b> , 95, e1640-e1649	6.5 7
880	Microfluidics-Based Systems in Diagnosis of Alzheimer's Disease and Biomimetic Modeling. <b>2020</b> , 11,	11
879	APOE and TREM2 regulate amyloid-responsive microglia in Alzheimer's disease. <b>2020</b> , 140, 477-493	31

878	Mechanisms of Pathogenic Tau and A $\beta$ Protein Spreading in Alzheimer's Disease. <b>2020</b> , 12, 265	29
877	Models to Study the Propagation of Prions and Prion-Like Proteins. <b>2020</b> , 10,	4
876	Proteomic Profiling of Extracellular Vesicles Derived from Cerebrospinal Fluid of Alzheimer's Disease Patients: A Pilot Study. <b>2020</b> , 9,	23
875	Unmasking selective path integration deficits in Alzheimer's disease risk carriers. <b>2020</b> , 6, eaba1394	13
874	Regional Cerebral Associations Between Psychometric Tests and Imaging Biomarkers in Alzheimer's Disease. <b>2020</b> , 11, 793	3
873	The coarse-grained plaque: a divergent A $\beta$ plaque-type in early-onset Alzheimer's disease. <b>2020</b> , 140, 811-830	20
872	Associations of mitochondrial genomic variation with corticobasal degeneration, progressive supranuclear palsy, and neuropathological tau measures. <b>2020</b> , 8, 162	6
871	Ubiquitin, Autophagy and Neurodegenerative Diseases. <b>2020</b> , 9,	18
870	Hippocampal subfield pathologic burden in Lewy body diseases vs. Alzheimer's disease. <b>2020</b> , 46, 707-721	7
869	Relationship between comprehensive geriatric assessment and amyloid PET in older persons with MCI. <b>2020</b> , 20, 337	7
868	T2 heterogeneity: a novel marker of microstructural integrity associated with cognitive decline in people with mild cognitive impairment. <b>2020</b> , 12, 105	8
867	Quantification of neurons in the hippocampal formation of chimpanzees: comparison to rhesus monkeys and humans. <b>2020</b> , 225, 2521-2531	3
866	Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid- $\beta$ plaques in Alzheimer's disease. <b>2020</b> , 140, 463-476	17
865	Distinct clinicopathologic clusters of persons with TDP-43 proteinopathy. <b>2020</b> , 140, 659-674	9
864	Tau and apolipoprotein E modulate cerebrovascular tight junction integrity independent of cerebral amyloid angiopathy in Alzheimer's disease. <b>2020</b> , 16, 1372-1383	12
863	Revisiting the Amyloid Cascade Hypothesis: From Anti-A $\beta$ Therapeutics to Auspicious New Ways for Alzheimer's Disease. <b>2020</b> , 21,	42
862	Radiomics Analysis of Magnetic Resonance Imaging Facilitates the Identification of Preclinical Alzheimer's Disease: An Exploratory Study. <b>2020</b> , 8, 605734	14
861	Experimental Evidence of the Benefits of Acupuncture for Alzheimer's Disease: An Updated Review. <b>2020</b> , 14, 549772	8



860	Alterations in resting-state network dynamics along the Alzheimer's disease continuum. <b>2020</b> , 10, 21990	9
859	Smelling the Dark Proteome: Functional Characterization of PITH Domain-Containing Protein 1 (C1orf128) in Olfactory Metabolism. <b>2020</b> , 19, 4826-4843	3
858	Neuropsychiatric symptoms in limbic-predominant age-related TDP-43 encephalopathy and Alzheimer's disease. <b>2020</b> , 143, 3842-3849	6
857	MAPT subhaplotypes in corticobasal degeneration: assessing associations with disease risk, severity of tau pathology, and clinical features. <b>2020</b> , 8, 218	4
856	Patterns of Mitochondrial TSPO Binding in Cerebral Small Vessel Disease: An PET Study With Neuropathological Comparison. <b>2020</b> , 11, 541377	4
855	APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer's disease: a systematic review. <b>2020</b> , 12, 141	34
854	Association of Subcortical Structural Shapes With Tau, Amyloid, and Cortical Atrophy in Early-Onset and Late-Onset Alzheimer's Disease. <b>2020</b> , 12, 563559	4
853	Contributions of Molecular and Optical Techniques to the Clinical Diagnosis of Alzheimer's Disease. <b>2020</b> , 10,	1
852	The MUC6/AP2A2 Locus and Its Relevance to Alzheimer's Disease: A Review. <b>2020</b> , 79, 568-584	8
851	Cell-to-Cell Transmission of Tau and $\beta$ Synuclein. <b>2020</b> , 26, 936-952	39
850	Aggregates of RNA Binding Proteins and ER Chaperones Linked to Exosomes in Granulovacuolar Degeneration of the Alzheimer's Disease Brain. <b>2020</b> , 75, 139-156	10
849	Cerebrovascular pathology and misdiagnosis of multiple system atrophy: An autopsy study. <b>2020</b> , 75, 34-40	5
848	No evidence for amyloid pathology as a key mediator of neurodegeneration post-stroke - a seven-year follow-up study. <b>2020</b> , 20, 174	14
847	Metabolic connectivity in Alzheimer's diseases. <b>2020</b> , 8, 157-166	2
846	CD8 T-cells infiltrate Alzheimer's disease brains and regulate neuronal- and synapse-related gene expression in APP-PS1 transgenic mice. <b>2020</b> , 89, 67-86	24
845	Extracellular Sortilin Proteopathy Relative to $\beta$ Amyloid and Tau in Aged and Alzheimer's Disease Human Brains. <b>2020</b> , 12, 93	3
844	Relevance of biomarkers across different neurodegenerative diseases. <b>2020</b> , 12, 56	15
843	Positron Emission Tomography Imaging With [ $^{18}$ F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. <b>2020</b> , 77, 829-839	105

842	Progressive dysexecutive syndrome due to Alzheimer's disease: a description of 55 cases and comparison to other phenotypes. <b>2020</b> , 2, fcaa068		36
841	Further understanding the connection between Alzheimer's disease and Down syndrome. <b>2020</b> , 16, 1065-1077	32	
840	Protective effect of maternal exercise against amyloid- $\beta$ neurotoxicity in the male rat offspring's cerebellum. <b>2020</b> , 11, 521-532		2
839	Tipping the Scales: Peptide-Dependent Dysregulation of Neural Circuit Dynamics in Alzheimer's Disease. <b>2020</b> , 107, 417-435		30
838	The lipid phosphatase Synaptojanin 1 undergoes a significant alteration in expression and solubility and is associated with brain lesions in Alzheimer's disease. <b>2020</b> , 8, 79		6
837	The presubiculum links incipient amyloid and tau pathology to memory function in older persons. <i>Neurology</i> , <b>2020</b> , 94, e1916-e1928	6.5	8
836	Alzheimer's Disease in Down Syndrome: Progress in the Design and Conduct of Drug Prevention Trials. <b>2020</b> , 34, 785-794		4
835	Head-to-Head Comparison of 18F-Florbetaben and 18F-Flutemetamol in the Cortical and Striatal Regions. <b>2020</b> , 76, 281-290		8
834	Synaptic Loss, ER Stress and Neuro-Inflammation Emerge Late in the Lateral Temporal Cortex and Associate with Progressive Tau Pathology in Alzheimer's Disease. <b>2020</b> , 57, 3258-3272		14
833	Clinical and pathologic features of cognitive-predominant corticobasal degeneration. <i>Neurology</i> , <b>2020</b> , 95, e35-e45	6.5	3
832	Senescence as an Amyloid Cascade: The Amyloid Senescence Hypothesis. <b>2020</b> , 14, 129		18
831	Clinical Experience in Treatment of Alzheimer's Disease with Jiannao Yizhi Formula ( ) and Routine Western Medicine. <b>2020</b> , 26, 212-218		1
830	A computerized version of the Short Form of the Face-Name Associative Memory Exam (FACEmemory $\square$ ) for the early detection of Alzheimer's disease. <b>2020</b> , 12, 25		13
829	Potential Role of Venular Amyloid in Alzheimer's Disease Pathogenesis. <b>2020</b> , 21,		14
828	Clinicopathological findings of a long-term survivor of V180I genetic Creutzfeldt-Jakob disease. <b>2020</b> , 14, 109-117		8
827	Upregulation of Neuronal Rheb(S16H) for Hippocampal Protection in the Adult Brain. <b>2020</b> , 21,		3
826	Circle of Willis abnormalities and their clinical importance in ageing brains: A cadaveric anatomical and pathological study. <b>2020</b> , 106, 101772		4
825	Confirmation of I-FP-CIT SPECT Quantification Methods in Dementia with Lewy Bodies and Other Neurodegenerative Disorders. <b>2020</b> , 61, 1628-1635		7

824	Protein transmission in neurodegenerative disease. <b>2020</b> , 16, 199-212	153
823	Functional Brain Network Connectivity Patterns Associated With Normal Cognition at Old-Age, Local Amyloid, Tau, and APOE4. <b>2020</b> , 12, 46	8
822	Clinical and striatal dopamine transporter predictors of Amyloid in dementia with Lewy bodies. <i>Neurology</i> , <b>2020</b> , 94, e1344-e1352	6.5 7
821	Association of Tripartite Motif Containing 11 rs564309 With Tau Pathology in Progressive Supranuclear Palsy. <b>2020</b> , 35, 890-894	1
820	Overview of Alzheimer's and Parkinson's diseases and the role of protein aggregation in these neurodegenerative diseases. <b>2020</b> , 29-53	
819	Association of hippocampal volume polygenic predictor score with baseline and change in brain volumes and cognition among cognitively healthy older adults. <b>2020</b> , 94, 81-88	0
818	SFPQ and Tau: critical factors contributing to rapid progression of Alzheimer's disease. <b>2020</b> , 140, 317-339	18
817	Selective Neuronal Vulnerability in Alzheimer's Disease: A Network-Based Analysis. <b>2020</b> , 107, 821-835.e12	35
816	Invited Review - Understanding cause and effect in Alzheimer's pathophysiology: Implications for clinical trials. <b>2020</b> , 46, 623-640	12
815	Longitudinal validity of PET-based staging of regional amyloid deposition. <b>2020</b> , 41, 4219-4231	8
814	Reduced repressive epigenetic marks, increased DNA damage and Alzheimer's disease hallmarks in the brain of humans and mice exposed to particulate urban air pollution. <b>2020</b> , 183, 109226	37
813	Brain areas with normatively greater cerebral perfusion in early life may be more susceptible to beta amyloid deposition in late life. <b>2020</b> , 1,	1
812	Hybrid PET/MRI enables high-spatial resolution, quantitative imaging of amyloid plaques in an Alzheimer's disease mouse model. <b>2020</b> , 10, 10379	3
811	Neuropathological profile of long-duration amyotrophic lateral sclerosis in military Veterans. <b>2020</b> , 30, 1028-1040	7
810	APOE-amyloid interaction: Therapeutic targets. <b>2020</b> , 138, 104784	27
809	Mixed neuropathology in frontotemporal lobar degeneration. <b>2020</b> , 21, 301-308	0
808	Disrupted functional connectivity of the locus coeruleus in healthy adults with parental history of Alzheimer's disease. <b>2020</b> , 123, 81-88	7
807	Fractional Anisotropy changes in Parahippocampal Cingulum due to Alzheimer's Disease. <b>2020</b> , 10, 2660	9

806	The Pattern of AQP4 Expression in the Ageing Human Brain and in Cerebral Amyloid Angiopathy. <b>2020</b> , 21,	7
805	The Leukotriene Receptor Antagonist Montelukast Reduces Alpha-Synuclein Load and Restores Memory in an Animal Model of Dementia with Lewy Bodies. <b>2020</b> , 17, 1061-1074	8
804	Decreased excitability of locus coeruleus neurons during hypercapnia is exaggerated in the streptozotocin-model of Alzheimer's disease. <b>2020</b> , 328, 113250	1
803	Brain mural cell loss in the parietal cortex in Alzheimer's disease correlates with cognitive decline and TDP-43 pathology. <b>2020</b> , 46, 458-477	15
802	Alzheimer disease starts in childhood in polluted Metropolitan Mexico City. A major health crisis in progress. <b>2020</b> , 183, 109137	30
801	Mild behavioral impairment is associated with $\beta$ amyloid but not tau or neurodegeneration in cognitively intact elderly individuals. <b>2020</b> , 16, 192-199	60
800	"Amyloid-beta accumulation cycle" as a prevention and/or therapy target for Alzheimer's disease. <b>2020</b> , 19, e13109	21
799	Intracerebral seeding of amyloid- $\beta$ and tau pathology in mice: Factors underlying prion-like spreading and comparisons with $\beta$ synuclein. <b>2020</b> , 112, 1-27	17
798	Longitudinal trajectory of Amyloid-related hippocampal subfield atrophy in nondemented elderly. <b>2020</b> , 41, 2037-2047	8
797	Renin-Angiotensin System and Alzheimer's Disease Pathophysiology: From the Potential Interactions to Therapeutic Perspectives. <b>2020</b> , 27, 484-511	10
796	Validation of machine learning models to detect amyloid pathologies across institutions. <b>2020</b> , 8, 59	11
795	Assessing circular RNAs in Alzheimer's disease and frontotemporal lobar degeneration. <b>2020</b> , 92, 7-11	12
794	Clinicopathologic and genetic features of multiple system atrophy with Lewy body disease. <b>2020</b> , 30, 766-778	7
793	Investigation of pathology, expression and proteomic profiles in human TREM2 variant postmortem brains with and without Alzheimer's disease. <b>2020</b> , 30, 794-810	4
792	Regional Amyloid Accumulation and White Matter Integrity in Cognitively Normal Individuals. <b>2020</b> , 74, 1261-1270	2
791	Visual contrast sensitivity is associated with the presence of cerebral amyloid and tau deposition. <b>2020</b> , 2, fcaa019	10
790	Changes in the left temporal microstate are a sign of cognitive decline in patients with Alzheimer's disease. <b>2020</b> , 10, e01630	8
789	Utility of spontaneous animal models of Alzheimer's disease in preclinical efficacy studies. <b>2020</b> , 380, 273-286	4

788	Contribution of mixed pathology to medial temporal lobe atrophy in Alzheimer's disease. <b>2020</b> , 16, 843-852	20
787	Proteomic and biological profiling of extracellular vesicles from Alzheimer's disease human brain tissues. <b>2020</b> , 16, 896-907	44
786	The histopathological staging of tau, but not amyloid, corresponds to antemortem cognitive status, dementia stage, functional abilities and neuropsychiatric symptoms. <b>2021</b> , 131, 800-809	5
785	Amide proton transfer-weighted magnetic resonance imaging of human brain aging at 3 Tesla. <b>2020</b> , 10, 727-742	2
784	Low-Dose Radiation Therapy: A New Treatment Strategy for Alzheimer's Disease?. <b>2020</b> , 74, 411-419	11
783	Frontotemporal Dementia: Correlations Between Psychiatric Symptoms and Pathology. <b>2020</b> , 87, 950-961	12
782	Repeatability of parametric methods for [F]florbetapir imaging in Alzheimer's disease and healthy controls: A test-retest study. <b>2021</b> , 41, 569-578	3
781	Hippocampal activation and connectivity in the aging brain. <b>2021</b> , 15, 711-726	3
780	Diagnosis of Alzheimer disease in MR brain images using optimization techniques. <b>2021</b> , 33, 223-237	2
779	Disposable immunoplatforms for the simultaneous determination of biomarkers for neurodegenerative disorders using poly(amidoamine) dendrimer/gold nanoparticle nanocomposite. <b>2021</b> , 413, 799-811	17
778	Disruption of metabolic, sleep, and sensorimotor functional outcomes in a female transgenic mouse model of Alzheimer's disease. <b>2021</b> , 398, 112983	1
777	A Clinicopathologic Study of Movement Disorders in Frontotemporal Lobar Degeneration. <b>2021</b> , 36, 632-641	2
776	Principal-Component Analysis-Based Measures of PET Data Closely Reflect Neuropathologic Staging Schemes. <b>2021</b> , 62, 855-860	1
775	Lewy pathology of the esophagus correlates with the progression of Lewy body disease: a Japanese cohort study of autopsy cases. <b>2021</b> , 141, 25-37	17
774	Clinicopathological investigation of the background of cognitive decline in elderly schizophrenia. <b>2021</b> , 33, 85-91	1
773	RAB39B is redistributed in dementia with Lewy bodies and is sequestered within $\alpha$ plaques and Lewy bodies. <b>2021</b> , 31, 120-132	3
772	Novel clinicopathological characteristics differentiate dementia with Lewy bodies from Parkinson's disease dementia. <b>2021</b> , 47, 143-156	8
771	Alzheimer's disease genetic risk and sleep phenotypes in healthy young men: association with more slow waves and daytime sleepiness. <b>2021</b> , 44,	1

770	Protein tyrosine phosphatase receptor type Q in cerebrospinal fluid reflects ependymal cell dysfunction and is a potential biomarker for adult chronic hydrocephalus. <b>2021</b> , 28, 389-400	5
769	The relation between tau pathology and granulovacuolar degeneration of neurons. <b>2021</b> , 147, 105138	2
768	Association of Initial $\beta$ Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. <b>2021</b> , 78, 217-228	13
767	A Multilevel View of the Development of Alzheimer's Disease. <b>2021</b> , 457, 283-293	18
766	Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum. <b>2021</b> , 144, 325-339	42
765	Lewy Body Disease is a Contributor to Logopenic Progressive Aphasia Phenotype. <b>2021</b> , 89, 520-533	6
764	Neuropathological Alzheimer's Disease Lesions in Nasu-Hakola Disease with TREM2 Mutation: Atypical Distribution of Neurofibrillary Changes. <b>2021</b> , 79, 25-30	2
763	Diagnostic Accuracy of Amyloid versus F-Fluorodeoxyglucose Positron Emission Tomography in Autopsy-Confirmed Dementia. <b>2021</b> , 89, 389-401	7
762	Coordination chemistry of ligands: Insights into the design of amyloid beta/tau-PET imaging probes and nanoparticles-based therapies for Alzheimer's disease. <b>2021</b> , 430, 213659	4
761	Mid to late-life scores of depression in the cognitively healthy are associated with cognitive status and Alzheimer's disease pathology at death. <b>2021</b> , 36, 713-721	2
760	Heterogenous deposition of $\beta$ Amyloid in the brain of aged dogs. <b>2021</b> , 99, 44-52	0
759	Multiple system aging-related tau astroglialopathy with complex proteinopathy in an oligosymptomatic octogenarian. <b>2021</b> , 41, 72-83	6
758	Alzheimer's Disease Neuropathological Comorbidities are Common in the Younger-Old. <b>2021</b> , 79, 389-400	10
757	The value of multimodal imaging with I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia. <b>2021</b> , 99, 11-18	1
756	Identification of intraneuronal amyloid beta oligomers in locus coeruleus neurons of Alzheimer's patients and their potential impact on inhibitory neurotransmitter receptors and neuronal excitability. <b>2021</b> , 47, 488-505	5
755	High-Contrast In Vivo Imaging of Tau Pathologies in Alzheimer's and Non-Alzheimer's Disease Tauopathies. <b>2021</b> , 109, 42-58.e8	53
754	Association of Cortical and Subcortical $\beta$ Amyloid With Standardized Measures of Depressive and Anxiety Symptoms in Adults Without Dementia. <b>2021</b> , 33, 64-71	4
753	Role of gut-brain axis, gut microbial composition, and probiotic intervention in Alzheimer's disease. <b>2021</b> , 264, 118627	65

752	Association of PET-based stages of amyloid deposition with neuropathological markers of A $\beta$ pathology. <b>2021</b> , 8, 29-42	2
751	Spatial Relationships between Molecular Pathology and Neurodegeneration in the Alzheimer's Disease Continuum. <b>2021</b> , 31, 1-14	12
750	Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias. <b>2021</b> , 79, 819-832	2
749	Genetic Insights into Alzheimer's Disease. <b>2021</b> , 16, 351-376	3
748	Analysis of amyloid and tau deposition in Alzheimer's disease using C-Pittsburgh compound B and F-THK 5351 positron emission tomography imaging. <b>2021</b> , 20, 61-72	1
747	PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer's disease-causing Presenilin-1 E280A mutation carriers. <b>2021</b> , 31, 102749	3
746	Early Selective Vulnerability of the CA2 Hippocampal Subfield in Primary Age-Related Tauopathy. <b>2021</b> , 80, 102-111	11
745	The mechanistic link between selective vulnerability of the locus coeruleus and neurodegeneration in Alzheimer's disease. <b>2021</b> , 141, 631-650	19
744	NGF and the Amyloid Precursor Protein in Alzheimer's Disease: From Molecular Players to Neuronal Circuits. <b>2021</b> , 1331, 145-165	4
743	Fibrillar A $\beta$ causes profound microglial metabolic perturbations in a novel APP knock-in mouse model.	2
742	Feasibility of pharmacokinetic parametric PET images in scaled subprofile modelling using principal component analysis. <b>2021</b> , 30, 102625	1
741	Klinik der Demenzen. <b>2021</b> , 59-92	
740	Absence of Uptake and Prion-Like Spreading of Alpha-Synuclein and Tau After Intravitreal Injection of Preformed Fibrils. <b>2020</b> , 12, 614587	3
739	Periodontitis and Alzheimer's disease. <b>2021</b> , 26, e43-e48	5
738	Extracellular Vesicles in Neurological Disorders. <b>2021</b> , 97, 411-436	0
737	Polyphenols attenuate mitochondrial dysfunction induced by amyloid peptides. <b>2021</b> , 317-337	
736	3D-visualization of amyloid- $\beta$ oligomer interactions with lipid membranes by cryo-electron tomography. <b>2021</b> , 12, 6896-6907	6
735	Pathobiology and Management of Alzheimer's Disease. <b>2021</b> , 57, 108-117	1

734	Gene therapy-mediated enhancement of protective protein expression for the treatment of Alzheimer's disease. <b>2021</b> , 1753, 147264	0
733	Traumatic rupture of the circle of Willis with closed head injury: Its pathology and possible pathogenesis. <b>2021</b> , 78, 102114	
732	Neurologin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers. <b>2021</b> , 9, 19	8
731	Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study. <b>2021</b> , 17, 1353-1364	38
730	Melatonin levels in the Alzheimer's disease continuum: a systematic review. <b>2021</b> , 13, 52	14
729	Contribution of rare homozygous and compound heterozygous VPS13C missense mutations to dementia with Lewy bodies and Parkinson's disease. <b>2021</b> , 9, 25	7
728	Hippocampal Sclerosis in Frontotemporal Dementia: When Vascular Pathology Meets Neurodegeneration. <b>2021</b> , 80, 313-324	1
727	Cognitive decline in amyotrophic lateral sclerosis: Neuropathological substrate and genetic determinants. <b>2021</b> , 31, e12942	1
726	Complex Inclusion Bodies and Defective Proteome Hubs in Neurodegenerative Disease: New Clues, New Challenges. <b>2021</b> , 1073858421989582	2
725	TMEM97 increases in synapses and is a potential synaptic A $\beta$ binding partner in human Alzheimer's disease.	1
724	Cerebrovascular and Neurodegenerative Pathologies in Long-Term Stable Mild Cognitive Impairment. <b>2021</b> , 79, 1269-1283	0
723	Deep Learning-Based Image Classification in Differentiating Tufted Astrocytes, Astrocytic Plaques, and Neuritic Plaques. <b>2021</b> , 80, 306-312	5
722	Differences between episodic and semantic memory in predicting observation-based activities of daily living in mild cognitive impairment and Alzheimer's disease. <b>2021</b> , 1-12	2
721	Crossed cerebellar diaschisis on F-FDG PET: Frequency across neurodegenerative syndromes and association with C-PIB and F-Flortaucipir. <b>2021</b> , 41, 2329-2343	3
720	Multi-scale brain simulation with integrated positron emission tomography yields hidden local field potential activity that augments machine learning classification of Alzheimer's disease.	2
719	Cryo-EM structures of tau filaments from Alzheimer's disease with PET ligand APN-1607. <b>2021</b> , 141, 697-708	29
718	The bvFTD phenocopy syndrome: a case study supported by repeated MRI, [F]FDG-PET and pathological assessment. <b>2021</b> , 27, 181-189	2
717	Recent Advances in Imaging of Preclinical, Sporadic, and Autosomal Dominant Alzheimer's Disease. <b>2021</b> , 18, 709-727	1



716	Concomitant neurodegenerative pathologies contribute to the transition from mild cognitive impairment to dementia. <b>2021</b> , 17, 1121-1133	17
715	Can blood amyloid levels be used as a biomarker for Alzheimer's disease?. <b>2021</b> , 7, 17-25	1
714	Amyloid pathology arrangements in Alzheimer's disease brains modulate in vivo seeding capability. <b>2021</b> , 9, 56	6
713	Mitochondrial dysfunction in neurodegenerative diseases: A focus on iPSC-derived neuronal models. <b>2021</b> , 94, 102362	5
712	A $\beta$ promotes amyloidogenic processing of APP through a G $\alpha$ /G $\beta$ signaling.	
711	Comorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease. <b>2021</b> , 144, 2186-2198	26
710	Inflammation, Nitro-Oxidative Stress, Impaired Autophagy, and Insulin Resistance as a Mechanistic Convergence Between Arterial Stiffness and Alzheimer's Disease. <b>2021</b> , 8, 651215	6
709	Neurodegenerative Disease and the NLRP3 Inflammasome. <b>2021</b> , 12, 643254	29
708	Relationship between brain AD biomarkers and episodic memory performance in healthy aging. <b>2021</b> , 148, 105680	2
707	Impact of Tracer Retention Levels on Visual Analysis of Cerebral [F]-Florbetaben PET Images. <b>2021</b> , 14, 70-77	
706	Defining early changes in Alzheimer's disease from RNA sequencing of brain regions differentially affected by pathology. <b>2021</b> , 11, 4865	6
705	New insights into atypical Alzheimer's disease in the era of biomarkers. <b>2021</b> , 20, 222-234	45
704	Early loss of cerebellar Purkinje cells in human and a transgenic mouse model of Alzheimer's disease. <b>2021</b> , 43, 570-581	1
703	Probing the Role of a Regional Quantitative Assessment of Amyloid PET. <b>2021</b> , 80, 383-396	2
702	Gray matter structural networks related to F-THK5351 retention in cognitively normal older adults and Alzheimer's disease patients. <b>2021</b> , 22, 100309	3
701	Cerebellar Calcium-Binding Protein and Neurotrophin Receptor Defects in Down Syndrome and Alzheimer's Disease. <b>2021</b> , 13, 645334	5
700	The Causal Role of Lipoxidative Damage in Mitochondrial Bioenergetic Dysfunction Linked to Alzheimer's Disease Pathology. <b>2021</b> , 11,	3
699	Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research. <b>2021</b> , 17, 1554-1574	11

698	New App knock-in mice that accumulate wild-type human Aβs rapidly as AppNL-G-F mice exhibit intensive cored plaque pathology and neuroinflammation.	
697	Asymmetry of Hippocampal Tau Pathology in Primary Age-Related Tauopathy and Alzheimer Disease. <b>2021</b> , 80, 436-445	3
696	Self-reported sleep relates to microstructural hippocampal decline in β-amyloid positive Adults beyond genetic risk. <b>2021</b> , 44,	1
695	Relationships Between Cognition and Neuropathological Tau in Alzheimer's Disease Assessed by 18F Flortaucipir PET. <b>2021</b> , 80, 1091-1104	4
694	Aging-related Alzheimer's disease-like neuropathology and functional decline in captive vervet monkeys ( <i>Chlorocebus aethiops sabaeus</i> ). <b>2021</b> , 83, e23260	8
693	AMYQ: An index to standardize quantitative amyloid load across PET tracers. <b>2021</b> , 17, 1499-1508	4
692	Superior Frontal Gyrus Locus DNA Methylation in Alzheimer's Disease. <b>2021</b> , 5, 275-282	2
691	Sequence of proteome profiles in preclinical and symptomatic Alzheimer's disease. <b>2021</b> , 17, 946-958	4
690	In vivo Characterization of Biochemical Variants of Amyloid-β in Subjects with Idiopathic Normal Pressure Hydrocephalus and Alzheimer's Disease Neuropathological Change. <b>2021</b> , 80, 1003-1012	2
689	The Use, Standardization, and Interpretation of Brain Imaging Data in Clinical Trials of Neurodegenerative Disorders. <b>2021</b> , 18, 686-708	4
688	Machine learning-based decision tree classifier for the diagnosis of progressive supranuclear palsy and corticobasal degeneration. <b>2021</b> , 47, 931-941	4
687	Multimodal, label-free fluorescence and Raman imaging of amyloid deposits in snap-frozen Alzheimer's disease human brain tissue. <b>2021</b> , 4, 474	5
686	Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease: Results From 2 Phase III Clinical Trials. <b>2021</b> , 78, 445-453	5
685	A human brain vascular atlas reveals diverse cell mediators of Alzheimer's disease risk.	13
684	Transcriptomic analysis to identify genes associated with selective hippocampal vulnerability in Alzheimer's disease. <b>2021</b> , 12, 2311	10
683	In vitro Characterization of the Regional Binding Distribution of Amyloid PET Tracer Florbetaben and the Glia Tracers Deprenyl and PK11195 in Autopsy Alzheimer's Brain Tissue. <b>2021</b> , 80, 1723-1737	10
682	Altered metabolic pathways in a transgenic mouse model suggest mechanistic role of amyloid precursor protein overexpression in Alzheimer's disease. <b>2021</b> , 17, 42	4
681	Coexisting Lewy body disease and clinical parkinsonism in amyotrophic lateral sclerosis. <b>2021</b> , 28, 2192-2199	4

680	Increasing the confidence of F-Florbetaben PET interpretations: Machine learning quantitative approximation.. <b>2022</b> , 41, 153-163	
679	Near-Infrared-Active Copper Molybdenum Sulfide Nanocubes for Phonon-Mediated Clearance of Alzheimer's $\beta$ Amyloid Aggregates. <b>2021</b> , 13, 18581-18593	5
678	Heparanase overexpression impedes perivascular clearance of amyloid- $\beta$ from murine brain: relevance to Alzheimer's disease. <b>2021</b> , 9, 84	2
677	3D Analysis of the Synaptic Organization in the Entorhinal Cortex in Alzheimer's Disease. <b>2021</b> , 8,	1
676	Alzheimer disease. <b>2021</b> , 7, 33	114
675	Graph Models of Pathology Spread in Alzheimer's Disease: An Alternative to Conventional Graph Theoretic Analysis. <b>2021</b> , 11, 799-814	2
674	Polyphenol-Peptide Interactions in Mitigation of Alzheimer's Disease: Role of Biosurface-Induced Aggregation. <b>2021</b> , 81, 33-55	0
673	Associations of Alzheimer's Disease Neuropathologic Changes with Clinical Presentations of Parkinson's Disease. <b>2021</b> , 81, 201-207	2
672	Longitudinal Assessment of Working Memory Performance in the APP <sup>swe</sup> /PSEN1 <sup>dE9</sup> Mouse Model of Alzheimer's Disease Using an Automated Figure-8-Maze. <b>2021</b> , 15, 655449	0
671	A $\beta$ 3 aggregates exhibit enhanced prion-like seeding activity in mice. <b>2021</b> , 9, 83	3
670	Network interdigitations of Tau and amyloid-beta deposits define cognitive levels in aging. <b>2021</b> , 42, 2990-3004	2
669	Relationship between F-18 florbetapir uptake in occipital lobe and neurocognitive performance in Alzheimer's disease. <b>2021</b> , 39, 984-993	1
668	Genome-wide analysis identifies a novel LINC-PINT splice variant associated with vascular amyloid pathology in Alzheimer's disease. <b>2021</b> , 9, 93	2
667	Old age genetically confirmed frontotemporal lobar degeneration with TDP-43 has limbic predominant TDP-43 deposition. <b>2021</b> , 47, 1050-1059	3
666	Water exchange rate across the blood-brain barrier is associated with CSF amyloid- $\beta$ 2 in healthy older adults. <b>2021</b> ,	6
665	The connections of Locus Coeruleus with hypothalamus: potential involvement in Alzheimer's disease. <b>2021</b> , 128, 589-613	3
664	VEGF counteracts amyloid- $\beta$ -induced synaptic dysfunction. <b>2021</b> , 35, 109121	2
663	Faster disease progression in Parkinson's disease with type 2 diabetes is not associated with increased $\beta$ synuclein, tau, amyloid- $\beta$ or vascular pathology. <b>2021</b> , 47, 1080-1091	2

662	Re-emphasizing early Alzheimer's disease pathology starting in select entorhinal neurons, with a special focus on mitophagy. <b>2021</b> , 67, 101307		18
661	Tacrolimus Protects against Age-Associated Microstructural Changes in the Beagle Brain. <b>2021</b> , 41, 5124-5133	3	
660	Alzheimer's Pathology Is Associated with Dedifferentiation of Intrinsic Functional Memory Networks in Aging. <b>2021</b> , 31, 4781-4793		4
659	Characteristics of Regional Cerebral Blood Flow in Alzheimer Disease and Amnesic Mild Cognitive Impairment by Single-Photon Emission Computerized Tomography: A Cross-Sectional Study. <b>2021</b> , 11, 91-98		1
658	Integrated phylogeny of the human brain and pathobiology of Alzheimer's disease: A unifying hypothesis. <b>2021</b> , 755, 135895		2
657	R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils. <b>2021</b> , 142, 475-494		5
656	Selective Neuron Vulnerability in Common and Rare Diseases-Mitochondria in the Focus. <b>2021</b> , 8, 676187		4
655	The clinical use of blood-test factors for Alzheimer's disease: improving the prediction of cerebral amyloid deposition by the QPLEX Alz plus assay kit. <b>2021</b> , 53, 1046-1054		1
654	Genome-wide association study identifies susceptibility loci of brain atrophy to NFIA and ST18 in Alzheimer's disease. <b>2021</b> , 102, 200.e1-200.e11		2
653	Clinical, Imaging, and Pathologic Characteristics of Patients With Right vs Left Hemisphere-Predominant Logopenic Progressive Aphasia. <i>Neurology</i> , <b>2021</b> , 97, e523-e534	6.5	1
652	Following spatial A $\beta$ aggregation dynamics in evolving Alzheimer's disease pathology by imaging stable isotope labeling kinetics. <b>2021</b> , 7,		3
651	Reversible GABAergic dysfunction involved in hippocampal hyperactivity predicts early-stage Alzheimer disease in a mouse model. <b>2021</b> , 13, 114		5
650	Olfactory Bulb Proteomics Reveals Widespread Proteostatic Disturbances in Mixed Dementia and Guides for Potential Serum Biomarkers to Discriminate Alzheimer Disease and Mixed Dementia Phenotypes. <b>2021</b> , 11,		0
649	An autopsy case of PARK2 due to a homozygous exon 2 deletion of parkin and associated with $\beta$ synucleinopathy. <b>2021</b> , 41, 293-300		1
648	Amyloid Beta-Mediated Changes in Synaptic Function and Spine Number of Neocortical Neurons Depend on NMDA Receptors. <b>2021</b> , 22,		1
647	The neural economics of brain aging. <b>2021</b> , 11, 12167		
646	Amyloid- $\beta$ p-tau, and reactive microglia load are correlates of MRI cortical atrophy in Alzheimer's disease.		0
645	Is Cerebral Amyloid- $\beta$ Deposition Related to Post-stroke Cognitive Impairment?. <b>2021</b> , 12, 946-957		5

644 [Neuropathology of dementia]. **2021**, 171, 257-273

643 Neuropathology of Aging in Cats and its Similarities to Human Alzheimer's Disease. **2021**, 2, 0

642 Early functional changes associated with alpha-synuclein proteinopathy in engineered human neural networks. **2021**, 320, C1141-C1152 1

641 Serum Corticosterone and Insulin Resistance as Early Biomarkers in the hAPP23 Overexpressing Mouse Model of Alzheimer's Disease. **2021**, 22, 5

640 Critical Appraisal of Amyloid Lowering Agents in AD. **2021**, 21, 39 9

639 COVID-19-related neuropathology and microglial activation in elderly with and without dementia. **2021**, 31, e12997 20

638 Olfactory neuropathology in Alzheimer's disease: a sign of ongoing neurodegeneration. **2021**, 54, 295-304 4

637 Subcortical and Cortical Regions of Amyloid- $\beta$  Pathology Measured by  $^{11}\text{C}$ -PiB PET Are Differentially Associated with Cognitive Functions and Stages of Disease in Memory Clinic Patients. **2021**, 81, 1613-1624 0

636 Refining the amyloid  $\beta$ -peptide and oligomer fingerprint ambiguities in Alzheimer's disease: Mass spectrometric molecular characterization in brain, cerebrospinal fluid, blood, and plasma. **2021**, 159, 234-257 0

635 Downstream effects of polypathology on neurodegeneration of medial temporal lobe subregions. **2021**, 9, 128 3

634 Combined Model of Aggregation and Network Diffusion Recapitulates Alzheimer's Regional Tau-Positron Emission Tomography. **2021**, 11, 624-638 3

633 Leveraging hallmark Alzheimer's molecular targets using phytoconstituents: Current perspective and emerging trends. **2021**, 139, 111634 0

632 Comparing amyloid- $\beta$  plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. **2021**, 142, 689-706 8

631 Dysregulated protein phosphorylation: A determining condition in the continuum of brain aging and Alzheimer's disease. **2021**, 31, e12996 4

630 Neurodegenerative proteinopathies associated with neuroinfections. **2021**, 128, 1551-1566 3

629 Spatially resolved transcriptomics reveals unique gene signatures associated with human temporal cortical architecture and Alzheimer's pathology. 4

628 The hot cross bun sign in corticobasal degeneration. **2021**, 41, 376-380 0

627 Basal Forebrain Cholinergic Neurons: Linking Down Syndrome and Alzheimer's Disease. **2021**, 13, 703876 1

626	Treatment by low-dose brain radiation therapy improves memory performances without changes of the amyloid load in the TgF344-AD rat model. <b>2021</b> , 103, 117-127	4
625	Accumulation of saposin in dystrophic neurites is linked to impaired lysosomal functions in Alzheimer's disease brains. <b>2021</b> , 16, 45	5
624	The complexity of Alzheimer's disease: an evolving puzzle. <b>2021</b> , 101, 1047-1081	7
623	Volumetry of Olfactory Structures in Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review and a Meta-Analysis. <b>2021</b> , 11,	2
622	Emergence of distinct and heterogeneous strains of amyloid beta as Alzheimer's disease progresses in Down syndrome.	
621	Investigating hypotheses of neurodegeneration by learning dynamical systems of protein propagation in the brain. <b>2021</b> , 235, 117980	3
620	Variability in the type and layer distribution of cortical A $\beta$ pathology in familial Alzheimer's disease. <b>2021</b> , e13009	1
619	Associations Between Amyloid and Tau Pathology, and Connectome Alterations, in Alzheimer's Disease and Mild Cognitive Impairment. <b>2021</b> , 82, 541-560	3
618	Multiple system atrophy variant with severe hippocampal pathology. <b>2021</b> , e13002	9
617	Structural (dys)connectivity associates with cholinergic cell density of the nucleus basalis of Meynert in Alzheimer's disease.	0
616	Exosomal tau with seeding activity is released from Alzheimer's disease synapses, and seeding potential is associated with amyloid beta. <b>2021</b> , 101, 1605-1617	6
615	Microglial activation and tau propagate jointly across Braak stages. <b>2021</b> , 27, 1592-1599	44
614	Mitochondrial pathway polygenic risk scores are associated with Alzheimer's Disease. <b>2021</b> , 108, 213-222	2
613	Phosphorylated tau fluid biomarker sites recognize earlier neurofibrillary tangle maturity levels in the postmortem Alzheimer's disease brain.	1
612	A Canonical Scheme of Bottom-Up and Top-Down Information Flows in the Frontoparietal Network. <b>2021</b> , 15, 691314	0
611	Deep learning-based model for diagnosing Alzheimer's disease and tauopathies. <b>2021</b> ,	2
610	Retinal Dysfunction in Alzheimer's Disease and Implications for Biomarkers. <b>2021</b> , 11,	1
609	Senile plaque calcification of the lamina circumvoluta medullaris in Alzheimer's disease. <b>2021</b> , 41, 366-370	1

608	Transmission iatrogène des protéines $\beta$ amyloïde et tau : importance clinique et pour la recherche biomédicale sur la maladie d'Alzheimer. <b>2021</b> , 205, 792-799	
607	Deep learning assisted quantitative assessment of histopathological markers of Alzheimer's disease and cerebral amyloid angiopathy. <b>2021</b> , 9, 141	3
606	Comparison of early F-18 Florbetaben PET/CT to Tc-99m ECD SPECT using voxel, regional, and network analysis. <b>2021</b> , 11, 16738	0
605	Tau Isoform Profile in Essential Tremor Diverges From Other Tauopathies. <b>2021</b> , 80, 835-843	0
604	Anxiety and Alzheimer's disease: Behavioral analysis and neural basis in rodent models of Alzheimer's-related neuropathology. <b>2021</b> , 127, 647-658	5
603	The Amyloid- $\beta$ Pathway in Alzheimer's Disease. <b>2021</b> ,	63
602	Neuronal excitation/inhibition imbalance: core element of a translational perspective on Alzheimer pathophysiology. <b>2021</b> , 69, 101372	13
601	Expression of the Excitatory Postsynaptic Scaffolding Protein, Shank3, in Human Brain: Effect of Age and Alzheimer's Disease. <b>2021</b> , 13, 717263	1
600	Diagnosi clinicolaboratoristica della malattia di Alzheimer. <b>2021</b> , 21, 1-15	
599	Selective extension of cerebral vascular calcification in an autopsy case of Fahr's syndrome associated with asymptomatic hypoparathyroidism. <b>2021</b> , 41, 387-395	
598	Objective Assessment of Hyposmia in Alzheimer's Disease From Image and Behavior by Combining Pleasant Odor With Unpleasant Odor. <b>2021</b> , 12, 697487	1
597	Metallobiology and therapeutic chelation of biometals (copper, zinc and iron) in Alzheimer's disease: Limitations, and current and future perspectives. <b>2021</b> , 67, 126779	14
596	Association of CD2AP neuronal deposits with Braak neurofibrillary stage in Alzheimer's disease. <b>2021</b> , e13016	1
595	Generation and characterization of a tractable <i>C. elegans</i> model of tauopathy. <b>2021</b> , 43, 2621-2631	0
594	Different Sides of Depression in the Elderly: An In-depth View on the Role of A $\beta$ Peptides. <b>2021</b> ,	2
593	Case Report: Coexistence of Alzheimer-Type Neuropathology in Fragile X-Associated Tremor Ataxia Syndrome. <b>2021</b> , 15, 720253	2
592	Exogenous A $\beta$ seeds induce A $\beta$ depositions in the blood vessels rather than the brain parenchyma, independently of A $\beta$ strain-specific information. <b>2021</b> , 9, 151	0
591	Neuronal Deposition of Amyloid- $\beta$ Oligomers and Hyperphosphorylated Tau Is Closely Connected with Cognitive Dysfunction in Aged Dogs. <b>2021</b> , 5, 749-760	0

590	Amyloid pathology and synaptic loss in pathological aging. <b>2021</b> , 159, 258-272	0
589	Phenylalanine Metabolism Is Dysregulated in Human Hippocampus with Alzheimer's Disease Related Pathological Changes. <b>2021</b> , 83, 609-622	2
588	An immune response characterizes early Alzheimer's disease pathology and subjective cognitive impairment in hydrocephalus biopsies. <b>2021</b> , 12, 5659	1
587	A third-generation mouse model of Alzheimer's disease shows early and increased cored plaque pathology composed of wild-type human amyloid $\beta$ peptide. <b>2021</b> , 297, 101004	5
586	Concurrent tau pathologies in frontotemporal lobar degeneration with TDP-43 pathology.	
585	Immune modulations and immunotherapies for Alzheimer's disease: a comprehensive review. <b>2021</b> ,	1
584	Inflammatory Cascade in Alzheimer's Disease Pathogenesis: A Review of Experimental Findings. <b>2021</b> , 10,	9
583	In vivo and neuropathology data support locus coeruleus integrity as indicator of Alzheimer's disease pathology and cognitive decline. <b>2021</b> , 13, eabj2511	11
582	Staging tau pathology with tau PET in Alzheimer's disease: a longitudinal study. <b>2021</b> , 11, 483	3
581	A Adenosine Receptor as a Potential Biomarker and a Possible Therapeutic Target in Alzheimer's Disease. <b>2021</b> , 10,	3
580	Chemical update on the potential for serotonin 5-HT and 5-HT receptor agents in the treatment of Alzheimer's disease. <b>2021</b> , 49, 128275	4
579	Unique regional patterns of amyloid burden predict progression to prodromal and clinical stages of Alzheimer's disease. <b>2021</b> , 106, 119-129	1
578	Cerebral blood flow in mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis. <b>2021</b> , 71, 101450	2
577	Two autopsy cases with injuries to the stomach following cardiopulmonary resuscitation. <b>2021</b> , 53, 101916	0
576	Higher motor cortical excitability linked to greater cognitive dysfunction in Alzheimer's disease: results from two independent cohorts. <b>2021</b> , 108, 24-33	3
575	Alzheimer's neuropathology in Down syndrome: From gestation to old age. <b>2022</b> , 11-44	
574	Biomarkers of Diseases: Their Role in Emergency Medicine.	
573	Evaluation of semi-quantitative measures of F-flutemetamol PET for the clinical diagnosis of Alzheimer's disease.. <b>2022</b> , 12, 493-509	0



572 The aging brain and brain banking. **2021**, 103-112

571 Interaction between A $\beta$  and Tau in the Pathogenesis of Alzheimer's Disease. **2021**, 17, 2181-2192 10

570 Amyloid  $\beta$  and tau pathology in brains of aged pinniped species (sea lion, seal, and walrus). **2021**, 9, 10 4

569 Maturation of neuronal AD-tau pathology involves site-specific phosphorylation of cytoplasmic and synaptic tau preceding conformational change and fibril formation. **2021**, 141, 173-192 8

568 Local predictors of anti-A $\beta$  therapy efficacy revealed by quantitative whole-brain microscopy.

567 Relationship between amyloid and tau levels and its impact on tau spreading. **2021**, 48, 2225-2232 8

566 Neuropathology of Alzheimer's Disease and its Variants. 62-91 14

565 Kognitive Störungen: Koma, Delir, Demenz. **2006**, 221-295 6

564 Amyloid Imaging with PET in Alzheimer's Disease, Mild Cognitive Impairment, and Clinically Unimpaired Subjects. **2009**, 119-147 4

563 The Pattern of Lesions During the Transition to the Symptomatic Phase and in Fully Developed Alzheimer's Disease. **2015**, 95-130 2

562 The Aged Dog as a Natural Model of Alzheimer's Disease Progression. **2017**, 69-92 2

561  $\beta$ Amyloid Imaging In Vivo and Its Possible Implications for Alzheimer's Disease. **2004**, 191-199 1

560 Neurodegenerative Diseases: Alzheimer Disease (AD). **2019**, 897-931 1

559 Neurobiological Mechanisms Involved in the Pathogenesis of Alzheimer's Disease. **2019**, 235-269 2

558 Oligodendroglial Cells in Alzheimer's Disease. **2019**, 1175, 325-333 25

557 Autophagy and Prion Disease. **2020**, 1207, 75-85 1

556 Relationship Between Tau,  $\beta$ Amyloid and  $\alpha$ Synuclein Pathologies. **2019**, 1184, 169-176 5

555 Identification of early pericyte loss and vascular amyloidosis in Alzheimer's disease retina. **2020**, 139, 813-836 49

554	The Dementias. <b>2008</b> , 1855-1907	1
553	Transcriptional Signatures of Tau and Amyloid Neuropathology. <b>2020</b> , 30, 2040-2054.e5	20
552	Gait and balance disturbances are common in young urbanites and associated with cognitive impairment. Air pollution and the historical development of Alzheimer's disease in the young. <b>2020</b> , 191, 110087	10
551	Introduction. 1-7	0
550	Alzheimer's disease. 80-108	1
549	Amyloid Imaging and (What is 'Normal') Aging. <b>2009</b> , 191-244	1
548	In-Vivo Imaging of Alzheimer Disease 'Amyloid With [11C]SB-13 PET. <b>2004</b> , 12, 584-595	11
547	3D Mapping Reveals Network-specific Amyloid Progression and Subcortical Susceptibility.	1
546	Alzheimer's Disease Neuropathological Comorbidities Are Common in the Younger-Old.	1
545	Whole brain optoacoustic tomography reveals strain-specific regional beta-amyloid densities in Alzheimer's disease amyloidosis models.	8
544	Molecular characterization of selectively vulnerable neurons in Alzheimer's Disease.	4
543	Alterations in resting-state network dynamics along the Alzheimer's disease continuum: a combined MEG-PET/MR approach.	2
542	Complement C3-dependent glutamatergic synapse elimination in the developing hippocampus is region- and synapse-specific.	1
541	Time course of phosphorylated tau181 in blood across the Alzheimer's disease spectrum.	2
540	3D-Visualization of Amyloid-Oligomer and Fibril Interactions with Lipid Membranes by Cryo-Electron Tomography.	1
539	Leveraging selective hippocampal vulnerability among Alzheimer's disease subtypes reveals a novel tau binding partner SERPINA5.	2
538	Tau seeding activity anticipates phospho-tau pathology in Alzheimer's disease.	1
537	In vivo characterization and quantification of neurofibrillary tau PET radioligand [18F]MK-6240 in humans from Alzheimer's disease dementia to young controls.	3

536	Neuropathology and cognitive performance in centenarians.	1
535	Whole brain imaging reveals distinct spatial patterns of amyloid beta deposition in three mouse models of Alzheimer's disease.	1
534	Selective neuronal vulnerability in Alzheimer's disease: a network-based analysis.	3
533	The histopathological staging of tau, but not amyloid, corresponds to antemortem cognitive status, dementia stage, functional abilities, and neuropsychiatric symptoms.	1
532	Altered synaptic ingestion by human microglia in Alzheimer's disease.	7
531	Factors associated with development and distribution of granular/fuzzy astrocytes in neurodegenerative diseases. <b>2020</b> , 30, 811-830	7
530	Neurodegeneration in normal brain aging and disease. <b>2004</b> , 2004, pe26	89
529	The development of amyloid beta protein deposits in the aged brain. <b>2006</b> , 2006, re1	142
528	Alzheimer's disease: many failed trials, so where do we go from here?. <b>2020</b> , 68, 1135-1140	6
527	Multimodality Review of Amyloid-related Diseases of the Central Nervous System. <b>2016</b> , 36, 1147-63	48
526	Pathobiological Subtypes of Alzheimer Disease. <b>2020</b> , 49, 321-333	10
525	APOE4-mediated amyloid- $\beta$ pathology depends on its neuronal receptor LRP1. <b>2019</b> , 129, 1272-1277	49
524	Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. <b>2012</b> , 122, 1316-38	1101
523	Familial Alzheimer's disease-associated presenilin-1 alters cerebellar activity and calcium homeostasis. <b>2014</b> , 124, 1552-67	76
522	[C]PIB amyloid quantification: effect of reference region selection. <b>2020</b> , 10, 123	4
521	Spill-in counts in the quantification of F-florbetapir on A $\beta$ negative subjects: the effect of including white matter in the reference region. <b>2019</b> , 6, 27	6
520	Late-onset Alzheimer Disease. <b>2019</b> , 25, 14-33	21
519	Longitudinal anatomic, functional, and molecular characterization of Pick disease phenotypes. <i>Neurology</i> , <b>2020</b> , 95, e3190-e3202	6.5 4

518	Dynamin1 concentration in the prefrontal cortex is associated with cognitive impairment in Lewy body dementia. <b>2014</b> , 3, 108	12
517	Misfolded Proteins in Neurodegenerative Dementias: Molecular Mechanisms. <b>2012</b> , 11, 38	2
516	Intravenous delivery of targeted liposomes to amyloid- $\beta$ pathology in APP/PSEN1 transgenic mice. <b>2012</b> , 7, e48515	44
515	Alzheimer's disease related markers, cellular toxicity and behavioral deficits induced six weeks after oligomeric amyloid- $\beta$ peptide injection in rats. <b>2013</b> , 8, e53117	80
514	Neocortex and allocortex respond differentially to cellular stress in vitro and aging in vivo. <b>2013</b> , 8, e58596	26
513	Increased levels of antigen-bound $\beta$ amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimer's disease patients. <b>2013</b> , 8, e68996	36
512	Three Dimensional Human Neuro-Spheroid Model of Alzheimer's Disease Based on Differentiated Induced Pluripotent Stem Cells. <b>2016</b> , 11, e0163072	90
511	Axonal and myelinic pathology in 5xFAD Alzheimer's mouse spinal cord. <b>2017</b> , 12, e0188218	27
510	A Perspective on Roles Played by Immunosenesence in the Pathobiology of Alzheimer's Disease. <b>2020</b> , 11, 1594-1607	8
509	Electrophysiological Characterization of Networks and Single Cells in the Hippocampal Region of a Transgenic Rat Model of Alzheimer's Disease. <b>2019</b> , 6,	4
508	A $\beta$ Plaques. <b>2020</b> , 1,	8
507	Pharmacological inhibition of G9a/GLP restores cognition and reduces oxidative stress, neuroinflammation and $\beta$ Amyloid plaques in an early-onset Alzheimer's disease mouse model. <b>2019</b> , 11, 11591-11608	20
506	Salvianolic Acid B improves cognitive impairment by inhibiting neuroinflammation and decreasing A $\beta$ level in -infected mice. <b>2020</b> , 12, 10117-10128	6
505	Identification of prefrontal cortex protein alterations in Alzheimer's disease. <b>2018</b> , 9, 10847-10867	19
504	Soluble amyloid- $\beta$ levels and late-life depression. <b>2014</b> , 20, 2547-54	21
503	Key Peptides and Proteins in Alzheimer's Disease. <b>2019</b> , 20, 577-599	14
502	Navigating Alzheimer's Disease via Chronic Stress: The Role of Glucocorticoids. <b>2020</b> , 21, 433-444	10
501	Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately?. <b>2009</b> , 3, 27-44	6

500	Unidirectional Influx and Net Accumulation of PIB. <b>2008</b> , 2, 114-25	44
499	Imaging of Neurotransmitter Systems in Dementia. <b>2016</b> , 271-296	9
498	Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. <b>2009</b> , 21, 117-28	95
497	Neuropathological Correlates of Cumulative Benzodiazepine and Anticholinergic Drug Use. <b>2020</b> , 74, 999-1009	2
496	Extracellular Amyloid Deposits in Alzheimer's and Creutzfeldt-Jakob Disease: Similar Behavior of Different Proteins?. <b>2020</b> , 22,	6
495	[ <sup>18</sup> F]THK5351 PET Imaging in Patients with Mild Cognitive Impairment. <b>2020</b> , 16, 202-214	4
494	A non-invasive, rapid method to genotype late-onset Alzheimer's disease-related apolipoprotein E gene polymorphisms. <b>2014</b> , 9, 69-75	13
493	Glutamate receptor delocalization in postsynaptic membrane and reduced hippocampal synaptic plasticity in the early stage of Alzheimer's disease. <b>2019</b> , 14, 1037-1045	13
492	Early stages of Alzheimer's disease are alarming signs in injury deaths caused by traffic accidents in elderly people (≥80 years of age): A neuropathological study. <b>2017</b> , 59, 471-477	1
491	Clinical neuropathology practice news 3-2012: the "ABC" in AD-revised and updated guideline for the neuropathologic assessment of Alzheimer's disease. <b>2012</b> , 31, 116-8	4
490	Neuroprotective effects of treadmill exercise on BDNF and PI3-K/Akt signaling pathway in the cortex of transgenic mice model of Alzheimer's disease. <b>2013</b> , 17, 151-60	35
489	Cortical tau deposition follows patterns of entorhinal functional connectivity in aging. <b>2019</b> , 8,	38
488	Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity. <b>2019</b> , 8,	27
487	Alzheimer's and Hyperglycemia: Role of the Insulin Signaling Pathway and GSK-3 Inhibition in Paving a Path to Dementia. <b>2020</b> , 12, e6885	6
486	Neuroimaging in Dementia: A Brief Review. <b>2020</b> , 12, e8682	4
485	Disturbance of phylogenetic layer-specific adaptation of human brain gene expression in Alzheimer's disease. <b>2021</b> , 11, 20200	
484	Going round in circles-The Papez circuit in Alzheimer's disease. <b>2021</b> , 54, 7668-7687	1
483	Cryo-EM Structures of Amyloid-β Filaments from Human Brain.	1

- 482 Frontal white matter lesions in Alzheimer's disease are associated with both small vessel disease and AD-associated cortical pathology. **2021**, 142, 937-950 5
- 481 Macroscopic modelling of Alzheimer's disease: difficulties and challenges. **2021**, 2, 100040 2
- 480 Alpha-synuclein is present in the nucleus in human brain tissue and is pathologically modified in Dementia with Lewy Bodies. 1
- 479 Dopamine, sleep, and neuronal excitability modulate amyloid-mediated forgetting in *Drosophila*. **2021**, 19, e3001412 0
- 478 In vivo staging of regional amyloid progression in healthy middle-aged to older people at risk of Alzheimer's disease. **2021**, 13, 178 1
- 477 The Clinical and Neuropathological Features of Sporadic (Late-Onset) and Genetic Forms of Alzheimer's Disease. **2021**, 10, 2
- 476 Les lésions de la maladie d'Alzheimer. Perspectives thérapeutiques ?. **2008**, 192, 303-321
- 475 Degeneration in Canine Brain Aging. **2008**, 171-182
- 474 Alzheimer's Disease: MRI Studies. **2009**, 269-273
- 473 Impact of Aging on Brain Structure and Function in Rodents and Canines. 125-138
- 472 Insight into Disrupted Spatial Patterns of Human Connectome in Alzheimer's Disease via Subgraph Mining. **2012**, 3, 23-38
- 471 Morbus Alzheimer und Altersveränderungen des Gehirns. **2012**, 193-208
- 470 [Study into molecular targets of a neuroprotective compound dimebon using a transgenic mice line]. **2014**, 60, 354-63
- 469 Amyloidosis. **2014**, 158-164
- 468 Dementia Due to Neurodegenerative Disease: Molecular Imaging Findings. **2014**, 185-211
- 467 Alzheimer's Disease: An Overview. **2014**,
- 466 Alzheimer-Associated Pathology in the Extracellular Space. **2015**, 75-93 1
- 465 Prions et transconformation protéique: une perspective historique. **2015**, 199, 787-796

- 464 Stratégie de recherche translationnelle sur la maladie d'Alzheimer : cibles, modèles animaux et biomarqueurs. **2015**, 199, 893-908
- 463 Genetic Models of Alzheimer's Disease: The Influence of Apolipoprotein E allele Isoforms on Behaviour in Laboratory Animals. **2016**, 199-228
- 462 FDG PET: Imaging Cerebral Glucose Metabolism with Positron Emission Tomography. **2016**, 247-270 1
- 461 TECPR2 a positive regulator of autophagy is implicated in healthy brain ageing. 0
- 460 Insular cortex sub-region-dependent distribution pattern of Synuclein immunoreactivity in Parkinson's disease and dementia with Lewy bodies. 1
- 459 Prion-Like Propagation in Neurodegenerative Diseases. **2018**, 189-242
- 458 CSF biomarkers are differentially related to structural and functional changes in dementia of the Alzheimer's type.
- 457 Neuropathological Assessment as an Endpoint in Clinical Trial Design. **2018**, 1750, 271-279
- 456 The Use of F-FDG PET in the Diagnostic Workup of Alzheimer's Dementia. **2018**, 1750, 213-219 1
- 455 Encyclopedia of Clinical Neuropsychology. **2018**, 1-2
- 454 Encyclopedia of Clinical Neuropsychology. **2018**, 216-217
- 453 Methods for Pathological Classification of Alzheimer's Disease. **2018**, 71-89
- 452 Progressive impairment of directional and spatially precise trajectories by TgF344-AD Rats in the Morris Water Task.
- 451 Common antigenic motif recognized by human VH5-51/VL4-1 tau antibodies with distinct functionalities.
- 450 Interpretable classification of Alzheimer's disease pathologies with a convolutional neural network pipeline.
- 449 Importance of Neuropathological Diagnosis of Dementia Patients in Family Practice. **2019**, 2, 148-154 1
- 448 Neurodegenerative Erkrankungen. **2019**, 117-164 1
- 447 Transcriptional Signatures of Progressive Neuropathology in Transgenic Models of Tau and Amyloid Pathology.

- 446 Encyclopedia of Gerontology and Population Aging. **2019**, 1-9 0
- 445 Molecular Chaperones and Protein Quality Control System in the Canine Model of Brain Aging and Neurodegenerative Diseases. **2019**, 115-129
- 444 Transcriptional signatures of progressive neuropathology in transgenic tau and amyloid mouse models.
- 443 Proteomic and Biological Profiling of Extracellular Vesicles from Alzheimer's Disease Human Brain Tissues. 1
- 442 Detecting prodromal Alzheimer's disease with MRI through deep learning.
- 441 Spatial navigation and Alzheimer's disease. **2020**, 677-692
- 440 Self-Reported Sleep Relates to Microstructural Hippocampal Decline in Amyloid Positive Adults Beyond Genetic Risk.
- 439 Measuring brain integrity using MRI: a novel biomarker for Alzheimer's disease using T2 relaxometry. 1
- 438 Identification of amyloid beta oligomers in locus coeruleus (LC) neurons of Alzheimer's patients and their impact on LC oxidative stress, inhibitory neurotransmitter receptors and neuronal excitability.
- 437 Relationship between comprehensive geriatric assessment and amyloid PET in older persons with MCI.
- 436 Amyloid-PET and CSF in an autopsy confirmed cohort.
- 435 18F-FDG-PET Hyperactivity in Alzheimer's Disease Cerebellum and Primary Olfactory Cortex.
- 434 Neurodegenerative Diseases in Elders. **2020**, 302-309
- 433 Quantitative detection of grey and white matter amyloid pathology using a combination of K114 and CRANAD-3 fluorescence. **2021**, 161, 105540 0
- 432 Re: The Second NINDS/NIBIB Consensus Meeting to Define Neuropathological Criteria for the Diagnosis of Chronic Traumatic Encephalopathy. J Neuropathol Exp Neurol 2021;80(3):210-9. **2021**, 80, 1007-1008 1
- 431 Severe histomorphological alterations in post-mortem olfactory glomeruli in Alzheimer's disease. **2021**, e13033 1
- 430 Dysregulated Protein Phosphorylation as Main Contributor of Granulovacuolar Degeneration at the First Stages of Neurofibrillary Tangles Pathology. **2021**, 0
- 429 P-tau235: a novel biomarker for staging preclinical Alzheimer's disease. **2021**, 13, e15098 4



- 428 Role of Retinoid X Receptors (RXRs) and dietary vitamin A in Alzheimer's disease: Evidence from clinicopathological and preclinical studies. **2021**, 161, 105542 2
- 427 SPECT and PET of the Brain. **2020**, 211-231
- 426 Deregulation of brain endothelial CD2AP in Alzheimer's disease impairs Reelin-mediated neurovascular coupling. 0
- 425 A Simplified Brain Blocking Protocol Optimized for the Diagnosis of Neurodegenerative Disease Saves Time and Money While Preserving Anatomic Relationships. **2021**, 145, 960-968 0
- 424 Age, sex and APOE- $\epsilon$  modify the balance between soluble and fibrillar  $\beta$ amyloid in cognitively intact individuals: topographical patterns and replication across two independent cohorts.
- 423 Deep Brain Stimulation for Alzheimer's Disease: Tackling Circuit Dysfunction. **2021**, 24, 171-186 9
- 422 Relationship between comprehensive geriatric assessment and amyloid PET in older persons with MCI.
- 421 Multiplex Connectome Changes across the Alzheimer's Disease Spectrum Using Gray Matter and Amyloid Data.. **2022**, 1
- 420 Alzheimer's disease and other dementias. **2020**, 5830-5859
- 419 Genetic risk for Alzheimer's disease influences neuropathology via multiple biological pathways. **2020**, 2, fcaa167 1
- 418 The signalosome malfunctions in age-associated neuropathologies. **2020**, 275-292
- 417 Alzheimer's disease genetic risk and sleep phenotypes: association with more slow-waves and daytime sleepiness.
- 416 Sloping Shoulders Sign: A Practical Radiological Sign for the Differentiation of Alzheimer's Disease and Argyrophilic Grain Disease. **2021**, 1
- 415 Neuropathology of Alzheimer's Disease. **2021**, 11
- 414 Associations of Mitochondrial Genomic Variation with Corticobasal Degeneration, Progressive Supranuclear Palsy, and Neuropathological Tau Measures.
- 413 Genetic risk for Alzheimer's disease influences neuropathology and cognition via multiple biological pathways.
- 412 Impact of  $\beta$ Amyloid on the Tau Pathology in Tau Transgenic Mouse and Tissue Culture Models. **2007**, 198-215
- 411 Neuroinflammation characterizes the earliest changes in Alzheimer's disease pathology and associated subjective cognitive impairment in adult hydrocephalus biopsies.

410	Imaging stable isotope labelling kinetics (iSILK) for following spatial A $\beta$ plaque aggregation dynamics in evolving Alzheimer's disease pathology.	
409	Alzheimer's pathology is associated with dedifferentiation of functional memory networks in aging.	
408	3D analysis of the synaptic organization in the Entorhinal cortex in Alzheimer's disease.	0
407	Mitochondrial pathway polygenic risk scores are associated with Alzheimer's Disease.	
406	Normal ageing of the brain: Histological and biological aspects. <b>2020</b> , 176, 649-660	3
405	Plasma P-tau 181, P-tau 217 and Other Blood-Based Alzheimer's Disease Biomarkers in a Multi-Ethnic, Community Study.	0
404	Amyotrophic lateral sclerosis and frontotemporal lobar degeneration. 209-248	2
403	Dimebon alters hippocampal amyloid pathology in 3xTg-AD mice. <b>2012</b> , 4, 115-27	17
402	Typical or atypical progressive supranuclear palsy: a comparative clinicopathologic study of three Chinese cases. <b>2015</b> , 8, 867-74	1
401	Separation of $\beta$ amyloid binding and white matter uptake of (18)F-flutemetamol using spectral analysis. <b>2015</b> , 5, 515-26	4
400	Amyloid-beta immunotherapy: the hope for Alzheimer disease?. <b>2016</b> , 47, 203-212	21
399	Altered mechanisms of protein synthesis in frontal cortex in Alzheimer disease and a mouse model. <b>2017</b> , 6, 15-25	19
398	Clustering of activated microglia occurs before the formation of dystrophic neurites in the evolution of A $\beta$ plaques in Alzheimer's disease. <b>2020</b> , 1,	1
397	Elevation of inactive cleaved annexin A1 in the neocortex is associated with amyloid, inflammatory and apoptotic markers in neurodegenerative dementias. <b>2021</b> , 152, 105251	1
396	Dimensional Changes in Lipid Rafts from Human Brain Cortex Associated to Development of Alzheimer's Disease. Predictions from an Agent-Based Mathematical Model. <b>2021</b> , 22,	
395	Is There Any Evidence of Monocytes Involvement in Alzheimer's Disease? A Pilot Study on Human Postmortem Brain.. <b>2021</b> , 5, 887-897	0
394	Revisit the Cellular Transmission and Emerging Techniques in Understanding the Mechanisms of Proteinopathies. <b>2021</b> , 15, 781722	
393	Amyloid- $\beta$ -p-tau and reactive microglia are pathological correlates of MRI cortical atrophy in Alzheimer's disease.. <b>2021</b> , 3, fcab281	0

- 392 Boosting the diagnostic power of amyloid- $\beta$ -PET using a data-driven spatially informed classifier for decision support. **2021**, 13, 185
- 391 Alzheimer's Disease. **2022**, 257-271
- 390 Multiplexed Ion Beam Imaging: Insights into Pathobiology. **2021**, 2
- 389 Aumento de la confianza en la interpretaci3n del PET con 18F-Florbetaben: machine learning basado en la aproximaci3n cuantitativa. **2021**,
- 388 Concurrent tau pathologies in frontotemporal lobar degeneration with TDP-43 pathology. **2021**, 0
- 387 Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model. **2021**, 3
- 386 Three-dimensional virtual histology of the human hippocampus based on phase-contrast computed tomography. **2021**, 118, 4
- 385 The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. **2021**, 17
- 384 Biological and methodological complexities of beta-amyloid peptide: Implications for Alzheimer's disease research. **2021**, 2
- 383 Oxidation Damage Accumulation Aging Theory (The Novel Role of Glutathione). **2021**, 3676-3684
- 382 The Neurochemistry of Alzheimer's Disease: One of the Most Common Causes of Reduced Capability in the Adult Population. **2022**, 81-93
- 381 Dysfunction of striatal MeCP2 is associated with cognitive decline in a mouse model of Alzheimer's disease.. **2022**, 12, 1404-1418 0
- 380 Concomitant AD and DLB pathologies shape subfield microglia responses in the hippocampus.
- 379 rPOP: Robust PET-Only Processing of community acquired heterogeneous amyloid-PET data. **2021**, 246, 118775 1
- 378 Cryo-EM structures of amyloid- $\beta$  filaments from human brains.. **2022**, 375, 167-172 27
- 377 Associating Alzheimer's disease pathology with its cerebrospinal fluid biomarkers.. **2022**, 1
- 376 Primary Age-Related Tauopathy (PART) in a Finnish Population-Based Study of the Oldest Old (Vantaa 85+).. **2021**, 1
- 375 Diffuse Lewy body disease presenting as Parkinson's disease with progressive aphasia.. **2022**, 0

374	Developmental deficits and staging of dynamics of age associated Alzheimer's disease neurodegeneration and neuronal loss in subjects with Down syndrome.. <b>2022</b> , 10, 2	1
373	Using intracerebral microdialysis to probe the efficacy of repurposed drugs in Alzheimer's disease pathology.	
372	Recent Developments in Positron Emission Tomography Tracers for Proteinopathies Imaging in Dementia.. <b>2021</b> , 13, 751897	2
371	Advances in Deep Neuropathological Phenotyping of Alzheimer Disease: Past, Present, and Future.. <b>2022</b> ,	1
370	White matter microstructure associations to amyloid burden in adults with Down syndrome.. <b>2021</b> , 33, 102908	
369	Neuroinflammation PET imaging of the translocator protein (TSPO) in Alzheimer's disease: an update.. <b>2022</b> ,	1
368	Unravelling the Association Between Amyloid-PET and Cerebrospinal Fluid Biomarkers in the Alzheimer's Disease Spectrum: Who Really Deserves an A+?. <b>2021</b> ,	1
367	An autopsy case of Alzheimer's disease with amygdala-predominant Lewy pathology presenting with frontotemporal dementia-like psychiatric symptoms.. <b>2022</b> ,	
366	Integrated Bioinformatics Analysis Identifies Hub Genes Associated with Viral Infection and Alzheimer's Disease.. <b>2021</b> ,	0
365	Detection of A $\beta$ oligomers in early Alzheimer's disease diagnose by in vivo NIR-II fluorescence imaging. <b>2022</b> , 358, 131481	2
364	Distinctive Temporal Trajectories of Alzheimer's Disease Biomarkers According to Sex and Genotype: Importance of Striatal Amyloid.. <b>2022</b> , 14, 829202	1
363	Nutrient-sensing amyloid metastasis.. <b>2022</b> ,	1
362	Artificial intelligence-driven meta-analysis of brain gene expression data identifies novel gene candidates in Alzheimer's Disease.	1
361	Phenotypic Heterogeneity of Variably Protease-Sensitive Prionopathy: A Report of Three Cases Carrying Different Genotypes at Codon 129.. <b>2022</b> , 14,	2
360	Partial Volume Correction Increases the Sensitivity of 18F-Florbetapir-Positron Emission Tomography for the Detection of Early Stage Amyloidosis.. <b>2021</b> , 13, 748198	1
359	Recent update on the heterogeneity of the Alzheimer's disease spectrum.. <b>2021</b> , 129, 1	5
358	Analysis of Expression of the Amyloid-Degrading Enzyme Nephrilysin in Brain Structures of 5xFAD Transgenic Mice. <b>2022</b> , 58, 193-203	0
357	Metals, Nanoparticles, Particulate Matter, and Cognitive Decline.. <b>2021</b> , 12, 794071	0

356	Difference in Amyloid Load Between Single Memory Domain and Multidomain Subjective Cognitive Decline: A Study from the SILCODE.. <b>2021</b> ,		
355	Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration.. <i>Neurology</i> , <b>2022</b> ,	6.5	1
354	Tau Imaging with 18F-MK6240 across the Alzheimer's Disease spectrum.		1
353	Clear-headed into old age: Resilience and resistance against brain aging - A PET imaging perspective.. <b>2022</b> ,		0
352	TDP-43 promotes tau accumulation and selective neurotoxicity in bigenic <i>C. elegans</i> .. <b>2022</b> ,		2
351	Droplet Degeneration of Hippocampal and Cortical Neurons Signifies the Beginning of Neuritic Plaque Formation.. <b>2021</b> ,		2
350	Unique Lewy pathology in myotonic dystrophy type 1.. <b>2022</b> ,		0
349	Hemispheric Asymmetry and Atypical Lobar Progression of Alzheimer-Type Tauopathy.. <b>2022</b> ,		0
348	The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics.. <b>2022</b> ,		24
347	A deep learning MRI approach outperforms other biomarkers of prodromal Alzheimer's disease.. <b>2022</b> , 14, 45		3
346	Oncogenic Pathways in Neurodegenerative Diseases.. <b>2022</b> , 23,		1
345	Structural (dys)connectivity associates with cholinergic cell density in Alzheimer's disease.. <b>2022</b> ,		0
344	An efficient combination of quadruple biomarkers in binary classification using ensemble machine learning technique for early onset of Alzheimer disease.		0
343	Alterations of Neuronal Lysosomes in Alzheimer's Disease and in APPxPS1-KI Mice.. <b>2022</b> ,		1
342	Patterns of Mixed Pathologies in Down Syndrome.. <b>2022</b> ,		1
341	Current concepts of mixed pathologies in neurodegenerative diseases.. <b>2022</b> , 1-43		2
340	Neuroimaging within the Dominantly Inherited Alzheimer's Network (DIAN): PET and MRI.		1
339	Multiple Cortical to Striatal Accumulation Trajectories of $\beta$ Amyloid: Do All Roads Lead to Rome?. <i>Neurology</i> , <b>2022</b> ,	6.5	

338	Frontotemporal Lobar Degeneration Case with an N-Terminal Mutation Exhibits Reduced TUBA4A Levels in the Brain and TDP-43 Pathology.. <b>2022</b> , 12,	
337	Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration.. <b>2022</b> ,	0
336	Clinical and pathological characteristics of later onset multiple system atrophy.. <b>2022</b> , 1	2
335	Microglia phenotypes are associated with subregional patterns of concomitant tau, amyloid- $\beta$ and $\beta$ -synuclein pathologies in the hippocampus of patients with Alzheimer's disease and dementia with Lewy bodies.. <b>2022</b> , 10, 36	1
334	Rates of $\beta$ -amyloid deposition indicate widespread simultaneous accumulation throughout the brain.. <b>2022</b> , 115, 1-11	
333	From synapses to circuits and back: bridging levels of understanding in animal models of Alzheimer disease.. <b>2022</b> ,	0
332	Age, sex and APOE- $\epsilon$ modify the balance between soluble and fibrillar $\beta$ -amyloid in non-demented individuals: topographical patterns across two independent cohorts.. <b>2022</b> ,	0
331	Microglial large extracellular vesicles propagate early synaptic dysfunction in Alzheimer's disease.. <b>2022</b> ,	4
330	Examining the association between blood-based biomarkers and human post mortem neuropathology in the University of Kentucky Alzheimer's Disease Research Center autopsy cohort.. <b>2022</b> ,	0
329	Aging the Brain: Multi-Region Methylation Principal Component Based Clock in the Context of Alzheimer's Disease.	0
328	Geropathology. An inside view of biological aging.. <b>2022</b> , 4, 23-24	0
327	Von symptombasierter Diagnostik hin zu einem biologischen Konzept. <b>2022</b> , 33, 36-43	
326	Spatial sequestration of misfolded proteins in neurodegenerative diseases.. <b>2022</b> ,	1
325	Enhanced expression of autophagy-related p62 without increased deposits of neurodegeneration-associated proteins in glioblastoma and surrounding tissue - An autopsy-based study.. <b>2022</b> , e13058	
324	DNA methylation signatures of Alzheimer's disease neuropathology in the cortex are primarily driven by variation in non-neuronal cell-types.	0
323	Caspase-cleaved tau is senescence-associated and induces a toxic gain of function by putting a brake on axonal transport.. <b>2022</b> ,	0
322	Cerebrospinal Fluid Profile of Tau, Phosphorylated Tau, A $\beta$ 2, and A $\beta$ 0 in Probable Cerebral Amyloid Angiopathy.. <b>2022</b> ,	1
321	Effect of reduction in brain amyloid levels on change in cognitive and functional decline in randomized clinical trials: an updated instrumental variable meta-analysis.	1

320	Quantification of amyloid PET for future clinical use: a state-of-the-art review.. <b>2022</b> , 1	1
319	A $\beta$ Assemblies Promote Amyloidogenic Processing of APP and Intracellular Accumulation of A $\beta$ 2 Through Go/G $\beta$ Signaling.. <b>2022</b> , 10, 852738	1
318	Trauma-like exposure alters neuronal apoptosis, Bin1, Fkbp5 and NR2B expression in an amyloid-beta (1-42) rat model of Alzheimer's disease.. <b>2022</b> , 107611	0
317	Patterns of amygdala region pathology in LATE-NC: subtypes that differ with regard to TDP-43 histopathology, genetic risk factors, and comorbid pathologies.. <b>2022</b> , 1	1
316	Label-free Raman and fluorescence imaging of amyloid plaques in human Alzheimer's disease brain tissue reveal carotenoid accumulations. <b>2022</b> , 24, 054005	2
315	Identifying Mild Alzheimer's Disease With First 30-Min C-PiB PET Scan.. <b>2022</b> , 14, 785495	
314	Combined effects of Aerobic exercise and 40Hz light flicker exposure on early cognitive impairments in Alzheimer's disease of 3xTg mice.. <b>2022</b> ,	0
313	Deciphering the prion-like behavior of pathogenic protein aggregates in neurodegenerative diseases.. <b>2022</b> , 155, 105307	1
312	Cerebrovascular insulin receptors are defective in Alzheimer's disease.	0
311	<sup>11</sup> C-PiB PET can underestimate brain amyloid- $\beta$ burden when cotton wool plaques are numerous.. <b>2021</b> ,	2
310	Ultrasound delivery of a TrkA agonist confers neuroprotection to Alzheimer-associated pathologies.. <b>2021</b> ,	2
309	Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts.	0
308	Parkinson's disease with a typical clinical course of 17 years overlapped by Creutzfeldt-Jakob disease: an autopsy case report. <b>2021</b> , 21, 480	
307	Emergence of distinct and heterogeneous strains of amyloid beta with advanced Alzheimer's disease pathology in Down syndrome.. <b>2021</b> , 9, 201	0
306	Neurodegenerative brain changes are associated with area deprivation in the United Kingdom: findings from the Brains for Dementia Research study.. <b>2021</b> , 9, 198	0
305	Association of Glial Tau Pathology and Late-Nc in the Ageing Brain.	
304	Progressive supranuclear palsy with predominant frontal presentation exhibiting progressive nonfluent aphasia due to crossed aphasia.. <b>2022</b> ,	0
303	Regional A $\beta$ tau interactions promote onset and acceleration of Alzheimer's disease tau spreading.. <b>2022</b> ,	1

302 A near-infrared probe for detecting and interposing amyloid beta oligomerization in early Alzheimer's disease.. **2022**,

o

301 Stereotaxic-assisted gene therapy in Alzheimer's and Parkinson's diseases: Therapeutic potentials and clinical frontiers.. **2022**,

300 Cerebral Atrophy. 222-248

299 Data\_Sheet\_1.docx. **2020**,

298 Image\_1.TIF. **2020**,

297 Image\_2.TIF. **2020**,

296 Image\_3.TIF. **2020**,

295 Image\_4.TIF. **2020**,

294 Table\_1.docx. **2020**,

293 Data\_Sheet\_1.PDF. **2019**,

292 Data\_Sheet\_2.PDF. **2019**,

291 Data\_Sheet\_3.CSV. **2019**,

290 Table\_1.doc. **2019**,

289 data\_sheet\_1.PDF. **2018**,

288 Data\_Sheet\_1.ZIP. **2019**,

287 Table\_1.DOCX. **2019**,

286 Data\_Sheet\_1.PDF. **2019**,

285 Data\_Sheet\_1.doc. **2019**,



284 Data\_Sheet\_1.pdf. **2019**,

283 Data\_Sheet\_1.PDF. **2019**,

282 Image\_1.JPEG. **2018**,

281 Image\_2.JPEG. **2018**,

280 Supplementary\_Table\_1.docx. **2018**,

279 Image\_1.tiff. **2020**,

278 Image\_2.tiff. **2020**,

277 Image\_3.tiff. **2020**,

276 Image\_4.tiff. **2020**,

275 Image\_5.tiff. **2020**,

274 Image\_6.tiff. **2020**,

273 Table\_1.DOCX. **2020**,

272 Data\_Sheet\_1.pdf. **2020**,

271 Data\_Sheet\_1.PDF. **2020**,

270 Image\_1.TIF. **2020**,

269 Image\_2.TIF. **2020**,

268 Data\_Sheet\_1.docx. **2019**,

267 Image\_1.TIF. **2019**,

266 Image\_2.TIF. 2019,

265 Image\_3.TIF. 2019,

264 Image\_4.TIF. 2019,

263 Image\_5.TIF. 2019,

262 Image\_6.TIF. 2019,

261 Image\_7.TIF. 2019,

260 Image\_8.TIF. 2019,

259 DataSheet\_1.docx. 2020,

258 APOE4 exacerbates  $\beta$ -synuclein seeding activity and contributes to neurotoxicity in Alzheimer's disease with Lewy body pathology.. 2022, 143, 641 ○

257 Neuropathology Studies of Dementia in US Persons other than Non-Hispanic Whites.. 2022, 3, ○

256 Amyloid- $\beta$  in Brain Aging and Alzheimer's Disease. 2022, 335-354

255 Loss of perivascular aquaporin-4 localization impairs glymphatic exchange and promotes amyloid  $\beta$  plaque formation in mice.. 2022, 14, 59 4

254 The Key Factors Predicting Dementia in Individuals With Alzheimer's Disease-Type Pathology.. 2022, 14, 831967 ○

253 Amyloid and Tau Positron Emission Tomography Imaging in Alzheimer's Disease and Other Tauopathies.. 2022, 14, 838034 4

252 CLARITY increases sensitivity and specificity of fluorescence immunostaining in long-term archived human brain tissue.

251 Association of Traumatic Brain Injury With and Without Loss of Consciousness With Neuropathologic Outcomes in Community-Dwelling Older Persons.. 2022, 5, e229311 2

250 Altered abundances of human immunoglobulin M and immunoglobulin G subclasses in Alzheimer's disease frontal cortex.. 2022, 12, 6934 ○

249 Parvalbumin neuroplasticity compensates for somatostatin impairment, maintaining cognitive function in Alzheimer's disease.. 2022, 11, 26 ○

248	Assessment of Alzheimer-related Pathologies of Dementia Using Machine Learning Feature Selection.	
247	Neuropathological associations of limbic-predominant age-related TDP-43 encephalopathy neuropathological change (LATE-NC) differ between the oldest-old and younger-old.. <b>2022,</b>	0
246	Natural Products from Plants and Algae for Treatment of Alzheimer’s Disease: A Review. <b>2022,</b> 12, 694	2
245	Neuropathology of Parkinson’s disease after focused ultrasound thalamotomy.. <b>2022,</b> 8, 59	
244	Amyloid, cerebrovascular disease, and neurodegeneration biomarkers are associated with cognitive trajectories in a racially and ethnically diverse, community-based sample. <b>2022,</b>	0
243	A Adenosine Receptor: A Possible Therapeutic Target for Alzheimer’s Disease by Regulating NLRP3 Inflammasome Activity?. <b>2022,</b> 23,	0
242	Obstructive sleep apnea, cerebrovascular disease, and amyloid in older adults with Down syndrome across the Alzheimer’s continuum.	
241	Classification of F-Flutemetamol scans in cognitively normal older adults using machine learning trained with neuropathology as ground truth.. <b>2022,</b> 1	0
240	Biomarker A+T-: is this Alzheimer’s disease or not? A combined CSF and pathology study.. <b>2022,</b>	0
239	Neurophysiological effects of human-derived pathological tau conformers in the APPKM670/671NL.PS1/L166P amyloid mouse model of Alzheimer’s disease.. <b>2022,</b> 12, 7784	
238	Assisting dementia diagnosis through the electrochemical immunosensing of glial fibrillary acidic protein.. <b>2022,</b> 246, 123526	1
237	Brain simulation augments machine-learning-based classification of dementia. <b>2022,</b> 8,	0
236	Utility of the ALSFRS-R for Predicting ALS and Comorbid Disease Neuropathology: The Veterans Affairs Biorepository Brain Bank.. <b>2022,</b>	
235	dose associates with increased brain iron and $\beta$ amyloid via blood-brain barrier dysfunction.. <b>2022,</b>	1
234	Patterns of Focal Amyloid Deposition Using 18F-Florbetaben PET in Patients with Cognitive Impairment. <b>2022,</b> 12, 1357	
233	Noradrenaline in Alzheimer’s Disease: A New Potential Therapeutic Target. <b>2022,</b> 23, 6143	0
232	A History of Senile Plaques: From Alzheimer to Amyloid Imaging. <b>2022,</b> 81, 387-413	0
231	Deep Learning-Based Diagnosis of Alzheimer’s Disease. <b>2022,</b> 12, 815	3

230	Early Forms of $\beta$ -Synuclein Pathology Are Associated with Neuronal Complex I Deficiency in the Substantia Nigra of Individuals with Parkinson's Disease. <b>2022</b> , 12, 747	1
229	The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review. <b>2022</b> , 63, 135-195	4
228	N-terminally truncated A $\beta$ -x proteoforms and their relevance for Alzheimer's pathophysiology. <b>2022</b> , 11,	0
227	Genome-wide association study of brain biochemical phenotypes reveals distinct genetic architecture of Alzheimer's Disease related proteins.	
226	Different Profiles of Spatial Navigation Deficits In Alzheimer's Disease Biomarker-Positive Versus Biomarker-Negative Older Adults With Amnesic Mild Cognitive Impairment. 14,	2
225	Mapping the Spatial Distribution of Fibrillar Polymorphs in Human Brain Tissue. <b>2022</b> , 16,	0
224	Cerebral A $\beta$ deposition in an A $\beta$ -precursor protein-transgenic rhesus monkey. <b>2022</b> , 2, 100044	1
223	Differentially Expressed miRNAs in Age-Related Neurodegenerative Diseases: A Meta-Analysis. <b>2022</b> , 13, 1034	
222	Progressive medial temporal degeneration with TDP-43 pathology is associated with upper limb and bulbar onset types of amyotrophic lateral sclerosis.	
221	Integrated Proteomics Identifies Neuritin (NRN1) as a Mediator of Cognitive Resilience to Alzheimer's Disease.	0
220	Multimodal deep learning for Alzheimer's disease dementia assessment. <b>2022</b> , 13,	2
219	Brain Structural and Functional Changes in Cognitive Impairment Due to Alzheimer's Disease. 13,	3
218	Pathological and neurophysiological outcomes of seeding human-derived tau pathology in the APP-KI NL-G-F and NL-NL mouse models of Alzheimer's Disease. <b>2022</b> , 10,	0
217	Amyloid-PET Levels in the Precuneus and Posterior Cingulate Cortices Are Associated with Executive Function Scores in Preclinical Alzheimer's Disease Prior to Overt Global Amyloid Positivity. <b>2022</b> , 1-9	3
216	TDP-43 Pathology Exacerbates Cognitive Decline in Primary Age-Related Tauopathy.	2
215	Association of Cognition and Dementia With Neuropathologic Changes of Alzheimer Disease and Other Conditions in the Oldest-Old. <i>Neurology</i> , 10.1212/WNL.0000000000200832	6.5 1
214	Neuropathology of Dementia Disorders. <b>2022</b> , 28, 834-851	0
213	Old age amyotrophic lateral sclerosis and limbic TDP-43 pathology.	0

212	Mouse Models of Alzheimer’s Disease. 15,	1
211	Diagnosis of coexistent neurodegenerative dementias in multiple sclerosis.	
210	Rodent Modeling of Alzheimer’s Disease in Down Syndrome: In vivo and ex vivo Approaches. 16,	0
209	Tau and Synuclein shape microtubule organization and microtubule-dependent transport in neuronal dendrites.	
208	Effect of cerebellum stimulation on cognitive recovery in patients with Alzheimer disease: A randomized clinical trial. <b>2022</b> , 15, 910-920	0
207	Autopsy Human Brain Dissection Protocol for Common Age-Related Neurodegenerative Disorders. <b>2022</b> , 255-279	
206	Olfactory Bulb Amyloid- $\beta$ Correlates With Brain Thal Amyloid Phase and Severity of Cognitive Impairment.	0
205	Synapse pathology in Alzheimer’s disease. <b>2022</b> ,	2
204	Four-repeat tauopathies and late-onset psychiatric disorders: Etiological relevance or incidental findings?.	1
203	Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia. <b>2022</b> , 17,	1
202	Identification and validation of Alzheimer’s disease-related metabolic brain pattern in biomarker confirmed Alzheimer’s dementia patients. <b>2022</b> , 12,	0
201	Novel PSEN1 (P284S) Mutation Causes Alzheimer’s Disease with Cerebellar Amyloid $\beta$ protein deposition. <b>2022</b> , 19,	
200	Manipulation of neuronal activity in the entorhinal-hippocampal circuit affects intraneuronal amyloid- $\beta$ levels.	0
199	Upregulated Blood miR-150-5p in Alzheimer’s Disease Dementia Is Associated with Cognition, Cerebrospinal Fluid Amyloid- $\beta$ and Cerebral Atrophy. <b>2022</b> , 1-18	
198	Nuclear alpha-synuclein is present in the human brain and is modified in dementia with Lewy bodies. <b>2022</b> , 10,	1
197	A multiplex pedigree with pathologically confirmed multiple system atrophy and Parkinson’s disease with dementia.	0
196	Mitochondrial genomic variation in dementia with Lewy bodies: association with disease risk and neuropathological measures. <b>2022</b> , 10,	
195	Differential Neuropathology, Genetics, and Transcriptomics in Two Kindred Cases with Alzheimer’s Disease and Lewy Body Dementia. <b>2022</b> , 10, 1687	

- 194 Blood-based A $\beta$ 2 increases in the earliest pre-pathological stage before decreasing with progressive amyloid pathology in preclinical models and human subjects: opening new avenues for prevention. 1
- 193 Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer's dementia. 1
- 192 Differential disruptions in population coding along the dorsal-ventral axis of CA1 in the APP/PS1 mouse model of A $\beta$  pathology.
- 191 Exploring the management approaches of cytokines including viral infection and neuroinflammation for neurological disorders. **2022**, 157, 155962 3
- 190 Crossing borders in Alzheimer's disease: A T cell's perspective. **2022**, 188, 114398 1
- 189 Evaluation of in vivo staging of amyloid deposition in cognitively unimpaired elderly aged 78-84. 0
- 188 Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts. 4
- 187 Neuropathology and cholinesterase expression in the brains of octogenarians and older. **2022**, 110065 0
- 186 Preclinical Alzheimer's disease biomarkers accurately predict cognitive and neuropathological outcomes. 0
- 185 The fractional amplitude of low-frequency fluctuations signals related to amyloid uptake in high-risk populations: a pilot fMRI study. 14, 0
- 184 Aging the brain: multi-region methylation principal component based clock in the context of Alzheimer's disease. **2022**, 14, 5641-5668 0
- 183 Evaluation of 18F-flutemetamol amyloid PET image analysis parameters on the effect of verubecestat on brain amyloid load in Alzheimer's disease. 0
- 182 Mutations in SORL1 and MTHFDL1 possibly contribute to the development of Alzheimer's disease in a multigenerational Colombian Family. **2022**, 17, e0269955
- 181 Cortical distribution of neurofilaments associates with pathological hallmarks and MRI measures of atrophy and diffusivity in Parkinson's disease.
- 180 Immunomodulation in age-related disorders and nanotechnology interventions.
- 179 Histopathological Analysis of Cerebral Microvasculature Pathology with Alzheimer's Disease Neuropathological Changes: An Autopsy Study.
- 178 Rainwater Charitable Foundation criteria for the neuropathologic diagnosis of progressive supranuclear palsy. 2
- 177 Protein Aggregation in Neurodegenerative Diseases. **2022**, 26-58

176	Specific associations between plasma biomarkers and post-mortem amyloid plaque and neurofibrillary tau tangle loads.	0
175	Cortical waste clearance in normal and restricted sleep with potential runaway tau buildup in Alzheimer's disease. <b>2022</b> , 12,	2
174	Intraneuronal sortilin aggregation relative to granulovacuolar degeneration, tau pathogenesis and sorfra plaque formation in human hippocampal formation. 14,	0
173	Focal amyloid and asymmetric tau in an imaging-to-autopsy case of clinical primary progressive aphasia with Alzheimer disease neuropathology. <b>2022</b> , 10,	0
172	Association between depression, gender and Alzheimer's neuropathology in older adults without dementia..	0
171	International Nuclear Medicine Consensus on the Clinical Use of Amyloid Positron Emission Tomography in Alzheimer's Disease.	
170	Spatial Extent of Amyloid- $\beta$ Levels and Associations With Tau-PET and Cognition.	0
169	Brain aging, Alzheimer's disease, and the role of stem cells in primate comparative studies.	
168	Combined targeting of pathways regulating synaptic formation and autophagy attenuates Alzheimer's disease pathology in mice. 13,	
167	Semi-quantitative Assessment of Alzheimer's-like Pathology in Two Aged Polar Bears ( <i>Ursus maritimus</i> ). <b>2022</b> , 72, 267-272	
166	Tau as a biomarker of cognitive impairment and neuropsychiatric symptom in Alzheimer's disease.	
165	Widespread cell stress and mitochondrial dysfunction occur in patients with early Alzheimer's disease. <b>2022</b> , 14,	3
164	Association of glial tau pathology and LATE-NC in the ageing brain. <b>2022</b> , 119, 77-88	0
163	Association of plasma biomarkers of amyloid and neurodegeneration with cerebrovascular disease and Alzheimer's disease. <b>2022</b> , 119, 1-7	
162	Neuronal network-based biomimetic chip for long-term detection of olfactory dysfunction model in early-stage Alzheimer's disease. <b>2022</b> , 216, 114619	
161	Optimal Stimulation Sites and Networks for Deep Brain Stimulation of the Fornix in Alzheimer's Disease.	0
160	Signaling interactions among neurons impact cell fitness and death in Alzheimer's disease. <b>2023</b> , 18, 784	0
159	Asymmetric amyloid deposition in preclinical Alzheimer's disease: A PET study. <b>2022</b> , 2, 100048	0

- 158 Neuropathology of the temporal lobe. **2022**, 407-427 ○
- 157 Expression of Regional Amyloid Deposition in Centiloid Scale and Used for Quantitative Analysis in Alzheimer's Disease-A Multi-Site Study. ○
- 156 Neurodegenerative Changes in the Structural and Ultrastructural Organization in the Piriform Cortex of 5xFAD Transgenic Mice. **2022**, 58, 1225-1239 ○
- 155 Mapping the association between tau-PET and A $\beta$  amyloid-PET using deep learning. **2022**, 12, ○
- 154 Effect of reduction in brain amyloid levels on change in cognitive and functional decline in randomized clinical trials: An instrumental variable meta-analysis. ○
- 153 Membrane interaction to intercellular spread of pathology in Alzheimer's disease. 16, ○
- 152 Level of Amyloid- $\beta$  Binding Leading to Differential Effects on Resting State Functional Connectivity in Major Brain Networks. **2022**, 10, 2321 ○
- 151 LATE-NC aggravates GVD-mediated necroptosis in Alzheimer's disease. **2022**, 10, 1
- 150 Somatic Mutations and Alzheimer's Disease. **2022**, 1-18 ○
- 149 An Alzheimer's Disease Mechanism Based on Early Pathology, Anatomy, Vascular-Induced Flow, and Migration of Maximum Flow Stress Energy Location with Increasing Vascular Disease. **2022**, 1-27 ○
- 148 Virtual histology of Alzheimer's Disease: why are amyloid- $\beta$  plaques visible with X-ray phase-contrast imaging?. ○
- 147 Random forest modelling demonstrates microglial and protein misfolding features to be key phenotypic markers in C9orf72 -ALS. ○
- 146 Relationship of serum beta-synuclein with blood biomarkers and brain atrophy. ○
- 145 Discrepancy between distribution of alpha-synuclein oligomers and Lewy-related pathology in Parkinson's disease. **2022**, 10, 1
- 144 Effect of long-term cannabidiol on learning and anxiety in a female Alzheimer's disease mouse model. 13, ○
- 143 Venular amyloid accumulation in transgenic Fischer 344 Alzheimer's disease rats. **2022**, 12, ○
- 142 Exploration of cortical A $\beta$  amyloid load in Alzheimer's disease using quantitative susceptibility mapping at 9.4T. ○
- 141 Amyloid-beta biomarkers in Braak stages and their predictive relationships with cognitive impairment: Support vector machine and deep learning approaches. ○



140	Chemical traits of cerebral amyloid angiopathy in familial British-, Danish-, and non-Alzheimer $\beta$ dementias.	0
139	DNA methylation signatures of Alzheimer $\beta$ disease neuropathology in the cortex are primarily driven by variation in non-neuronal cell-types. <b>2022</b> , 13,	2
138	Neuronal loss of the nucleus basalis of Meynert in primary progressive aphasia is associated with Alzheimer's disease neuropathological changes.	0
137	Targeting the cannabinoid system to counteract the deleterious effects of stress in Alzheimer $\beta$ disease. 14,	0
136	Towards an understanding of the pathological basis of senile depression and incident dementia: implications for treatment.	1
135	Seeding, maturation and propagation of amyloid $\beta$ peptide aggregates in Alzheimer $\beta$ disease. <b>2022</b> , 145, 3558-3570	0
134	The VTA dopaminergic system as diagnostic and therapeutical target for Alzheimer's disease. 13,	0
133	Clinical, radiologic, and pathologic features of the globular glial tauopathy subtype of frontotemporal lobar degeneration in right temporal variant frontotemporal dementia with salient features of Geschwind syndrome. 1-7	0
132	Digital Histological Study of Neocortical Grey and White Matter Tau Burden Across Tauopathies.	0
131	Hypothesis review: Alzheimer's overture guidelines.	1
130	A $\beta$ Deposits in the Neocortex of Adult and Infant Hypoxic Brains, Including in Cases of COVID-19. <b>2022</b> , Publish Ahead of Print,	1
129	Mixed Pathologies in a Subject with a Novel PSEN1 G206R Mutation. <b>2022</b> , 1-14	0
128	Cerebrovascular insulin receptors are defective in Alzheimer $\beta$ disease.	1
127	Semiquantitative Approach to Amyloid Positron Emission Tomography Interpretation in Clinical Practice.	0
126	Determinants of Perivascular Spaces in the General Population: A Pooled Cohort Analysis of Individual Participant Data. 10.1212/WNL.0000000000201349	1
125	Global neuropathologic severity of Alzheimer $\beta$ disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels.	0
124	Distinct spatiotemporal subtypes of amyloid deposition are associated with diverging disease profiles in cognitively normal and mild cognitive impairment individuals.	0
123	Pathological Appearance of a Case of Preclinical Multiple System Atrophy: A Comparison With Advanced Cases.	0

122	Structural Determinant of $\beta$ Amyloid Formation: From Transmembrane Protein Dimerization to $\beta$ Amyloid Aggregates. <b>2022</b> , 10, 2753	1
121	Unravelling the relationship between amyloid accumulation and brain network function in normal aging and very mild cognitive decline: a longitudinal analysis.	0
120	The central role of tau in Alzheimer's disease: From neurofibrillary tangle maturation to the induction of cell death. <b>2022</b> , 190, 204-217	2
119	Severe cerebrovascular pathology of the first supercentenarian to be autopsied in the world.	0
118	Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer's Disease and Identifying Promising Drug Targets. <b>2022</b> , 12, 1676	3
117	Alzheimer's Disease: Treatment Strategies and Their Limitations. <b>2022</b> , 23, 13954	0
116	Neocortical Lewy body pathology parallels Parkinson's dementia, but not always.	1
115	Whole-brain microscopy reveals distinct temporal and spatial efficacy of anti-A $\beta$ therapies.	0
114	Association of Longitudinal Cognitive Decline with Diffusion MRI in Gray Matter, Amyloid, and Tau Deposition. <b>2022</b> ,	1
113	A $\beta$ and Tau Prions Causing Alzheimer's Disease. <b>2023</b> , 293-337	0
112	Artificial intelligence-driven meta-analysis of brain gene expression identifies novel gene candidates and a role for mitochondria in Alzheimer's disease. <b>2023</b> , 21, 388-400	0
111	State-of-the-art imaging of neuromodulatory subcortical systems in aging and Alzheimer's disease: Challenges and opportunities. <b>2023</b> , 144, 104998	0
110	Brain PET Imaging. <b>2023</b> , 18, 103-113	0
109	State-dependent and region-specific alterations of cerebellar connectivity across stable human wakefulness and NREM sleep states. <b>2023</b> , 266, 119823	0
108	The metal ion hypothesis of Alzheimer's disease and the anti-neuroinflammatory effect of metal chelators. <b>2023</b> , 131, 106301	3
107	Somatic copy number variant load in neurons of healthy controls and Alzheimer's disease patients. <b>2022</b> , 10,	0
106	Physiological Roles of $\beta$ Amyloid in Regulating Synaptic Function: Implications for AD Pathophysiology.	1
105	ApoE isoforms differentially regulate neuronal membrane proteasomes to shift the threshold for pathological aggregation of endogenous Tau.	0

104	The Spectrum of Alzheimer-Type Pathology in Cognitively Normal Individuals. <b>2022</b> , 1-13	1
103	Evidence of Filamin A loss of solubility at the prodromal stage of neuropathologically-defined Alzheimer's disease. 14,	0
102	Cell type-specific changes identified by single-cell transcriptomics in Alzheimer's disease. <b>2022</b> , 14,	0
101	Cognitive resistance to and resilience against multiple comorbid neurodegenerative pathologies and the impact of APOE status.	1
100	Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease.	0
99	TDP-43 Proteinopathy and Tauopathy: Do They Have Pathomechanistic Links?. <b>2022</b> , 23, 15755	0
98	Decoding the heterogeneity of Alzheimer's disease diagnosis and progression using multilayer networks.	0
97	Leptin-based hexamers facilitate memory and prevent amyloid-driven AMPA receptor internalisation and neuronal degeneration.	0
96	Phosphorylated tau in the retina correlates with tau pathology in the brain in Alzheimer's disease and primary tauopathies.	0
95	Virus-Like Cytosolic and Cell-Free Oxidatively Damaged Nucleic Acids Likely Drive Inflammation, Synapse Degeneration, and Neuron Death in Alzheimer's Disease. 1-19	0
94	The electrophysiological and neuropathological profiles of cerebellum in APP swe /PS1 E9 mice: A hypothesis on the role of cerebellum in Alzheimer's disease.	0
93	Brain regions show different metabolic and protein arginine methylation phenotypes in frontotemporal dementias and Alzheimer's disease. <b>2022</b> , 102400	0
92	LATE-NC staging in routine neuropathologic diagnosis: an update.	2
91	Association Between Orthostatic Hypotension and Dementia in Patients With Parkinson Disease and Multiple System Atrophy. 10.1212/WNL.0000000000201659	0
90	Axonal degeneration in the anterior insular cortex is associated with Alzheimer's co-pathology in Parkinson's disease and dementia with Lewy bodies. <b>2022</b> , 11,	0
89	The PSEN1 E280G mutation leads to increased amyloid- $\beta$ 3 production in induced pluripotent stem cell neurons and deposition in brain tissue.	0
88	TDP-43 pathology effect on volume and flortaucipir uptake in Alzheimer's disease.	1
87	Brain and spinal cord arteriolosclerosis and its associations with cerebrovascular disease risk factors in community-dwelling older adults.	0

86	Pyroptosis in Alzheimer's disease: cell type-specific activation in microglia, astrocytes and neurons.	0
85	Entorhinal cortex dysfunction in Alzheimer's disease. <b>2022</b> ,	0
84	Design and application of a customizable relational DataBase to assess clinicopathological correlations and concomitant pathology in neurodegenerative diseases.	0
83	Lack of difference between amyloid-beta burden at gyral crests and sulcal depths in diverse neurodegenerative diseases.	0
82	Optimal deep brain stimulation sites and networks for stimulation of the fornix in Alzheimer's disease. <b>2022</b> , 13,	0
81	Spatially resolved transcriptomics reveals genes associated with the vulnerability of middle temporal gyrus in Alzheimer's disease. <b>2022</b> , 10,	1
80	Multimodal Assessment of Bottlenose Dolphin Auditory Nuclei Using 7-Tesla MRI, Immunohistochemistry and Stereology. <b>2022</b> , 9, 692	1
79	A novel human tau knock-in mouse model reveals interaction of A $\beta$ and human tau under progressing cerebral amyloidosis in 5xFAD mice. <b>2023</b> , 15,	0
78	Genome-wide association study of brain biochemical phenotypes reveals distinct genetic architecture of Alzheimer's disease related proteins. <b>2023</b> , 18,	0
77	Differences in structural MRI and diffusion tensor imaging underlie visuomotor performance declines in older adults with an increased risk for Alzheimer's disease. 14,	0
76	Global neuropathologic severity of Alzheimer's disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels. <b>2022</b> , 17,	0
75	Effects of non-modifiable risk factors of Alzheimer's disease on intracortical myelin content. <b>2022</b> , 14,	0
74	Emerging Roles of Extracellular Vesicles in Alzheimer's Disease: Focus on Synaptic Dysfunction and Vesicle-Neuron Interaction. <b>2023</b> , 12, 63	0
73	Invertebrate and Vertebrate Models of Tauopathies. <b>2011</b> , 69-85	0
72	Update on Alzheimer's Disease. 82-90	0
71	The status of digital pathology and associated infrastructure within Alzheimer's Disease Centers. <b>2023</b> , Publish Ahead of Print,	0
70	Evolutionary and genomic perspectives of brain aging and neurodegenerative diseases. <b>2023</b> ,	0
69	Alteration of neural network and hippocampal slice activation through exosomes derived from 5XFAD nasal lavage fluid.	0

- 68 Robustness of CSF A $\beta$ 2/40 and A $\beta$ 2/P-tau181 measured using fully automated immunoassays to detect AD-related outcomes.
- 67 Deciphering the clinico-radiological heterogeneity of dysexecutive Alzheimer’s disease.
- 66 Higher Angiotensin I Converting Enzyme 2 (ACE2) levels in the brain of individuals with Alzheimer’s disease.
- 65 Progressive Spread of Beta-amyloid Pathology in an Olfactory-driven Amyloid Precursor Protein Mouse Model. **2023**,
- 64 Neurofilament light chain is increased in the parahippocampal cortex and associates with pathological hallmarks in Parkinson’s disease dementia. **2023**, 12,
- 63 The association between white matter hyperintensities and amyloid and tau deposition. **2023**, 38, 103383
- 62 Predicting continuous amyloid PET values with CSF and plasma A $\beta$ 2/A $\beta$ 0. **2023**, 15,
- 61 Alzheimer’s Disease Neuropathologic Change and Vitamin Supplement Use Decades Earlier. **2023**, 37, 1-6
- 60 Argyrophilic grain disease is common in older adults and may be a risk factor for suicide: a study of Japanese forensic autopsy cases. **2023**, 12,
- 59 TDP -43 and tau concurrence in the entorhinal subfields in primary age-related tauopathy and preclinical Alzheimer’s disease.
- 58 The cognitive dysfunction of claustrum on Alzheimer’s disease: A mini-review. 15,
- 57 Docosahexaenoic acid inhibits ischemic stroke to reduce vascular dementia and Alzheimer’s disease. **2023**, 106733
- 56 Cognitive reserve moderates the association between cerebral blood flow and language performance in older adults with mild cognitive impairment. **2023**, 125, 83-89
- 55 Diagnosis of Alzheimer Disease and Tauopathies on Whole-Slide Histopathology Images Using a Weakly Supervised Deep Learning Algorithm. **2023**, 103, 100127
- 54 Characterization of apathy-like behaviors in the 5xFAD mouse model of Alzheimer’s disease. **2023**, 126, 113-122
- 53 The unique neuropathological vulnerability of the human brain to aging. **2023**, 87, 101916
- 52 Untangle the mystery behind DS-associated AD ¶s APP the main protagonist?. **2023**, 87, 101930
- 51 Presenilins regulate synaptic plasticity in the perforant pathways of the hippocampus. **2023**, 16,

- 50 Genetic Risk for Alzheimer Disease and Plasma Tau Are Associated With Accelerated Parietal Cortex Thickness Change in Middle-Aged Adults. **2023**, 9, e200053 1
- 49 Distinct spatiotemporal subtypes of amyloid deposition are associated with diverging disease profiles in cognitively normal and mild cognitive impairment individuals. **2023**, 13, 0
- 48 The relationship between hippocampal amyloid beta burden and spatial distribution of neurofibrillary degeneration. 1
- 47 Longitudinal Spatial Relationships Between Atrophy and Hypometabolism Across the Alzheimer Disease Continuum. **2023**, 92, 513-527 0
- 46 Human striatal glia differentially contribute to AD- and PD-specific neurodegeneration. **2023**, 3, 346-365 0
- 45 Retinal pathological features and proteome signatures of Alzheimer disease. **2023**, 145, 409-438 1
- 44 The remarkable complexity of the brain microbiome in health and disease. 0
- 43 Cognitive Trajectories and Associated Biomarkers in Patients with Mild Cognitive Impairment. **2023**, 92, 803-814 0
- 42 Impact of Nut Consumption on Cognition across the Lifespan. **2023**, 15, 1000 0
- 41 Cognitive and Neuropsychological Profiles in Alzheimer Disease and Primary Age-Related Tauopathy and the Influence of Comorbid Neuropathologies. **2023**, 92, 1037-1049 0
- 40 Soluble and insoluble protein aggregates, endoplasmic reticulum stress, and vascular dysfunction in Alzheimer disease and cardiovascular diseases. 0
- 39 Low-Dose Radiation Therapy (LDRT) against Cancer and Inflammatory or Degenerative Diseases: Three Parallel Stories with a Common Molecular Mechanism Involving the Nucleoshuttling of the ATM Protein?. **2023**, 15, 1482 0
- 38 Hybrid Whale and Gray Wolf Deep Learning Optimization Algorithm for Prediction of Alzheimer Disease. **2023**, 11, 1136 0
- 37 An autopsy case of progressive multifocal leukoencephalopathy with massive iron deposition in juxtacortical lesions. 0
- 36 24-Hydroxycholesterol Induces Tau Proteasome-Dependent Degradation via the SIRT1/PGC1 $\alpha$ /Nrf2 Pathway: A Potential Mechanism to Counteract Alzheimer Disease. **2023**, 12, 631 0
- 35 Clinicopathological associations of hemispheric dominance in primary progressive apraxia of speech. **2023**, 30, 1209-1219 0
- 34 Entorhinal Cortex Functional Connectivity during Item Long-Term Memory and the Role of Sex. **2023**, 13, 446 0
- 33 Defining the phenotypic spectrum of sporadic Creutzfeldt-Jakob disease MV2K: the kuru plaque type. 0

- 32 Beyond the amyloid cascade: An update of Alzheimer's disease pathophysiology. **2023**, ○
- 31 The common marmoset as a model of neurodegeneration. **2023**, 46, 394-409 ○
- 30 Assessment of Alzheimer-related pathologies of dementia using machine learning feature selection. **2023**, 15, ○
- 29 Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads. ○
- 28 New Pathways Identify Novel Drug Targets for the Prevention and Treatment of Alzheimer's Disease. **2023**, 24, 5383 ○
- 27 Postmortem Cerebellar Volume Is Not Reduced in Essential Tremor: A Comparison with Multiple System Atrophy and Controls. **2023**, 1-9 ○
- 26 Early amygdala and ERC atrophy linked to 3D reconstruction of rostral neurofibrillary tau tangle pathology in Alzheimer's disease. **2023**, 38, 103374 ○
- 25 Perspectives on pain in Down syndrome. ○
- 24 Fluorine-18-Labeled Diaryl-azines as Improved Amyloid Imaging Tracers: From Bench to First-in-Human Studies. **2023**, 66, 4603-4616 ○
- 23 MicroRNAs in tear fluids predict underlying molecular changes associated with Alzheimer's disease. **2023**, 6, e202201757 ○
- 22 Dementias. **2013**, 609-658 ○
- 21 Probing neural circuit mechanisms in Alzheimer's disease using novel technologies. ○
- 20 Tau Transfer via Extracellular Vesicles Disturbs the Astrocytic Mitochondrial System. **2023**, 12, 985 ○
- 19 TREM2 gene expression associations with Alzheimer's disease neuropathology are region-specific: implications for cortical versus subcortical microglia. ○
- 18 Cerebral A $\beta$  deposition precedes reduced cerebrospinal fluid and serum A $\beta$ 2/A $\beta$ 0 ratios in the AppNLG/NLg knock-in mouse model of Alzheimer's disease. **2023**, 15, ○
- 17 Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts. **2023**, 15, ○
- 16 Identification of gene networks mediating regional resistance to tauopathy in late-onset Alzheimer's disease. **2023**, 19, e1010681 ○
- 15 Oligomeric, phosphorylated, and truncated tau and spliceosome pathology within the entorhinal hippocampal connectome across stages of Alzheimer's disease. ○

- 14 Visual-somatosensory integration (VSI) as a novel marker of Alzheimer's disease: A comprehensive overview of the VSI study. 15,
- 13 Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease.
- 12 Integrated Proteomics to Understand the Role of Neuritin (NRN1) as a Mediator of Cognitive Resilience to Alzheimer's Disease. **2023**, 100542
- 11 The emerging era of staging Alzheimer's disease pathology using plasma biomarkers.
- 10 Low clinical sensitivity and unexpectedly high incidence for neuropathologically diagnosed progressive supranuclear palsy. **2023**, 82, 438-451
- 9 Cortical microstructural associations with CSF amyloid and pTau.
- 8 Movement disorders are linked to TDP-43 burden in the substantia nigra of FTLD-TDP brain donors. **2023**, 11,
- 7 Loss of hypothalamic MCH decreases food intake in amyotrophic lateral sclerosis.
- 6 Compilation of all known protein changes in the human Alzheimer's disease brain.
- 5 Pre-symptomatic synaptic dysfunction and longitudinal decay of hippocampal synaptic function in APPPS1 mouse model of Alzheimer's disease is sex-independent. **2023**, 198, 36-49
- 4 How to Prevent and/or Revert Alzheimer's Disease Continuum During Preclinical Phases. 1-8
- 3 Regulation of the E/I-balance by the neural matrisome. 16,
- 2 Brain Kynurenine Pathway Metabolite Levels May Reflect Extent of Neuroinflammation in ALS, FTD and Early Onset AD. **2023**, 16, 615
- 1 Proteostasis failure exacerbates neuronal circuit dysfunction and sleep impairments in Alzheimer's disease. **2023**, 18,